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1.1 Introduction 
 
 The pyrimidine fragment is present in the molecules of a series of biologically 
active compounds, many of which have found use in medical practice (soporific, anti-
inflammatory, antitumor, and other products).1,2 In this connection, great attention has 
recently been paid to the derivatives of pyrimidine, including their hydrogenation 
products. The first investigation into the synthesis of pyrimidine nucleus appeared 
more than a hundred years ago and subsequently several methods for the synthesis of 
dihydropyrimidine were reported and their physicochemical properties has been 
studied (e.g., the Biginelli reaction).3 Further, the high reactivity and wide range of 
biological activity associated with these scaffolds have been demonstrated in the 
literature. For example, 2-substituted 5-alkoxycarbonyl-4-aryl-l,4-dihydropyrimidines 
(structural analogs of Hantzsch esters) are modulators of the transport of calcium 
through membranes.4-7 Many hydrogenated pyrimidines exhibit antimicrobial,8 
hypoglemic,9 herbicidal,10 and pesticidal11 activity. Publications devoted to these 
problems have been summarized in a number of reviews.9-14 
 Pyrimidines have a long and distinguished history extending from the days of 
their discovery as important constituents of several biological molecules such as 
nucleic acids, cofactors, various toxins, to their current use in the chemotherapy of 
AIDS. All these compounds yield great promise for the treatment of retro virus 
infections in humans. 
 Alloxan (1) is known for its diabetogenic action in a number of animals.15 
Uracil (2), thymine (3) and cytosine (4) are the three important constituents of nucleic 
acids (Figure-1). 
 
Figure-1 
 The pyrimidine ring is also found in vitamins such as thiamine (5), riboflavin 
(6) (Figure-2) and folic acid (7).16 Barbitone (8) is the first barbiturate hypnotic, 
sedative and anticonvulsant are pyrimidine derivatives (Figure-3). 
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Figure-2 
 
Figure-3 
 
1.2 Biological Activity Associated with 4-Aryl dihydropyrimidine 
derivatives 
 
 Among the dihydropyrimidines, 4-Aryl-1,4-dihydropyridines (DHPs, e.g. 
nifedipine) are the most studied class of organic calcium channel modulators. More 
than 30 years after the introduction of nifedipine many DHP analogs have now been 
synthesized and numerous second-generation commercial products have appeared on 
the market.17,18 
 Nowadays, interest has also been focused on aza-analogs such as 
dihydropyrimidines (DHPMs) which showed a very similar pharmacological profile 
to the classical dihydropyridine calcium channel modulators.5-7, 19-20 Over the past few 
years several lead-compounds were developed (i.e. SQ 32,926) that are superior in 
potency and duration of antihypertensive activity to classical DHP drugs, and 
compare favorable with second-generation analogs such as amlodipine and 
nicardipine (Figure-4). 
 
Figure-4 
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 Barrow et al. has reported in vitro and in vivo evaluation of 
dihydropyrimidinone C-5 amides as potent and selective r1A receptor antagonists for 
the treatment of benign prostatic hyperplasia (Figure-5). R1 Adrenergic receptors 
mediate both vascular and lower urinary tract tone, and R1 receptor antagonists such 
as terazosin are used to treat both hypertension and benign prostatic hyperplasia 
(BPH). Recently, three different subtypes of this receptor have been identified, with 
the R1A receptor being most prevalent in lower urinary tract tissue. Barrow et al. has 
also reported 4-aryldihydropyrimidinones attached to an aminopropyl-4-
arylpiperidine via a C5 amide as selective R1A receptor subtype antagonists. In 
receptor binding assays, these types of compounds generally display Ki values for the 
R1a receptor subtype <1 nM while being greater than 100-fold selective versus the 
R1b and R1d receptor subtypes. Many of these compounds were also evaluated in 
vivo and found to be more potent than terazosin in both a rat model of prostate tone 
and a dog model of intra-urethral pressure without significantly affecting blood 
pressure. While many of the compounds tested displayed poor pharmacokinetics, one 
compound was found to have adequate bioavailability (>20%) and half-life (>6 h) in 
both rats and dogs. Due to its selectivity for the R1a over the R1b and R1d receptors 
as well as its favorable pharmacokinetic profile, it has the potential to relieve the 
symptoms of BPH without eliciting effects on the cardiovascular system.21,22 
N
H
NH
F
F
OR1
N
H
O
N
R3 R2  
Figure-5 
 The 4-aryldihydropyrimidinone attached to an aminopropyl-4-arylpiperidine 
via a C5 amide has proved to be an excellent template for selective R1A receptor 
subtype antagonists. Those compounds are exceptionally potent in both cloned 
receptor binding studies as well as in vivo pharmacodynamic models of prostatic tone. 
 Atwal et al. have examined a series of novel dihydropyrimidine calcium 
channel blockers that contain a basic group attached to either C5 or N3 of the 
heterocyclic ring (Figure-6).  
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Structure-activity studies showed that l-(phenylmethyl)-4-piperidinylcarbamate 
moiety at N3 and sulfur at C2 are optimal for vasorelaxant activity in vitro and impart 
potent and long-acting antihypertensive activity in vivo. One of these compounds was 
identified as a lead, and the individual enantiomers were synthesized. Two key steps 
of the synthesis were (1) the efficient separation of the diastereomeric ureido 
derivatives and (2) the high-yield transformation of 2-methoxy intermediate to the    
(p-methoxybenzyl)thio intermediates. Chirality was demonstrated to be a significant 
determinant of biological activity, with the DHP receptor recognizing the enamines 
ester moiety but not the carbamate moiety. DHPM is equipotent to nifidepine and 
amlodipine in vitro. In the spontaneously hypertensive rat, DHPM is more potent and 
longer acting than both nifidepine and the long-acting amlodipine (DHP derivative). 
DHPM has the potential advantage of being a single enantiomer.23,24 
N
H
N
i-PrO2C
S
O2
C
N
R
F3C
N
H
N
i-PrO2C
S
O2
C
N
F
F3C
HCl
 
Figure-6 
 In order to explain the potent antihypertensive activity of the modestly active 
(ICw = 3.2 pM) DHPM calcium channel blocker, Atwal et al. carried out drug 
metabolism studies in the rat and found that two of the metabolites (ICw = 16 nM) 
and (ICw = 12 nM), were responsible for antihypertensive activity of compound. 
Potential metabolism in vivo precluded interest in pursuing compounds related to it. 
Structure-activity studies aimed at identifying additional aryl-substituted analogues 
led to comparable potential in vivo, though these compounds were less potent in vitro. 
To investigate the effects of absolute stereochemistry on potency, authors resolved via 
diastereomeric ureas, prepared by treatment with (R)-α-methylbenzylamine. The 
results demonstrate that the active R-(-)-enantiomer is more potent and longer acting 
than nifedipine as an antihypertensive agent in the SHR. The in vivo potency and 
duration is comparable to the long-acting DHP amlodipine. The superior oral 
antihypertensive activity compared to that of previously described carbamates 
(R2=COOEt) could be explained by its improved oral bioavailability, possibly 
resulting from increased stability of the urea functionality (Figure-7).6 
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Figure-7 
 Authors modified the structure of previously described DHPM i.e. 3-
substituted 1,4-dihydropyrimidines. Structure-activity studies using potassium-
depolarized rabbit aorta show that ortho, meta-disubstituted aryl derivatives are more 
potent than either ortho or meta-monosubstituted compounds. While vasorelaxant 
activity was critically dependent on the size of the C5 ester group, isopropyl ester 
being the best, a variety of substituents (carbamate, acyl, sulfonyl, and alkyl) were 
tolerated at N3. The results showed that DHPMs are significantly more potent than 
corresponding 2- heteroalkyl-l,4-dihydropyrimidines and only slightly less potent than 
similarly substituted 2-heteroalkyl-1-4-dihydropyridines (Figure-8). Where as DHP 
enantiomer usually show 10-15-fold difference in activity, the enantiomer of DHPM 
show more than a 1000-fold difference in activity. These results strengthen the 
requirement of an enaminoester for binding to the dihydropyridine receptor and 
indicate a nonspecific role for the N3-substituent. 
 
Figure 8 
 2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylicesters 
(Figure 9), which lack the potential symmetry of DHP calcium channel blockers, 
were prepared and evaluated for biological activity. Biological assays using 
potassium-depolarized rabbit aorta and radio ligand binding techniques showed that 
some of these compounds are potent mimics of DHP calcium channel blockers.25 
 
Figure 9 
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 Bryzgalov A. O. et al. has studied the antiarrhythmic activity of 4,6-
di(het)aryl-5-nitro-3,4-dihydropyrimidin-(1H)-2-ones (Figure-10) toward two types 
of experimental rat arrhythmia. With CaCl2 induced arrhythmia model, several agents 
have demonstrated high antiarrhythmic activity and the lack of influence on arterial 
pressure of rats.26 
 
Figure 10 
 Remennikov G. et al.27 has synthesized some novel 4-aryl-5-nitro substituted 
DHPMs (Figure 11) using nitro acetone and screened as calcium modulators. They 
have studied the pharmacological properties of 6-methyl- and 1,6-dimethyl-4-aryl-5-
nitro-2-oxo-l,2,3,4-tetrahydropyrimidines with different substituents in the aryl 
fragment, i.e. unsubstituted, ortho, meta, para, di, and tri-substituted compounds and 
observed that 5-nitro DHPMs bearing unsubstituted, ortho and tri-substitution on aryl 
moieties at C4 position reduced blood pressure and inhibited myocardial contractile 
activity. The second group consisted meta, para and di-substituted aryl moieties with 
DHPMs increased blood pressure and had positive inotropic effects. The compounds 
with the highest hypotensive activity were containing substituent in the ortho position 
of the phenyl fragment. Thus, compounds having substitution on aryl moieties which 
had pronounced vasodilator and weak cardio depressive actions, increased cardiac 
pump function (SV). When inhibition of myocardial contractile function 
predominated, there was a reduction in SV. The effect of compounds of the first group 
on heart rate was variable, though most reduced heart rate. In addition, a reflex 
increase in heart rate might be expected because of the reduction in blood pressure. 
The reference preparations for compounds of this group were the calcium antagonist 
nifedipine.  
 
Figure-11 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
Department of Chemistry, Saurashtra University, Rajkot-360005   7 
 
 
The pharmacological profile of compounds of the first group was analogous to that of 
nifedipine. This suggests that they share a common mechanism of action - blockade of 
calcium ion influx. 
 Brain C. Shook et al.28 has synthesized a novel series of arylindeno- 
pyrimidines (Figure-12) identified as A2A and A1 receptor antagonists. The series was 
optimized for vitro activity by substituting the 8-and-9- positions with methylene 
amine substituents. The compounds show excellent activity in mouse models of 
parkinson’s disease when dosed orally. 
N
N
O
Ar
NH2R'RN  
Figure-12 
 
1.3. Synthetic strategies for the dihydropyrimidines (DHPMs) 
  
 Having tremendous important of DHPMs in medicinal chemistry, a literature 
survey on the synthetic methods for the biologically active dihydropyrimidines 
(DHPMs) has been carried out and described as follows. Various modifications have 
been applied to Biginelli reaction to get better yield and to synthesize biologically 
active analogs. Different catalysts have been reported to increase the yield of the 
reaction. Microwave synthesis strategies have also been applied to shorten the 
reaction time. Solid phase synthesis and combinatorial chemistry has made possible to 
generate library of DHPM analogs. The various modifications are discussed in the 
following section. 
 
? Catalysts 
 Min Yang and coworkers29 have synthesized the different DHPMs by using 
various inorganic salts as a catalyst (Figure-13). They found that the yields of the 
one-pot Biginelli reaction can be increased from 20-50% to 81-99%, while the 
reaction time shorted for 18-24 hrs to 20-30 min. This modification was developed by 
using Yb(OTf)3 and YbCl3 as a catalyst under solvent free conditions. One additional 
important feature of this protocol is the catalyst can be easily recovered and reused.  
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Figure-13 
 Lewis acid such as, Indium (III) chloride was emerged as a powerful Lewis 
catalyst imparting high region and chemo selectivity in various chemical 
transformations. B. C. Ranu and co-workers30 have reported indium (III) chloride 
(InCl3) as an efficient catalyst for the synthesis of 3,4-dihydropyrimidn-2(1H)-ones 
(Figure-14). A variety of substituted aromatic, aliphatic and heterocyclic aldehydes 
have been subjected to this condensation very efficiently. Thiourea has been used 
with similar success to provide the corresponding dihydropyrimidin-2(1H)-thiones. 
 
Figure-14 
 Majid M. Heravi et al. has reported a simple, efficient and cost-effective 
method for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones by one pot 
three-component cyclocondensation reaction of a 1,3-dicarbonyl compound, an 
aldehyde and urea or thiourea using 12-tungstophosphoric acid31 and 12-
molybdophosphoric acid32 as  recyclable catalyst (Figure-15). 
 
Figure-15 
 Hydroxyapatite doped with ZnCl2, CuCl2, NiCl2 and CoCl2 efficiently 
catalyzes the three components Biginelli reaction between an aldehyde, ethyl 
acetoacetate and urea in refluxing toluene to afford the corresponding 
dihydropyrimidinones in high yields.33 
 Sc(III)triflate catalyzes the three-component condensation reaction of an 
aldehyde, a β-ketoester and urea in refluxing acetonitrile to afford the corresponding 
3,4-dihydropyrimidin-2(1H)-ones in excellent yields (Figure-16). The catalyst can be 
recovered and reused, making this method friendly and environmentally acceptable.34 
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Figure-16 
 
? Solid phase synthesis 
 The generation of combinatorial libraries of heterocyclic compounds by solid 
phase synthesis is of great interest for accelerating lead discovery and lead 
optimization in pharmaceutical research. Multi-component reactions (MCRs)35,36-37 
leading to heterocycles are particularly useful for the creation of diverse chemical 
libraries, since the combination of any 3 small molecular weight building blocks in a 
single operation leads to high combinatorial efficiency. Therefore, solid phase 
modifications of MCRs are rapidly become the cornerstone of combinatorial synthesis 
of small-molecule libraries.  
 The first solid-phase modification of the Biginelli condensation was reported 
by Wipf and Cunningham38 in 1995 (Figure-17). In this sequence, γ-aminobutyric 
acid derived urea was attached to Wang resin using standard procedures. The 
resulting polymer-bound urea was condensed with excess β-ketoester and aromatic 
aldehydes in THF at 55 °C in the presence of a catalytic amount of HCl to afford the 
corresponding immobilized DHPMs. Subsequent cleavage of product from the resin 
by 50 % trifluoroacetic acid (TFA) provided DHPMs in high yields and excellent 
purity. 
 
Figure-17 
 Li W. and Lam Y.39 have described the synthesis of 3,4-dihydropyrimidin-2- 
(1H)ones/thiones using sodium benzene sulfinate as a traceless linker (Figure-18). 
The key steps involved in the solid-phase synthetic procedure were sulfinate 
acidification, condensation of urea or thiourea with aldehydes and sulfinic acid and 
traceless product release by a one-pot cyclization-dehydration process. Since a variety 
of reagents can be used, the overall strategy appears for library generation. 
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Figure-18 
 
? Liquid phase synthesis 
 In the solid phase synthesis there are some disadvantages in compared to 
standard solution-phase synthesis, such as difficulties to monitor reaction progress, 
the large excess of reagents typically used in solid-phase supported synthesis, low 
loading capacity and limited solubility during the reaction progress and the 
heterogeneous reaction condition with solid phase.40 Recently, organic synthesis of 
small molecular compounds on soluble polymers, i.e. liquid phase chemistry has 
increasingly become attractive field.41  
 Moreover, owing to the homogeneity of liquid-phase reactions, the reaction 
conditions can be readily shifted from solution-phase systems without large changes 
and the amount of excessive reagents is less than that in solid-phase reactions. In the 
recent years, Task Specific room temperature Ionic Liquids (TSILs) has emerged as a 
powerful alternative to conventional molecular organic solvents or catalysts. Liu Z. et 
al.42 have reported cheap and reusable TSILs for the synthesis of 3,4-
dihydropyrimidin-2(1H)-ones via one-pot three component Biginelli reaction. Ionic 
liquid-phase bound acetoacetate reacts with thiourea and various aldehydes with a 
cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-
thiones, which has been reported by Bazureau J. P. and co- workers43 (Figure-19). 
3,4-Dihydropyrimidinones were synthesized in one-pot, by the reaction of aldehydes, 
β-dicarbonyl compounds and urea, catalyzed by non-toxic room temperature ionic 
liquid 1-n-butyl-3-methylimidazolium saccharinate (BMImSac).44 
 
Figure-19 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
Department of Chemistry, Saurashtra University, Rajkot-360005   11 
 
 
? Microwave assisted synthesis 
 In general, the standard procedure for the Biginelli condensation involves one 
pot condensation of the three building blocks in a solvent such as ethanol using a 
strongly acidic catalyst that is hydrochloric acid. One major drawback of this 
procedure, apart from the long reaction time involving reflux temperature, is the 
moderate yields frequently observed when using more complex building blocks. 
Microwave irradiation (MW) has become accepted tool in organic synthesis, because 
the rate enhancement, higher yields and often, improved selectivity with respect to 
conventional reaction conditions.45 The publication by Dandia A. et al.46 described 
microwave-enhanced solution-phase Biginelli reactions employing ethyl acetoacetate, 
thiourea and a wide variety of aromatic aldehydes as building blocks (Figure-20). 
Upon irradiation of the individual reaction mixtures (ethanol, catalytic HCl) in an 
open glass beaker inside the cavity of a domestic microwave oven the reaction times 
were reduced from 2–24 hours of conventional heating 80 °C, reflux to 3–11 minutes 
under microwave activation (ca. 200 –300 W). At the same time the yields of DHPMs 
obtained were distinctly improved compared to those reported earlier using 
conventional conditions. 
 
Figure-20 
 In recent years, solvent free reactions using either organic or inorganic solid 
supports have received more attention.47 There are several advantages to perform 
synthesis in dry media: (i) short reaction times, (ii) increased safety, (iii) economic 
advantages due to the absence of solvent. In addition, solvent free MW processes are 
also clean and efficient. Gopalakrishnan M. and co-workers have reported Biginelli 
reaction under microwave irradiation in solvent-free conditions using activated fly ash 
as catalyst, an industrial waste (pollutant) is an efficient and novel catalyst for some 
selected organic reactions in solvent free conditions under microwave irradiation.48 
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? Ultrasound assisted synthesis 
 Ultrasound as a green synthetic approach has gradually been used in organic 
synthesis over the last three decades. Compared with the traditional methods, it is 
more convenient, easier to be controlled and consumes less power. With the use of 
ultrasound irradiation, a large number of organic reactions can be carried out in milder 
conditions with shorter reaction time and higher product yields.49 Ultrasound 
irradiated and amidosulfonicacid (NH2SO3H) catalyzed synthesis of 3,4-
dihydropyrimidi-2-(1H)ones have been reported by Li J. T. and co-workers50 using 
aldehydes, β-ketoester and urea. 
 Liu C. et al.51 have synthesized a novel series of 4-substituted pyrazolyl-3,4-
dihydropyrimidin-2(1H)-thiones under ultrasound irradiation using magnesium 
perchlorate [Mg(ClO4)2] as catalyst (Figure-21), by the condensation of 5-
chloro/phenoxyl-3-methyl-1-phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and 
urea or thiourea in moderate yields. The catalyst exhibited remarkable reactivity and 
can be recycled. 
 
Figure-21 
 Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of 
solvent (ethanol) or solvent-less dry media (bentonite clay) by supporting-zirconium 
chloride (ZrCl4)  as catalyst at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl esters proficiently in high yields, 
which reported by Harish Kumar et al. (Figure 22).52 
 
Figure-22 
 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
Department of Chemistry, Saurashtra University, Rajkot-360005   13 
 
 
? Synthetic Methods for the Oxidative Dehydrogenation of DHPM Ring 
System 
 The production of heteroaromatics by oxidative dehydrogenations is of 
fundamental importance in organic synthesis. The dehydrogenation of 
dihydropyrimidines and dihydropyrimidinones has received much attention because 
of their facile access via the Biginelli three-component coupling. Different methods 
were reported in the literature for oxidative dehydrogenations of DHPM, which are 
described as under. 
 Hamid Reza Memarian et al.53 have developed dehydrogenation of 5-acetyl-
3,4-dihydropyrimidin-2(1H)-ones by potassium peroxydisulfate in aqueous 
acetonitrile under thermal and sonothermal conditions (Figure-23). 
N
H
NH
R
O N
H
N
RO
O
O
K2S2O
CH3CN/H2O
Ultrasound/
Heat
H
 
Figure-23 
 Sam Sik Kim et al.54 reported that oxidation of dihydropyrimidin-2(1H)-ones 
by KMnO4 formed 2-hydroxypyrimidine in excellent yield, whereas attempted direct 
desulfurative aromatization of dihydropyrimidin-2(1H)-thiones by KMnO4 resulted in 
the formation of 2-hydroxypyrimidines (Figure-24). 
 
Figure-24 
 Masoud Nasr-Esfahani et al.55 reported photolytic oxidation of some ethyl 3,4-
dihydropyrimidin-2(1H)-one-5-carboxylates to their corresponding ethyl pyrimidin-
2(1H)-one-5-carboxylates using a TiO2/O2 system under UV irradiation by a 400 W 
high pressure mercury lamp in acetonitrile (Figure-25). 
 
Figure-25 
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 Rui Liang et al.56 has shown the oxidation of 3,4-Dihydropyrimidin-2(1H)-
ones (DHPMs) with 1.2 eq. of nitrosonium tetrafluoroborate (NO+BF4-) to pyrimidin-
2(1H)-ones in acetonitrile at room temperature in high yields (Figure-26). 
 
Figure-26 
 Nandkishor N. Karade et al.57 has achieved oxidative dehydrogenation of 3,4-
dihydropyrimidin-2(1H)-ones to 1,2-dihydropyrimidines through a novel combination 
of (diacetoxyiodo)benzene and tert-butylhydroperoxide in CH2Cl2 (Figure-27). 
 
Figure-27 
 Kana Yamamoto et al.58 has reported method for oxidative dehydrogenation of 
dihydropyrimidinones and dihydropyrimidines by using catalytic amounts of a Cu 
salt, K2CO3, and tert-butylhydroperoxide (TBHP) as a terminal oxidant (Figure-28). 
 
Figure-28 
 
? Synthetic Methods for the Synthesis of 2-Chloropyrimidine Derivatives 
 Several methods were reported in the literature for the chlorination of 2-
hydroxypyrimidines, few of them are described herein. 
 Driwedi Shriprakash Dhar et al.59 has reported synthesis of 2-halopyrimidine 
derivative from 2-hydroxypyrimidine by using thionyl chloride and dimethyl 
formamide and toluene as a solvent at 80 oC (Figure-29). 
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Figure-29 
 Atul R. Gholap et al.60 has described the synthesis of 2-chloropyrimidine 
derivatives from 2-hydroxypyrimidine derivatives using N,N-dimethylaniline and 
POCl3 as chlorinating agent under reflux condition (Figure-30). 
 
Figure-30 
 
? Synthetic methods for the Suzuki-Miyaura coupling 
 The well known Suzuki reaction61 is the organic reaction of an aryl or vinyl-
boronicacid with an aryl or vinyl-halide catalyzed by a palladium(0)complex forming 
carbon-carbon bond. Some reported methods are described as under. 
 In 1981, Suzuki and Miyaura et al. have made a breakthrough in the 
methodology for biaryl compounds using aryl boronicacids and aryl bromide under 
homogeneous palladium catalyzed conditions in the presence of base62 (Figure- 31). 
B
OH
OH
Br 3 mol% Pd(Ph3)4
Aq. Na2CO3
Benzene, refulx
Z Z
 
Figure-31 
 S. Li et al.63 have synthesized Pd(OAc)2-catalyzed room temperature Suzuki 
cross coupling reaction in aqueous media under aerobic conditions (Figure-32). 
 
Figure-32 
 Y. M. A. Yamada et al.64 have prepared highly active catalyst for the 
heterogeneous Suzuki-Miyaura reaction by assembled complex of palladium and non-
cross linked amphiphilic polymer (Figure-33). 
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Figure-33 
 Zhengyin Du et al.65 has reported an ultrafast and highly efficient ligand-free 
Suzuki-Miyaura cross-coupling reaction between aryl bromides/iodides and aryl 
boronicacids using palladium chloride as catalyst in PEG-400/H2O in air at room 
temperature. TEM showed that palladium nanoparticles were generated in situ from 
PdCl2/PEG-400/H2O without use of other reductants. The catalyst system can be 
recycled to reuse three times with good yields (Figure-34). 
 
Figure-34 
 Yu-Long Zhao et al.66 has prepared a highly practical and reliable Nickel 
catalyst for Suzuki–Miyaura coupling of aryl halides with various aryl boronicacid 
(Figure-35). 
 
Figure-35 
 Sha Lou et al.67 has developed Palladium/Tris(tert-butyl)phosphine-Catalyzed 
Suzuki Cross-Couplings of aryl and heteroaryl halides with aryl and heteroaryl 
boronic acids in the Presence of Water (Figure-36). 
 
Figure-36 
 Ruonan Zhang et al.68 has synthesized a series of novel 5-arylidenefuran-
2(5H)-ones and 5-arylidene-4-arylfuran-2(5H)-ones via the Suzuki-Miyaura reactions 
(Figure-37). 
 
Figure-37 
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 Yongda Zhang et al.69 has been developed one-pot process for the synthesis of 
8-arylquinolines via Pd-catalyzed borylation of quinoline-8-yl halides and subsequent 
Suzuki-Miyaura coupling with aryl halides using n-BuPAd2 as ligand (Figure-38). 
Figure-38 
 John Spencer et al.70 has reported synthesis of a (piperazin-1-ylmethyl)biaryl 
library via microwave-mediated Suzuki–Miyaura cross-couplings (Figure 39). 
Figure-39 
 Qing Tang et al.71 has developed Suzuki–Miyaura coupling reactions of 5-
chloro-1-phenyl-tetrazole with various functionalized aryl boronicacids in the 
presence of catalytic amounts of SPhos/Pd(OAc)2 or RuPhos/Pd(OAc)2 (Figure-40). 
 
Figure-40 
 V. P. Mehta et al.72 has reported a novel and versatile entry to asymmetrically 
substituted pyrazine derivatives (Figure 41). 
 
Figure-41 
 Jeanne-Marie Begouin et al.73 has reported cobalt-catalyzed cross-coupling 
between in situ prepared aryl zinc halides and 2-chloropyrimidine/2-chloropyrazine 
(Figure- 42). 
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Figure-42 
 Takahiro Itoh et al.74 has discovered a direct synthesis of hetero-biaryl 
compounds containing an unprotected NH2 group via Suzuki–Miyaura reaction by 
using Pd(OAc)2 and D-t-BPF ligand as a catalyst (Figure-43). 
Figure-43 
 Lisa C. W. Chang et al.75 synthesized 2,6-disubstituted and 2,6,8-trisubstituted 
purines as adenosine receptor antagonists via Suzuki–Miyaura reaction (Figure-44). 
Figure-44 
 Atul R. Gholap et al.60 has developed an efficient synthesis of antifungal 
pyrimidines via palladium catalyzed Suzuki/Sonogashira cross-coupling reaction from 
Biginelli 3,4-dihydropyrimidin-2(1H)-ones (Figure-45). 
 
Figure-45 
 Christoph A. et al.76 has reported an efficient Suzuki-Miyaura coupling of 
(hetero)aryl chlorides with Thiophene- and Furan boronicacids in aqueous n-butanol 
(Figure-46).  
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Figure-46 
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 David X. Yang et al.77 has reported palladium-catalyzed Suzuki-Miyaura 
coupling of Pyridyl-2-boronic esters with aryl halides using highly active and air-
stable phosphine chloride and oxide Ligands (Figure-47). 
N B
O
O
FG ArX
or
HetArX N
FG
Ar
or
N HetAr
FG
Dichloropalladiuym oxide/chloride
Base, solvent
Figure-47 
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1.4. Current research work 
 
 The literature survey described above has demonstrated that the pyrimidine 
derivatives possesses a variety of biological activity, among which are the analgesic, 
antihypertensive, antipyretic, antiviral and anti-inflammatory activity. These agents 
are also associated with nucleic acid, antibiotic, antimalarial and anti cancer drugs. 
Many of the pyrimidine derivatives are reported to possess potential CNS depressant 
properties. However, to our knowledge functionalized pyrimidines such as 4-
isopropyl-2,6-di-phenylsubstituted derivatives are less studied (Figure-48). The 
tremendous biological potential of pyrimidine derivatives encouraged us to prepare 
some novel highly functionalized pyrimidines bearing 4-isopropyl-2-6-di-
substitutedphenylpyrimidine-5-carboxylate functions.  
N
N
O
O
R
R1
ASM-4a-t  
Figure-48 
 Herein we described a series of novel and efficient protocol for the synthesis 
of diversely substituted pyrimidines. A series of chlorinated pyrimidines were 
synthesized from easily available Biginelli 3,4-dihydropyrimidin-2(1H)-ones. The 
chlorinated pyrimidines were subjected to the Suzuki-Miyaura coupling reactions 
with various phenylboronicacid derivatives to obtain C-phenyl pyrimidines. The 
newly synthesized compounds are characterized by IR, Mass, 1H NMR, 13C NMR 
spectroscopy and elemental analysis. 
 
. 
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1.5.  Results and discussion 
Scheme:-1 Synthesis of substituted pyrimidines via Suzuki-Miyaura coupling. 
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 The synthetic route for the targeted compounds (ASM-4a-t) is shown in 
scheme 1. Initially, various  substituted 3,4-dihydropyrimidine-2-(1H)-ones (DHPMs) 
(ASM-01a-e) were synthesized by well-known multi-component Biginelli reaction of 
substituted benzaldehyde, methyl isobutyrate acetate and urea fusion at 150 oC in the 
presence of 2-3 drops of DMF as a catalyst (scheme-01). Thus obtained DHPMs 
(ASM-01a-e) were subjected the oxidative dehydrogenation using 60% Con. HNO3 to 
furnish corresponding 2-hydroxypyrimidines (ASM-02a-e) in excellent yield. The 
reaction of compounds ASM-02a-e with POCl3 under reflux for 2-3 hrs afforded 2-
chloropyrimidine derivatives ASM-03a-e up to 85-95% yield. The chlorinated 
pyrimidines ASM-03a were subjected to Suzuki-Miyaura carbon-carbon coupling 
reaction with various phenylboronicacid derivatives using tetrakis(triphenylphosphine) 
palladium(0) as a catalyst in 1,4-dioxane:water (6:4) and K2CO3 as a base to achieve 
the cross-coupled final products ASM-04a-t with good yields. 
 The structures of ASM-02a-e, ASM-03a-e and ASM-04a-t were established 
on the basis of their elemental analysis and spectral data (MS, IR, 1H NMR and 13C 
NMR). Some representative examples for each step are described here. 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
Department of Chemistry, Saurashtra University, Rajkot-360005   22 
 
 
 The analytical data for ASM-02a revealed a molecular formula C15H16N2O3 
(m/z 273). The 1H NMR spectrum revealed one doublet at δ = 1.42-1.44 ppm assigned 
to isopropyl-CH3, a multiplet at δ = 3.20-3.26 ppm assigned to the isopropyl-CH 
protons, a singlet at δ = 3.57 ppm assigned to the –OCH3 protons, a multiplet at δ = 
7.44–7.51 ppm assigned to the aromatic protons, and also a doublet at δ = 7.58–7.60 
ppm (j=6.9Hz) assigned to the aromatic protons, one singlet at δ = 12.94 ppm 
assigned to -OH group. 
Table 1: Synthesis of substituted pyrimidines via Suzuki-Miyaura coupling. 
Entry R R1 Yield Time hrs. 
ASM-04a H 4-CN 82 6.0 
ASM-04b 4-CH3 3-N(CH3)2 80 8.0 
ASM-04c 4-OCH3 4-F 87 6.5 
ASM-04d 3-NO2 4-OCH3 92 6.0 
ASM-04e 4-F H 83 7.5 
ASM-04f H 3-N(CH3)2 78 8.5 
ASM-04g 4-CH3 4-F 86 7.5 
ASM-04h 4-OCH3 4-OCH3 82 7.0 
ASM-04i 3-NO2 H 89 7.0 
ASM-04j 4-F 4-CN 87 5.5 
ASM-04k H 4-OCH3 83 6.5 
ASM-04l 4-CH3 H 85 7.0 
 ASM-04m 4-OCH3 4-CN 82 6.5 
ASM-04n 3-NO2 3-N(CH3)2 75 7.5 
ASM-04o 4-F 4-F 80 6.0 
ASM-04p H H 84 7.5 
ASM-04q 4-CH3 4-CN 89 6.0 
ASM-04r 4-OCH3 3-N(CH3)2 80 7.5 
ASM-04s 3-NO2 4-F 90 6.5 
ASM-04t 4-F 4-OCH3 86 6.0 
 
 The structures of ASM-03a was supported by its mass (m/z 291), which agrees 
with its molecular formula C15H15FN2O3, its 1H NMR spectrum had signals at δ = 
1.32-1.35 (d, 6H, 2 x iprCH3), 3.14-3.20 (m, 1H, iprCH), 3.72 (s, 3H, OCH3), 7.43-
7.48 (m, 3H, Ar-H), 7.65-7.67 (t, 2H, Ar-H). 
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 The analytical data for ASM-04a revealed a molecular formula C22H19N3O2 
(m/z 358). Its 1H NMR spectrum had signals at δ = 1.16-1.32 (d, 6H, 2 x iprCH3), 
3.15-3.19 (m, 1H, iprCH), 3.66 (s, 3H, OCH3), 7.39-7.42 (m, 3H, Ar-H), 7.65-7.70 
(m, 4H, Ar-H), 8.61-8.63 (d, 2H, Ar-H). 
 The proposed mechanism of the Suzuki-Miyaura coupling reaction for the 
formation of C-phenyl pyrimidines is depicted in figure 35. 
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Figure 35: Mechanism of Suzuki-Miyaura coupling reaction leading 
to the formation of C-phenyl pyrimidines. 
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1.6 Conclusion 
 
 In conclusion, we have developed an efficient four step protocols for the 
synthesis of diversely substituted novel pyrimidines. A series of chlorinated 
pyrimidines were synthesized from easily available biginelli 3,4-dihydropyrimidin-
2(1H)-ones. The chlorinated pyrimidines were then subjected to condition normally 
employed Suzuki-Miyaura coupling reaction with various phenylboronicacid 
derivatives in the presence of palladium catalyst to obtain C-phenyl pyrimidines with 
good yields. A variety of commercially available 1,3-diketones and various 
substituted aldehydes and boronic acids can be used as building blocks to generate 
diversity on the core pyrimidine ring systems. 
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1.7 Experimental section 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (300 MHz), 1H (400 MHz), 13C (75 MHz) and 13C (100 MHz)  
NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl3 and 
DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal 
standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 
mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were measured in open capillaries and are uncorrected. 
 
? General synthetic procedure for the 3,4-dihydropyrimidine-2-(1H)-ones 
(ASM-01a-e). 
 
 A 100mL round bottom flask equipped with magnetic stirrer and septum was 
charged with the methyl 4-methyl-3-oxopentanoate (0.01M), aldehyde (0.01M) and 
urea (0.015M). Few drops of DMF were added to the reaction mixture as a catalyst. 
The reaction mixture was then heated at 145-150 oC for 15-30 minutes. The progress 
of reaction was monitored by thin layer chromatography. The reaction mixture was 
allowed to cool at rt. Then, methanol (20 mL) was added and the resulting mixture 
was refluxed for 30 min. The solid separated upon cooling was filtered, washed with 
methanol and dried. The products thus obtained (ASM-01a-e) were directly used for 
the next step. 
 
? General synthetic procedure for the 2-hydroxypyrimidine derivatives 
(ASM-02a-e). 
 
 In a 100mL round bottom flask equipped with magnetic stirrer and 
thermometer was added nitric acid (60%) (10 mL). To the nitric acid slowly added 
ASM-01a-e (10 mmol) at 0 oC. After complete addition, the mixture was stirred at 
this temperature for 30 min. The progress of reaction was monitored by thin layer 
chromatography. The reaction mixture was poured into cold water and neutralized 
with saturated sodium bicarbonate solution. The solid separated was filtered, washed 
with water and dried. The crude products (ASM-02a-e) were directly used for the 
next step. 
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? General synthetic procedure for the 2-chloropyrimidine derivatives 
(ASM-03a-e). 
 
 In a 50mL round bottom flask equipped with magnetic stirrer and thermometer 
was placed ASM-02a-e (10 mmol) and POCl3 (15 mL). Reaction mixture heated up to 
reflux temperature and maintain for 2-3 hrs. The progress of reaction was monitored 
by thin layer chromatography. After completion of reaction, the mixture was poured 
in to crushed ice and neutralized with saturated sodium bicarbonate solution. The 
products was filtered, washed with water and dried. Crystallize crude product from 
methanol and used for next step without further purification. 
 
? General synthetic procedure for the 2-substitutedpyrimidine derivatives 
via Suzuki-Miyaura coupling (ASM-03a-e). 
 
 A mixture of 2-choropyrimidine derivatives ASM-03a-e (1.0 mmol) and 
phenylboronicacid derivatives (1.2 mmol) in 1,4-dioxane (12 mL) was stirred for 10 
min at rt. To this mixture, saturated solution of K2CO3 (8 mL) was added followed by 
tetrakis(triphenylphosphine)palladium(0) (5 mol%). The reaction mixture was heated 
at 110 oC for 5-8 hrs. After completion, the reaction mixture was cooled to room 
temperature, diluted with ethyl acetate and filtered through pad of celite. The filtrate 
was washed with water (2 x 100 mL) and brine solution (100 mL). The organic layer 
was separated, dried over anhydrous sodium sulfate, and filtered. The filtrate was 
evaporated to dryness under vacuo. The residue was purified by using column 
chromatography using EtOAc/Ether (0.5:9.5) to afford analytically pure products 
ASM-04a-e. 
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? Spectral data for the newly prepared compounds. 
 
Methyl 1,2-dihydro-6-isopropyl-2-oxo-4-phenylpyrimidine-5-carboxylate (ASM-
02a). White solid; Rf 0.45 (1:1 hexane-EtOAc); mp 158-160 °C; IR (KBr): 3459, 3070, 
2930, 2850, 1730, 1650, 1583, 1470, 1335, 1064, 760, 700 cm-1; 1H NMR (300 MHz, 
CDCl3): δ 1.42-1.44 (d, 6H, 2 x iprCH3), 3.20-3.26 (m, 1H, iprCH), 3.57 (s, 3H, 
OCH3), 7.44-7.51 (m, 3H, Ar-H), 7.58-7.60 (d, 2H, Ar-H, j=6.9Hz), 12.94 (s, 1H, 
OH); 13C NMR (DEPT):(75 MHz, CDCl3): 21.40, 31.31, 56.47, 56.58, 114.99, 
115.28, 131.85, 131.96; MS (m/z): 273 (M+); Anal. Calcd for C15H16N2O3: C, 66.16; 
H, 5.92; N, 10.29; Found: C, 66.13; H, 5.97; N, 10.27. 
 
Methyl 4-(4-fluorophenyl)-1,2-dihydro-6-isopropyl-2-oxopyrimidine-5-carboxyl-
ate (ASM-2e). White solid; Rf 0.48 (1:1 hexane-EtOAc); mp 180-182 °C; IR (KBr): 
3470, 3093, 2999, 1735, 1648, 1586, 1450, 1261, 755, 700, cm-1; 1H NMR (300 MHz, 
CDCl3): δ 1.14-1.16 (d, 6H, 2 x iprCH3), 3.06-3.11 (m, 1H, iprCH), 3.54 (s, 3H, 
OCH3), 6.92-6.98 (t, 2H, Ar-H), 7.29-7.40 (d, 2H, Ar-H), 8.0 (s, 1H, NH); 13C NMR 
(DEPT):(75 MHz, CDCl3): 20.82, 31.98, 52.28, 115.28, 115.56, 129.82, 129.93; MS 
(m/z): 291 (M+); Anal. Calcd for C15H15FN2O3: C, 62.06; H, 5.21; N, 9.65; Found: C, 
62.13; H, 5.17; N, 9.67. 
 
Methyl 2-chloro-4-isopropyl-6-phenylpyrimidine-5-carboxylate (ASM-03a). 
White solid; Rf 0.62 (8:2 hexane-EtOAc); mp 138-142 °C; IR (KBr): 3057, 3034, 
2972, 2931, 2872, 1828, 1726, 1687, 1572, 1541, 871, 767, 730, 702 cm-1; 1H NMR 
(300 MHz, CDCl3): δ 1.32-1.35 (d, 6H, 2 x iprCH3), 3.14-3.20 (m, 1H, iprCH), 3.72 
(s, 3H, OCH3), 7.43-7.48 (m, 3H, Ar-H), 7.65-7.67 (t, 2H, Ar-H);13C NMR (100 
MHz, CDCl3): 21.63, 33.62, 52.96, 123.49, 128.29, 128.78, 130.79, 136.37, 161.26, 
166.15, 167.88, 176.53; MS (m/z): 291 (M+); Anal. Calcd for C15H15FN2O3: C, 61.97; 
H, 5.20; N, 12.19; Found: C, 61.90; H, 5.17; N, 12.27. 
 
Methyl 2-(4-cyanophenyl)-4-isopropyl-6-phenylpyrimidine-5-carboxylate (ASM-
04a). White solid; Rf 0.72 (8:2 hexane-EtOAc); mp 108-110 °C; IR (KBr): 3194, 3154, 
2976, 2929, 2290, 1722, 1683, 1456, 1300, 858, 829, 777, 698 cm-1; 1H NMR (400 
MHz, CDCl3): δ 1.16-1.32 (d, 6H, 2 x iprCH3), 3.15-3.19 (m, 1H, iprCH), 3.66 (s, 3H, 
OCH3), 7.39-7.42 (m, 3H, Ar-H), 7.65-7.70 (m, 4H, Ar-H), 8.61-8.63 (d, 2H, Ar-H, 
j=7.8Hz); 13C NMR (100 MHz, CDCl3): 21.93, 29.69, 33.55, 52.80, 114.18, 
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118.87, 123.36, 128.34, 128.72, 129.07, 130.34, 132.31, 137.82, 141.45, 162.01, 
163.63, 168.77, 172.48; MS (m/z): 358 (M+); Anal. Calcd for C22H19N3O2: C, 73.93; 
H, 5.36; N, 11.76; Found: C, 73.90; H, 5.37; N, 11.77. 
 
Methyl 2-(3-(dimethylamino)phenyl)-4-isopropyl-6-p-tolylpyrimidine-5-carboxy-
late (ASM-04b). White solid; Rf 0.76 (8:2 hexane-EtOAc); mp 122-124 °C; IR (KBr): 
3150, 2980, 2867, 1728, 1578, 1520, 1480, 1258, 780, 708  cm-1; 1H NMR (300 MHz, 
DMSO): δ 1.30-1.32 (d, 6H, 2 x iprCH3), 2.38 (s, 3H, CH3), 2.97 (s, 6H, CH3), 3.13-
3.15 (m, 1H, iprCH), 3.74 (s, 3H, OCH3), 6.94-6.95 (d, 1H, Ar-H,  j=2.1Hz), 7.32-
7.37 (m, 3H, Ar-H), 7.60-7.63 (m, 2H, Ar-H, j=8.4Hz), 7.78-7.80 (d, 1H, Ar-H, 
j=7.8Hz), 7.85-7.87 (m, 1H, Ar-H); MS (m/z): 391 (M+); Anal. Calcd for C24H27N3O2: 
C, 74.01; H, 6.99; N, 10.79; Found: C, 74.02; H, 6.97; N, 10.77. 
 
Methyl 2-(4-fluorophenyl)-4-isopropyl-6-(4-methoxyphenyl)pyrimidine-carboxy-
late (ASM-04c). White solid; Rf 0.80 (8:2 hexane-EtOAc); mp 148-150 °C; IR (KBr): 
3158, 2967, 2850, 1735, 1558, 1503, 1430, 1268, 748, 698  cm-1; MS (m/z): 381 (M+); 
Anal. Calcd for C22H21FN2O3: C, 69.46; H, 5.56; N, 7.36; Found: C, 69.45; H, 5.57; 
N, 7.37. 
 
Methyl 4-isopropyl-2-(4-methoxyphenyl)-6-(3-nitrophenyl)pyrimidine-5-carboxy 
-late (ASM-04d). Yellow solid; Rf 0.75 (8:2 hexane-EtOAc); mp 104-106 °C; IR 
(KBr): 3130, 3053, 2986, 2832, 1726, 1548, 1498, 1369, 1238, 700 cm-1; MS (m/z): 
408 (M+); Anal. Calcd for C22H21FN2O3: C, 64.86; H, 5.20; N, 10.31; Found: C, 
64.84; H, 5.20; N, 10.32. 
 
Methyl 4-(4-fluorophenyl)-6-isopropyl-2-phenylpyrimidine-5-carboxylate (ASM-
04e). White solid; Rf 0.84 (8:2 hexane-EtOAc); mp 134-136°C; IR (KBr): 3030, 2925, 
2832, 1726, 1553, 1430, 1238, 720, 678 cm-1; MS (m/z): 352 (M+); Anal. Calcd for 
C21H19FN2O2: C, 71.98; H, 5.47; N, 8.00; Found: C, 71.94; H, 5.46; N, 8.02. 
 
Methyl 2-(3-(dimethylamino)phenyl)-4-isopropyl-6-phenylpyrimidine-5-carboxy-
late (ASM-04f). White solid; Rf 0.69 (8:2 hexane-EtOAc); mp 162-168 °C; IR (KBr): 
3093, 2999, 1648, 1586, 1261, 1061, 758  cm-1; MS (m/z): 376 (M+); Anal. Calcd for 
C23H25N3O2: C, 73.57; H, 6.71; N, 11.19; Found: C, 73.56; H, 6.72; N, 11.22. 
 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
Department of Chemistry, Saurashtra University, Rajkot-360005   29 
 
 
Methyl 2-(4-fluorophenyl)-4-isopropyl-6-p-tolylpyrimidine-5-carboxylate (ASM-
04g). White solid; Rf 0.73 (8:2 hexane-EtOAc); mp 117-119 °C; IR (KBr): 3083, 2958, 
1731, 1503, 1430, 1352, 1282, 1050 698 cm-1; MS (m/z): 365 (M+); Anal. Calcd for 
C22H21FN2O2: C, 72.51; H, 5.21; N, 7.69; Found: C, 72.56; H, 5.22; N, 7.62. 
   
Methyl 4-isopropyl-2,6-bis(4-methoxyphenyl)pyrimidine-5-carboxylate (ASM-
04h). Yellow solid; Rf 0.77 (8:2 hexane-EtOAc); mp 171-173 °C; IR (KBr): 3028, 
2924, 2868, 1729, 1523, 1480, 1430, 1268, 720 cm-1; MS (m/z): 392 (M+); Anal. 
Calcd for C23H24N2O4: C, 70.39; H, 6.16; N, 7.14; Found: C, 70.40; H, 6.12; N, 7.12. 
 
Methyl 4-isopropyl-6-(3-nitrophenyl)-2-phenylpyrimidine-5-carboxylate (ASM-
04i). Yellow solid; Rf 0.80 (8:2 hexane-EtOAc); mp 182-184 °C; IR (KBr): 3056, 
2967, 2850, 1735, 1505, 1480, 1320, 1252, 763 cm-1; MS (m/z): 378 (M+); Anal. 
Calcd for C21H19N3O4: C, 66.83; H, 5.07; N, 11.13; Found: C, 66.84; H, 5.06; N, 
11.12. 
 
Methyl 2-(4-cyanophenyl)-4-(4-fluorophenyl)-6-isopropylpyrimidine-5-carboxy-
late (ASM-04j). White solid; Rf 0.85 (8:2 hexane-EtOAc); mp 98-100 °C; IR (KBr): 
3058, 2931, 2858, 2235, 1725, 1522, 1492, 1268, 758, 704 cm-1; MS (m/z): 376 (M+); 
Anal. Calcd for C22H18FN3O2: C, 70.39; H, 4.83; N, 11.19; Found: C, 70.37; H, 4.86; 
N, 11.17. 
 
Methyl 4-isopropyl-2-(4-methoxyphenyl)-6-phenylpyrimidine-5-carboxylate (AS 
M-04k). White solid; Rf 0.74 (8:2 hexane-EtOAc); mp 131-133 °C; IR (KBr): 3083, 
2954, 2825, 1731,1600, 1536, 1458, 1368, 1020, 738  cm-1; MS (m/z): 362(M+); Anal. 
Calcd for C22H22N2O3: C, 72.91; H, 6.12; N, 7.73; Found: C, 72.91; H, 6.14; N, 7.74. 
 
Methyl 4-isopropyl-2-phenyl-6-p-tolylpyrimidine-5-carboxylate (ASM-04l). 
Yellow solid; Rf 0.83 (8:2 hexane-EtOAc); mp 143-145°C; IR (KBr): 3126, 2999, 
1740, 1648, 1586, 1261, 1061, 720, 658 cm-1; MS (m/z): 346(M+); Anal. Calcd for 
C22H22N2O2: C, 76.28; H, 6.40; N, 8.09; Found: C, 76.29; H, 6.41; N, 8.11. 
 
Methyl 2-(4-cyanophenyl)-4-isopropyl-6-(4-methoxyphenyl)pyrimidine-5-carbo- 
xylate (ASM-04m). Brown solid; Rf  0.72 (8:2 hexane-EtOAc); mp 177-179 °C; IR 
(KBr): 3064, 2935, 2831, 1728, 1558, 1503, 1430, 1268, 883, 778 cm-1; MS (m/z):  
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387 (M+); Anal. Calcd for C23H21N3O3: C, 71.30; H, 5.46; N, 10.85; Found: C, 71.31; 
H, 5.44; N, 10.86. 
 
Methyl 2-(3-(dimethylamino)phenyl)-4-isopropyl-6-(3-nitrophenyl)pyrimidine-5-
carboxylate (ASM-04n). Yellow solid; Rf  0.82 (8:2 hexane-EtOAc); mp 152-157 °C; 
IR (KBr): 3123, 2999, 2863,1731,1648, 1586, 1261, 1053, 850, 738, cm-1; MS (m/z): 
420 (M+); Anal. Calcd for C23H24N4O4: C, 65.70; H, 5.75; N, 13.33; Found: C, 65.71; 
H, 5.74; N, 13.36. 
 
Methyl 2,4-bis(4-fluorophenyl)-6-isopropylpyrimidine-5-carboxylate (ASM-04o). 
White solid; Rf 0.68 (8:2 hexane-EtOAc); mp 194-196 °C; IR (KBr): 3135, 3089, 
2856, 1726, 1580, 1436, 1358, 1050, 780, cm-1; MS (m/z): 368 (M+); Anal. Calcd for 
C21H18F2N2O2: C, 68.47; H, 4.93; N, 7.60; Found: C, 68.48; H, 4.94; N, 7.61. 
 
Methyl 4-isopropyl-2,6-diphenylpyrimidine-5-carboxylate (ASM-04p). White 
solid; Rf  0.74 (8:2 hexane-EtOAc); mp 132-134°C; IR (KBr): 3120, 3025, 2868, 1745 
1600, 1480, 1380, 1068, 790, 745, cm-1; MS (m/z): 332 (M+); Anal. Calcd for 
C21H20N2O2: C, 75.88; H, 6.06; N, 8.43; Found: C, 75.87; H, 6.06; N, 8.44. 
 
Methyl 2-(4-cyanophenyl)-4-isopropyl-6-p-tolylpyrimidine-5-carboxylate (ASM-
04q). Yellow solid; Rf 0.78 (8:2 hexane-EtOAc); mp 114-116 °C; IR (KBr): 3051, 
2967, 2850, 2253, 1725, 1568, 1503, 1430, 1268, 748, 698 cm-1; MS (m/z): 371 (M+); 
Anal. Calcd for C23H21N3O2: C, 74.37; H, 5.70; N, 11.31; Found: C, 74.38; H, 5.71; 
N, 11.34. 
 
Methyl 2-(3-(dimethylamino)phenyl)-4-isopropyl-6-(4-methoxyphenyl)pyrimidi-
ne-5-carboxylate (ASM-04r). White solid; Rf 0.84 (8:2 hexane-EtOAc); mp 198-200 
oC; IR (KBr): 3068, 2983, 2899, 1728, 1648, 1586, 1261, 1061, 780, 712 cm-1; 1H 
NMR (300 MHz, DMSO): δ 1.30-1.32 (d, 6H, 2 x iprCH3), 2.97 (s, 6H, CH3), 3.11-
3.16 (m, 1H, iprCH), 3.76-7.83 (s, 6H, OCH3), 6.91-6.95 (dd, 1H, Ar-H, j=2.1Hz,  
j=2.7Hz), 7.09-7.12 (d, 2H, Ar-H, j=9.0Hz), 7.32-7.37 (t, 2H, Ar-H), 7.69-7.72 (d, 
2H, Ar-H, j=9.0Hz), 7.78-7.80 (d, 1H, Ar-H, j=7.8Hz); 7.86 (s, 1H, Ar-H); MS (m/z): 
406 (M+); Anal. Calcd for C24H27N3O3: C, 71.09; H, 6.71; N, 10.36; Found: C, 71.07; 
H, 6.73; N, 10.37. 
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Methyl 2-(4-fluorophenyl)-4-isopropyl-6-(3-nitrophenyl)pyrimidine-5-carboxy-
late (ASM-04s). White solid; Rf  0.73 (8:2 hexane-EtOAc); mp 145-147 °C;IR (KBr): 
3021, 2856, 1725, 1648, 1422, 1369, 1254, 1068, 790, 720 cm-1; MS (m/z): 395 (M+); 
Anal. Calcd for C21H18FN3O4: C, 63.79; H, 4.59; N, 10.63; Found: C, 63.79; H, 4.58; 
N, 10.64. 
 
Methyl 4-(4-fluorophenyl)-6-isopropyl-2-(4-methoxyphenyl)pyrimidine-5-carbo-
xylate (ASM-04t). White solid; Rf 0.85 (8:2 hexane-EtOAc); mp 103-105 °C; IR 
(KBr): 3158, 3036, 2869, 1735, 1658, 1450, 1356, 800, 720 cm-1; MS (m/z): 380 
(M+); Anal. Calcd for C22H21FN2O3: C, 69.46; H, 5.56; N, 7.36; Found: C, 69.45; H, 
5.58; N, 7.34. 
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1H NMR spectrum of compound ASM-02a 
 
 
1H NMR spectrum of compound ASM-03a 
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1H NMR spectrum of compound ASM-04a 
 
 
Expanded 1H NMR spectrum of compound ASM-04a 
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1H NMR spectrum of compound ASM-04b 
 
 
Expanded 1H NMR spectrum of compound ASM-04b 
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1H NMR spectrum of compound ASM-04r 
 
 
Expanded 1H NMR spectrum of compound ASM-04r 
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13C NMR spectrum of compound ASM-04a 
  
 
Expanded 13C NMR spectrum of compound ASM-04a 
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Mass spectrum of compound ASM-03b 
 
 
Mass spectrum of compound ASM-03e 
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Mass spectrum of compound ASM-04a 
 
 
Mass spectrum of compound ASM-04s 
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IR spectrum of compound ASM-03a 
 
 
IR spectrum of compound ASM-04a 
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Synthesis and Biological Activity of
Novel Pyrimidine Derivatives via Wittig
Reaction in Aqueous Media
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2.1 Introduction 
 
 As described in chapter-1 the pyrimidine scaffold represents an important 
pharmacophore endowed with a wide range of pharmacological activities according to 
the specific decoration of the heterocycle. Nitrogen-containing heterocycles are 
widely distributed in nature and are essential to life, playing a vital role in the 
metabolism of all living cells. Among these, pyrimidines represent one of the most 
prevalent heterocycles found in natural products such as amino acid derivatives 
(willardiine, tingitanine),1 vitamins (vitamin B1),2 antibiotics (bacimethrin, 
sparsomycin, bleomycin),3 alkaloids (heteromines, crambescins, manzacidins, 
variolins, meridianins, psammopemmins etc.),4 and toxins.5 From a synthetic point of 
view, the first pyrimidine derivative (alloxan) was obtained as early as 1818, by 
Brugnatelli, oxidizing uric acid with HNO3.6 In 1848, a second pyrimidine synthesis 
was pioneered by Frankland and Kolbe, who heated propionitrile with metallic 
potassium to give a pure product (2,6-diethyl-5-methyl-4-pyrimidinamine),7 while in 
1878 Grimaux prepared barbituric acid by condensation of malonic acid with urea. 
The latter procedure has been later named after Pinner who gave the name to the 
pyrimidine scaffold and was the first to understand the chemical nature of this 
structure. Pyrimidine nucleus present in rosuvastatin (Figure-1),8 which is member of 
drug class of statins, used to treat high cholesterol and related condition to prevent 
cardiovascular diseases. 
 
Figure-1 
 Due to the long-lasting interest in pyrimidine derivatives as potential drugs, 
the synthetic community has dedicated much effort to the investigation of new 
approaches to those derivatives. Accordingly, we have described here an overview of 
the most interesting synthetic strategies recently reported for the generation of highly 
functionalized pyrimidines. 
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2.2 A literature review on the biological activity associated with 
pyrimidine derivatives 
 
 In medicinal chemistry pyrimidine derivatives have been very well known for 
their therapeutic applications. Many pyrimidine derivatives have been developed as 
chemotherapeutic agents. Over the years, the pyrimidine system turned out to be an 
important pharmacophore endowed with drug like properties and a wide range of 
pharmacological activities depending on the decoration of the scaffold. A few 
illustrative examples of pyrimidine derivatives active as inhibitors of HIV,9 HCV,10 
CDK,11 CB2,12 VEGFR13 and Adenosine A1/A2a/A314 are reported in Figure-2.  
Figure-2 
 Microbes are causative agents for various types of disease like pneumonia, 
amoebiasis, typhoid, malaria, common cough and cold various infections and some 
severe diseases like tuberculosis, influenza, syphilis, and AIDS as well. Various 
approaches were made to check the role of pyrimidine moiety as antimicrobial agent 
from the discovery of molecule to the present scenario. Naik et al.15 synthesized 2-[{2 
(Morpholino)-3-pyridinyl-5-thio}-2-oxoethyloxadiazolyl]-amino-4-(2,4-dichloro-5- 
fluorophenyl)-6-(aryl)pyrimidines, which exhibit maximum zone of inhibition against 
E.coli, S. aureus, S.typhiiand B.subtilis (Figure-3).  
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Figure-3 
 Mishra et al.16 have synthesized various derivatives of pyrimidines. The 
fungicidal activities of the compound were evaluated against P. infestans and C. 
falcatum by the usual agar plate method (Figure-4).  
NH
N O
O
R'
N
N NH
R
 
Figure-4 
 The pyrimidine moiety with some substitution showed to have promising 
antitumor activity as there are large numbers of pyrimidine based antimetabolites. The 
structural modification may be on the pyrimidine ring or on the pendant sugar groups. 
Early metabolite prepared was 5-fluorouracil,17 a pyrimidine derivative followed by 
5-thiouracil which also exhibits some useful antineoplastic activities (Figure-5).18 
 
Figure-5 
 Palwinder Singh et al.19 has reacted 5-benzoyl/5-carbaldehyde-/5-(3-phenyl 
acryloyl)-6-hydroxy-1H-pyrimidine-2,4diones with amines provided the 
corresponding enamines (Figure-6). The investigation for anticancer activity of 
molecule at 59 human tumor cell lines was done representing leukemia, melanoma 
and cancer of lung, colon, brain, ovary, breast as well as kidney.  
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Figure-6 
 Stephanepedeboscq et al.20 has synthesized 4-(2-Methylanilino) 
benzo[b]thieno[2,3-d]pyrimidine (1) and 4-(2-Methoxyanilino)benzo[b]thieno[2,3-d] 
pyrimidine (2) (Figure-7), which showed a similar cytotoxicity to the standard anti-
EGFR geftinib suggesting a blockade of the EGFR pathway by binding to the tyrosine 
kinase receptor. 
NH2
S
N
N
NH
R2
R1
R1=CH3, R2=H for (1)
R1=OCH3, R2=H for (2)  
Figure-7 
 Fathalla et al.21 has synthesized a series of some new pyrimidine derivatives 
like 7-(2-methoxyphenyl)-3-methyl-5-thioxo-5, 6-dihydro[1, 2, 4]-triazolo[4,3-c] 
pyrimidine-8-carbo-nitrile via reaction of ethyl cyanoacetate with thiourea and the 
appropriate aldehydes namely 2-methyl-benzaldehyde and 2-methoxy-benzaldehyde 
followed reaction with different reagents. All structures were than screened for 
bacterial activity and anticancer activity (Figure-8).  
N NH
N
N
S
CN
OCH3
 
Figure-8 
 Pyrimidine has a remarkable pharmacological efficiency and therefore an 
intensive research has been focused on anti-inflammatory activity of pyrimidine 
nucleus. Recently two PCT international applications have been filed for 2-
thiopyrimidine derivatives possessing potent activity against inflammation and 
immune disorders.22 
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 Padama shale et al.23 have been reported Naphtho[2,1-b]furo[3,2-d]pyrimidine 
and Carrageen induced rat paw edema method was employed for evaluating the anti- 
inflammatory activity. The compounds were given at a dose of 80 mg/kg body weight 
in albino rats weighing between 150 and 200 g. The oedema was produced by 
injecting carrageenan solution at the left hind paw (Figure-9).  
O
N
N
R
R1  
Figure-9 
 Lee et al.24 has synthesized some novel pyrimidines derivative having 
thiazolidinedione. These compounds were evaluated for their glucose and lipid 
lowering activity using pioglitazone and rosiglitazone as reference compound. 
Desenko et al.25 has synthesized azolopyrimidine derivatives and compounds were 
evaluated for hypoglycemic activity (Figure-10).  
N
N
N
 
Figure-10 
 Many pyrimidine ring containing drugs have exhibited antihypertensive 
activity. A quinozoline derivative, prazosin, is a selective α1-adrenergic antagonist.26 
Its related analogues bunazosin,27 trimazosin28 and terazosin29 are potent 
antihypertensive agents(Figure-11).  
N
N
NH2
N
N
R
O
O
R= O
Et
for Prazocin
R= CH2OOCH2COH(CH3)2 for Bunazosin
R= COCH2CH2CH3 for Trimazosin
O
O
for Terazosin
R=
 
Figure-11 
 Ketanserin30 has a similar effect and is an antagonist of both a1-adrenergic and 
serotonin-S2 receptors. A triaminopyrimidine derivative, minoxidil,  
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whose mechanism of action and therapeutic action are similar to prazosin, has been 
introduced in therapy for its side effects, in the treatment of alopecia, male baldness 
etc (Figure-12).31 
 
Figure-12 
 Rahaman et al.32 has synthesized novel pyrimidines by the condensation of 
chalcones of 4΄-piperazine acetophenone with guanidine HCl (Figure-13). It showed 
significant antihistaminic activity when compared to the reference antihistaminic drug 
mepiramine.  
N N
NH2
R
N
HN
 
Figure-13 
 A small library of 20 tri-substituted pyrimidines was synthesized by Anu et 
al.33 evaluated for their in vitro anti-malarial and anti-tubercular activities. Out of all 
screened compound, 16 compounds have shown in-vitro anti-malarial activity against 
Plasmodium falciparum in the range of 0.25- 2μg/ml and 8 compounds have shown 
anti-tubercular activity against Mycobacterium tuberculosis at a concentration 12.5 
μg/ml (Figure-14). 
 
Figure-14 
 Apart from these activities, pyrimidines also possess diuretic, antianthelmentic 
and calcium channel blocking activity.34 
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2.3 Various synthetic approaches for highly substituted 
pyrimidines 
  
 A brief literature review on the new synthetic strategies for pyrimidine 
derivatives is presented as follows. 
 In recent years, several interesting Pinner-like approaches have been 
developed: Karpov and Muller have been reported the employment of alkynones (β-
keto aldehydes’ synthetic equivalents) in a three-component one-pot pyrimidine 
synthesis (Figure-15).35 The coupling of acid chlorides (1) with terminal alkynes (2) 
under modified Sonogashira conditions (Et3N used in stoichiometric amount) 
followed by the addition of aminium or guanidinium salts (4) in the presence of 
sodium carbonate gave the 2,4-disubstituted or 2,4,6-trisubstituted pyrimidines (5). 
 
Figure-15 
 Kiselyov36 was reported an efficient one-pot approach for the synthesis of 
2,4,5,6-tetrasubstituted pyrimidines (Figure-16). Reaction of alkyl- or 
benzylphosphonates with aryl nitriles formed unstable aza-Wittig species which were 
converted into α,β-unsaturated imines by reaction with aromatic aldehydes. The latter 
intermediates were converted into the desired pyrimidine derivatives after 
nucleophilic attack by a bidentate nuclophile, usually guanidine or amidine. 
Figure-16 
 Mohammad Movassaghi et al.37 has described a procedure for the synthesis of 
pyrimidine derivatives. It was applicable to a wide range of secondary amides and 
nitriles using 2-chloropyridine as a base additive in the presence of Tf2O (Figure-17). 
 
Figure-17 
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 T. Sasada et al.38 have been reported a ZnCl2-catalyzed three-component 
coupling reaction allows the synthesis of various 4,5-disubstituted pyrimidine 
derivatives in a single step from functionalized enamines, triethylorthoformate, and 
ammonium acetate (Figure-18). The procedure can be successfully applied to the 
efficient synthesis of mono- and disubstituted pyrimidine derivatives, using methyl 
ketone derivatives instead of enamines. 
R
R'H2N
or
R
OR'
3 eq. HC(OEt)3
2 eq. NH4OAc
0.1 eq. ZnCl2
Toluene
100 oC, 3- 72 hrs
N
N
R
R'
 
Figure-18 
 M. G. Barthakur et al.39 have been developed a novel and efficient synthesis of 
pyrimidine from β-formylen amide involves samarium chloride catalyzed cyclization 
of β-formelene amides using urea as source of ammonia under microwave irradiation 
(Figure-19). 
 
Figure-19 
 P. Zhichkin et al.40 described a method for the synthesis of 2-substituted 
pyrimidine-5-carboxylic esters. The sodium salt of 3, 3-dimethoxy-2-
methoxycarbonylpropen-1-ol has been found to react with a variety of amidinium 
salts to afford the corresponding 2-substituted pyrimidine-5-carboxylic esters 
(Figure-20). 
 
Figure-20 
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2.4 Applications of Wittig reaction 
 The Wittig reaction occupies a central role in organic synthesis as it generates 
double bond with high level of stereocontrol: non stabilized ylides give high Z-
selectivity, where as stabilized ylides furnish high E-selectivity.41 Here we discuss 
various synthetic approaches for synthesize new chemical entities via Wittig reaction.  
 R. Antonioletti et al.42 have developed a mild and practical procedure for the 
Wittig olefination, promoted by lithium hydroxide and triphenylbenzyl phosphonium 
bromide, has been set up for the synthesis of stilbenes and styrenes (Figure-21). 
P
Ph
Ph
Ph
Br R CHO
LiOH·H2O
Solvent, refulx
R
E/Z isomer  
Figure-21 
 Jesse Dambacher et al.43 has reported that water is demonstrated to be an 
excellent medium for the Wittig reaction employing stabilized ylides and aldehydes. 
Although the solubility in water appears to be an unimportant characteristic in 
achieving good chemical yields and E/Z-ratios, the rate of reactions in water is 
unexpectedly accelerated (Figure-22). 
 
Figure-22 
 Elsie Ramirez et al.44 have been developed a highly efficient and rapid 
protocol for the preparation of the unsaturated 7,3-lactone-a-D-xylofuranose 
derivatives (Versatile chiral synthon for naturally important compounds) via selective 
Wittig olefination in aqueous media (Figure-23). 
 
Figure-23 
 James McNulty et al.45 has reported direct synthesis of 1,3-dienes and 1,3,5-
trienes from the reaction of semi-stabilized ylides via Wittig reaction under aqueous 
media employing sodium hydroxide as base (Figure-24). 
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Figure-24 
 De-Jun Dong et al.46 have developed a simple and efficient protocol to 
improve the stereoselectivity significantly for the olefination reaction of semi-
stabilized triphenylphosphonium ylides by replacing the aldehydes used in the Wittig 
reaction with N-sulfonyl imines, which possess distinct electronic and steric 
properties relative to aldehydes (Figure-25). 
 
Figure-25 
 Douglass F. Taber et al.47 were utilized a Potassium hydride in paraffin KH(P) 
as a base in  Wittig condensation of phosphonium salt with aromatic, aliphatic, and 
α,β-unsaturated aldehydes in THF proceeds with high Z selectivity (Figure-26). 
 
Figure-26 
 Fulvia Orsini et al.48 has synthesized α,β-unsaturated esters in open 
atmosphere via mild and efficient one-pot Wittig reactions performed in both water 
and sodium dodecyl sulfate (SDS)-water solution(Figure-27). 
Figure-27 
 Y.k. Liu et al.49 has discovered a highly stereoselective tandem Michael 
addition-Wittig reaction of (3-carboxy-2-oxopropylidene) triphenylphosphorane and 
α,β-unsaturated aldehydes gives multifunctional 6-carboxycyclohex-2-en-1-ones in 
excellent diastereo- and enantioselectivities by employing the combined catalysis of a 
bulky chiral secondary amine, LiClO4, and DABCO (Figure-28). 
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Figure-28 
 Peter Shu-Wai Leung et al.50 have developed chromatography free Wittig 
reaction by utilizing newly prepared bifunctional polymeric reagents , in this 
phosphine and amine functionalized material was used in one-pot Wittig reactions 
with an aldehyde and either an r-halo-ester, -ketone, or -amide. Due to the 
heterogeneous nature of the polymer, the desired alkene product of these reactions 
could be isolated in excellent yield in essentially pure form (Figure-29). 
Figure-29 
 A. El-Batta et al.51 was carried out Wittig reactions in water media employing 
stabilized ylides with aldehydes. They described the use of a saturated aqueous 
NaHCO3 solution to achieve the aqueous one pot Wittig reactions at +20 to 90°Cusing 
Ph3P, R-bromoesters, and aromatic carboxaldehydes (Figure-30). 
 
Figure-30 
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2.5 Application of sodium tripolyphosphate 
 
 Sodium tripolyphosphate (STPP) is white powder an inorganic compound 
with formula Na5P3O10. It is the sodium salt of the polyphosphate  penta-anion, which 
is the conjugate base of triphosphoric acid (Figure-31). STPP is widely used in 
detergents, and as a preservative for seafood, meats, poultry, and animal feeds. It is 
also use in ceramics, anticaking, setting retarders, flame retardants, paper, 
anticorrosion pigments, textiles, rubber manufacture, fermentation, antifreeze. 
 
Figure-31 
 There is some limited application of STTP in organic synthesis; however 
Zhiqiang Zhang et al.52 have described a conversion of methyl lactate to acrylic acid, 
methyl acrylate and lactic acid via various reactions such as dehydration, 
decomposition, decarbonylation, hydrolysis and esterification has been determined by 
using sodium tripolyphosphate as a catalyst.  
 Tert-butyl-2-bromoacetate was synthesized by a reaction of 2-bromoacetyl 
chloride with tert-butanol at room temp used stoichiometric sodium tripolyphosphate 
as catalyst and acid-scavenger, chloroform as solvent to afford 93% yield.53 α-
Bromoisobutyric acid tert-butyl ester was synthesized by reaction of tert-Bu alc. with 
α-bromoisobutyryl bromide using stoichiometric sodium tripolyphosphate as a base to 
afford 96.5% yield.54 
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2.6 Current research work 
 
 As described in earlier, the chemistry of pyrimidines is one of the most widely 
studied subjects because of the occurrence of such heterocycles in biologically 
relevant systems such as nucleic acids, cofactors, various toxins, and other products. 
Pyrimidine derivatives are biologically interesting molecules that have established 
utility for the treatment of Alzheimer’s disease and proliferative disorders; they are 
also capable of showing antiviral activity, anti-HIV agents, anti hypertensive agents, 
antimicrobial agents and fungicide. The witting product of pyrimidine derivatives 
such as rosuvastatin and its salt, which are HMG-CoA reductase inhibitor and useful 
in treatment of hypercholesteromia, hyperlipoproteinemia and atherosclerosis.  
 The Wittig olefination reaction is regarded as one of the most strategic, widely 
applicable carbon–carbon double bond-forming processes available in organic 
synthesis. This reliable reaction allows for olefination with complete positional 
selectivity, predictable chemoselectivity and may be conducted in many cases with 
reliable and high stereocontrol. 
 Nowadays, a great deal of effort has been focused on the field of green 
chemistry in adopting methods and processes. As a part of this “green” concept, toxic 
and/or flammable organic solvents are replaced by alternative non-toxic and 
nonflammable media. In this context, many efforts have been made to use aqueous 
media. Among alternative green solvents, water has been the solvent of choice for a 
variety of transformations. 
 During the course of our ongoing interest on the synthesis various 
heterocycles and development of useful synthetic methodology, we have developed a 
small library of pyrimidines via Wittig reaction using sodium tripolyphosphate as 
base in aqueous media. The newly synthesized compounds were characterized by IR, 
Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. All the newly 
synthesized compounds were evaluated for their antimicrobial activity. 
 
 
 
 
 
 
 
Chapter 2                                               Synthesis of substituted pyrimidines via Wittig  
Department of Chemistry, Saurashtra university, Rajkot-360005   57 
 
 
2.7 Results and discussion                   
Scheme:-1 Synthesis of pyrimidine derivatives via Wittig reaction in aqueous        
media. 
N
NCl
O
O
F
N
NCl
OH
F
DIBAL 1) PBr3/MDC
Wittig reaction
N
NCl
P
F
Br
N
NCl
F
R
ASM-3e INT-01 INT-02
AW-01 to AW-20
STPP
R-CHO
2) TPP/TolueneToluene
Water
 
 The synthetic route for the targeted compounds (AW-01 to AW-20) is shown 
in Scheme 1. Compound ASM-03e was prepared by following the methods described 
in chapter-1. The reaction of ASM-03e with diisobutylaluminium hydride (DIBAL) in 
toluene at 0 oC for 3 h. afforded (2-chloro-4-(4-fluorophenyl)-6-isopropyl pyrimidin-
5-yl)methanol (INT-01) in good yield. INT-01 was then treated with phosphorous 
tribromide in MDC at 0-5 oC for 2-3 h. The crude oily residue was reacted with 
triphenyl phosphine in toluene at reflux temperature for 3-4 h. to afford triphenyl[2-
chloro-{4-(4-flourophenyl)-6-isopropyl-pyrimidin-5-ylmethyl}phosphonium]bromide 
(INT-02) in excellent yield.  
 Optimization for reaction condition the pyrimidine phosphorous ylide (INT-
02) was treated with benzaldehyde using various bases such as NaH2PO4, Na2HPO4, 
and sodium tripolyphosphate in three different solvents, DMSO, THF, and water 
(Table-1). Sodium tripolyphosphate as base in aqueous media was found to be an 
effective method to afford highly (E)-selective product of AW-01 in moderate to good 
yield (Table-1). 
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Table 1: Optimization of reaction condition for synthesis of Aw-01 using variety                        
of bases and solvents. 
Entry Base Solvents Yield Time hrs. 
1 NaH2PO4 DMSO 65 7.0 
2 NaH2PO4 THF 70 7.5 
3 NaH2PO4 water 76 5.0 
4 Na2HPO4 DMSO 68 6.5 
5 Na2HPO4 THF 77 6.0 
6 Na2HPO4 water 80 4.5 
7 Na5P3O10 DMSO 85 7.0 
8 Na5P3O10 THF 83 5.0 
9 Na5P3O10 water 90 3.0 
 
 The structure of INT-01 was established on the basis of their elemental 
analysis and spectral data (MS, IR, 1HNMR, and 13C NMR). The analytical data for 
INT-01 revealed a molecular formula C14H14ClFN2O (m/z 280). The 1H NMR 
spectrum revealed doublet at δ = 1.30-1.33 ppm assigned to isopropyl-CH3, a singlet 
at δ = 2.09 ppm assigned to the –OH protons, a multiplet at δ = 3.67-3.69 ppm 
assigned to the isopropyl -CH protons, a singlet at δ = 4.69 ppm assigned to the –CH2 
protons, two triplet at δ = 7.28-7.34 ppm and 7.88-7.92 assigned to the aromatic 
protons. 
 The structure of INT-02 was established on the basis of their elemental 
analysis and spectral data (MS, IR, 1H NMR, and 13C NMR). Structure INT-02 was 
supported by its mass (m/z 605), which agrees with its molecular formula 
C32H28BrClFN2P, its 1H NMR spectrum had signals at δ = 0.90 (s, 6H, 2 x iprCH3), 
2.99-3.03 (m, 1H, iprCH), 5.67 (s, 2H, CH2), 6.97-7.02 (t, 2H, Ar-H), 7.26-7.33 (m, 
8H, Ar-H), 7.57 (s, 6H, Ar-H), 7.75-7.80 (m, 3H, Ar-H). 
 Reaction of pyrimidine phosphorous ylide (INT-02) with various 
benzaldehydes using Sodium tripolyphosphate as base in aqueous media to afford 
highly (E)-selective product AW-01 to AW-20 in moderate to excellent yield. 
Require reaction time and obtained (%) of yield summarized in Table-2. 
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Table-2: Synthesis of substituted pyrimidines via Wittig reaction using sodium 
     tripolyphosphate under aqueous media. 
Entry R Yield (%) Time hrs 
AW-01 C6H4 90 3.0 
AW-02 4-NO2C6H4 92 2.5 
AW-03 4-ClC6H4 84 3.0 
AW-04 C5H4S 89 3.5 
AW-05 C5H4O 90 4.0 
AW-06 C8H7N 82 3.5 
AW-07 2-NO2C6H4 79 3.0 
AW-08 4-ClC6H4 85 3.5 
AW-09 3-0CH3,4-OHC6H4 93 3.5 
AW-10 3,4-di-OCH3C6H3 95 3.0 
AW-11 4-N(CH3)2C6H4 82 3.0 
AW-12 4-FC6H4 83 3.5 
AW-13 3-NO2C6H4 94 4.0 
AW-14 4-BrC6H4 90 4.5 
AW-15 2-OHC6H4 88 3.0 
AW-16 4-OCH3C6H4 76 3.5 
AW-17 2,5-di-OCH3C6H3 89 3.0 
AW-18 3-BrC6H4 83 4.0 
AW-19 4-ClC6H4 81 3.0 
AW-20 3-OHC6H4 77 4.0 
 
 The structure of AW-01 to AW-20 was established on the basis of their 
elemental analysis, spectral data (MS, IR, 1H NMR, and 13C NMR) and (E)-selectivity 
of products was supported by NMR spectrum. Structure of AW-02 was supported by 
its mass (m/z 398), which agrees with its molecular formula C21H17ClFN3O2, its 1H 
NMR spectrum had signals at δ = 1.34-1.36 (d, 6H, 2 x iprCH3), 3.44-3.49 (m, 1H, 
iprCH), 6.55-6.61 (d, 1H, j=16.5Hz, ethylene-H), 7.08-7.17 (m, 3H, Ar-H & ethylene-
H), 7.48-7.51 (d, 2H, j=20.4Hz, Ar-H), 7.64-7.68 (t, 2H, Ar-H), 8.19-8.22 (d, 2H, 
j=8.4Hz, Ar-H). 
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2.8 Antimicrobial sensitivity testing 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
 In vitro effectivity of antimicrobial agents can be demonstrated by observing 
their capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective than many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive than using disk method. 
 
Principle  
 
 When antimicrobial substance is added in agar cup (made in a medium 
previously inoculated with test organism) the redial diffusion of an antimicrobial 
agent through the agar, produces a concentration gradient. The test organism is 
inhibited at the minimum inhibitory concentration (MIC), giving rise to a clear zone 
of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
 Inoculum was prepared by selecting 4-5 colonies from slope of stock culture 
of the indicator organism and emulsifying them in a suitable broth. The inoculated 
broth was incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This 
happens in 2-8 h. 
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Procedure 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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? Antibiotic Sensitivity Assay 
 
(Concentration250/500/ 1000 µG/ml) 
Sr. 
No. 
CODE 
No. 
Pseudomonas 
aeruginosa 
Proteus vulgaris Escherichia  
coli 
Staphylococcus 
aureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  AW-01 R R 1.2 1.0 1.4 2.0 1.1 1.5 2.0 1.0 1.4 2.0 R 1.3 2.0 
2.  AW-02 1.5 1.8 2.0 1.4 1.6 2.0 R R 1.8 R 1.2 1.8 1.0 1.4 2.0 
3.  AW-03 1.1 1.4 2.0 1.0 1.3 2.0 R R R R R R R 1.3 2.0 
4.  AW-04 R 1.3 1.8 R 1.1 1.4 R R 1.2 1.1 1.4 2.0 1.1 1.4 2.0 
5.  AW-05 R 1.2 1.8 R 1.3 2.0 R 1.1 1.8 R 1.2 1.9 1.2 1.4 2.0 
6.  AW-06 R R 1.2 R 1.2 1.8 R 1.1 1.8 1.0 1.3 2.0 R 1.2 2.0 
7.  AW-07 1.1 1.4 2.0 R 1.2 1.8 1.0 1.3 2.0 1.1 1.4 2.0 R R 1.2 
8.  AW-08 R 1.2 2.0 1.0 1.3 2.0 R 1.1 2.0 R 1.2 2.0 1.0 1.3 2.0 
9.  AW-09 R R 1.2 R 1.2 2.0 1.0 1.3 2.0 R 1.0 2.0 R 1.4 2.0 
10.  AW-10 1.1 1.3 1.8 1.5 1.8 2.0 R 1.0 1.7 R 1.2 2.0 1.0 1.3 2.0 
11.  AW-11 R R 1.2 R R R 1.0 1.4 2.0 R 1.1 1.8 1.0 1.3 2.0 
12.  AW-12 1.5 1.8 2.0 1.1 1.4 2.0 R 1.0 1.8 R 1.2 2.0 R 1.3 2.0 
13.  AW-13 1.6 1.8 2.0 1.5 1.8 2.0 R 1.2 2.0 1.0 1.3 2.0 R 1.2 2.0 
14.  AW-14 1.4 1.8 2.0 1.3 1.5 2.0 R R R R R R 1.0 1.3 2.0 
15.  AW-15 R 1.2 1.5 R R R R R R R R R R 1.2 2.0 
16.  AW-16 1.3 1.6 1.8 1.0 1.2 1.6 R 1.0 1.3 1.2 1.5 1.7 R 1.1 1.8 
17.  AW-17 1.1 1.4 1.6 1.0 1.3 1.5 1.2 1.5 2.0 1.3 1.5 2.0 1.5 1.7 2.0 
18.  AW-18 1.0 1.3 1.8 1.1 1.3 1.6 1.5 1.8 2.0 1.4 1.6 2.0 R 1.5 1.9 
19.  AW-19 R R 1.2 R 1.3 1.8 1 1.2 2.0 1.1 1.6 2.0 1.3 1.6 2.0 
20.  AW-20 R 1.3 1.8 1.1 1.3 1.2 1.0 1.2 1.4 1.0 1.2 1.5 1.2 1.5 1.7 
21.  A 1.8 1.8 1.9 1.9 - 
22.  CPD 2.2 2.1 2.1 2.2 - 
23.  GF 1.8 1.9 2.0 2.0 - 
24.  GRF - - - - 2.6 
25.  FLC - - - - 2.8 
 
Note: Zone of inhibition interpretation is as follows    STD Antibiotic Sensitivity Assay Concentration 40 µg/ml
1. Zone size < 1.0 cm- Resistent (R)  
2. Zone size  1.0 to 1.5 cm – Intermediate 
3. Zone size > 1.5 – Sensitive 
 
      A:    Ampicillin     
     CPD:   Cefpodoxime 
     GF:   Gatifloxacin 
GRF: Gresiofulvin 
 FLC: Fluconazole 
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2.9 Conclusion 
 
 We have described a versatile synthesis of novel 2-chloro-4-(4-fluorophenyl)-
6-isopropyl-5-(E)-substituted pyrimidines from triphenyl[2-chloro-{4-(4-flouro 
phenyl)-6-isopropyl-pyrimidin-5-ylmethyl}phosphonium]bromide with different 
aldehydes via Wittig reaction in the presence of sodium tripolyphosphate as a base in 
aqueous media. Inorganic base sodium tripolyphosphate has the further advantage of 
low cost, stability and low toxicity. All the synthesized compounds were evaluated 
for their antimicrobial activity. The investigation of antibacterial and antifungal 
screening data revealed that all the tested compounds AW-01 to AW-20 showed 
moderate to significant activity. For example, compounds AW-02, 12, 13 and 18 
showed comparatively good activities against all the bacterial strains and thus 
warrant further study. 
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2.10 Experimental section 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (300 MHz), 1H (400 MHz), 13C (100 MHz) and 13C (75 MHz)  
NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl3 and 
DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal 
standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 
mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were measured in open capillaries and are uncorrected. 
 
? Synthesis of (2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl) 
methanol. (INT-01) 
 
 To a solution of ASM-03e (0.003 mole) in toluene (100 mL) at 0 oC was 
added drop wise a 20% solution of diisobutylaluminium hydride (DIBAL) in toluene 
(85 mL). The reaction mixture was further stirred for 2-3 h. at 0 oC. The progress of 
reaction was monitored by thin layer chromatography. After completion, the reaction 
mixture was quenched with saturated ice cold hydrochloric acid. The toluene layer 
was washed with water and brine. The organic layer was separated, dried over 
anhydrous sodium sulfate and filtered. The filtrate was dried under vacuum. The solid 
product was purified by stirring in hexane or diisopropylether (DIPE) to give 
analytically pure product INT-01 with 85% yield. 
 
? Synthesis of triphenyl[2-chloro-{4-(4-flourophenyl)-6-isopropyl-
pyrimidin-5-ylmethyl}phosphonium]bromide. (INT-02) 
 
 A solution of 2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl) 
methanol (INT-01, 16mmol) in MDC (50 mL) was cooled to 0-5 oC. Phosphorus 
tribromide (13mmol) was slowly added in to the reaction mixture at 0-5 oC and stirred 
for 2-3 h. The progress of reaction was monitored by thin layer chromatography. 
After completion, the reaction mixture was washed with 10% sodium bicarbonate 
solution and sodium thiosulphate solution. The organic layer was separated, dried 
over anhydrous sodium sulfate and filtered. The filtrate was evaporated to dryness 
under vacuo. 
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 The oily residue was dissolve in toluene (80 mL) and triphenyl phosphine 
(30mmol) was added. The reaction mixture was heated at 115 oC for 3-4 h. After 
completion of the reaction determined by TLC, the reaction mixture was cooled to 
room temperature. The solid separated was filtered, washed with toluene and dried to 
afford 90% yield.  
 
? General synthetic procedure for the Wittig reaction of pyrimidine yilde 
and aldehyde using STTP as a base in aqueous media. (AW-01 to AW-20) 
 
 A mixture of pyrimidine phosphonium bromide ylide (INT-02, 1 mmol), 
benzaldehyde (1.3 mmol), and Sodium tripolyphosphate (3 mmol) in water (20 mL) 
was refluxed at 60-70 oC for 2-5 h. The progress of reaction was monitored by thin 
layer chromatography. After completion, the reaction mixture was cooled to room 
temperature, diluted with water (50 mL) and extracted with MDC (2x 50mL). The 
organic layer was washed with water (2 x 50 mL), organic layer dried over sodium 
sulfate and evaporated to dryness under vacuo. The residue was crystallized from 
isopropyl alcohol to afford analytically pure products AW-01 to AW-20. 
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? Spectral data of the synthesized compounds 
 
Methyl 2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine-5-carboxylate (ASM-
03e). White solid; Rf 0.83 (8:2 hexane-EtOAc); mp 130-132°C; IR (KBr): 3070, 2930, 
2850, 1730, 1650, 1583, 1470, 1335, 1064, 830 cm-1MS (m/z): 309 (M+); Anal. Calcd 
for C15H14ClFN2O2: C, 58.35; H, 4.57; N, 9.07; Found: C, 58.38; H, 4.47; N, 9.07. 
 
(2-Chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl)methanol (INT-01). 
White solid; Rf 0.52 (8:2 hexane-EtOAc); mp 110-112°C; IR (KBr): 3459, 3327, 3193, 
2999, 1648, 1586, 1261, 1061, 832 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.30-1.33 (d, 
6H, 2 x iprCH3), 2.09 (s, 1H, OH), 3.67-3.69 (m, 1H, iprCH), 4.69 (s, 2H, CH2), 7.28-
7.34 (t, 2H, Ar-H), 7.88-7.92 (t, 2H, Ar-H); 13C NMR (DEPT):(75 MHz, CDCl3): 
21.40, 31.31, 56.47, 56.58, 114.99, 115.28, 131.85, 131.96; MS (m/z): 280 (M+); 
Anal. Calcd for C14H14ClFN2O: C, 59.90; H, 5.03; N, 9.98; Found: C, 59.93; H, 5.07; 
N, 9.97. 
 
Triphenyl[2-chloro-{4-(4-flourophenyl)-6-isopropyl-pyrimidin-5-ylmethyl}- 
phosphonium]bromide (INT-02). White solid; Rf 0.16 (1;1 hexane-EtOAc); mp 
>320oC ; IR (KBr): 3193, 3070, 3024, 2999, 2830, 1648, 1586, 1261, 1061, 830, 780, 
770, 700 cm-1; 1H NMR (300 MHz, CDCl3): δ 0.90 (s, 6H, 2 x iprCH3), 2.99-3.03 (m, 
1H, iprCH), 5.67 (s, 2H, CH2), 6.97-7.02 (t, 2H, Ar-H), 7.26-7.33 (m, 8H, Ar-H), 7.57 
(s, 6H, Ar-H), 7.75-7.80 (m, 3H, Ar-H); 13C NMR (DEPT):(75 MHz, CDCl3): 24.92, 
25.53, 33.42, 116.24, 116.53, 130.35, 130.52, 131.17, 131.28, 133.97, 134.10, 135.42, 
135.46; MS (m/z): 605 (M+); Anal. Calcd for C32H28BrClFN2P: C, 63.43; H, 4.66; N, 
4.62; Found: C, 63.45; H, 4.67; N, 5.67. 
 
2-Choloro-4-(4-flurophenyl)-6-isopropyl-5-(E)-styrylpyrimidine (AW-01). White 
solid; Rf 0.75 (8:2 hexane-EtOAc); mp 80-82°C; IR (KBr): 3087, 3070, 3040, 2930, 
2856, 1658, 1450, 1430, 1368, 830, 753, 700 cm-1; 1H NMR (300 MHz, CDCl3): δ 
1.30-1.33 (d, 6H, 2 x iprCH3), 3.03-3.08 (m, 1H, iprCH), 6.75-6.81 (d, 1H, 
j=16.4Hz,ethylene-H), 7.04-7.23 (m, 3H, Ar-H & ethylene-H), 7.53-7.56 (d, 2H, Ar-
H), 7.72-7.74 (t, 2H, Ar-H), 8.23-8.26 (d, 2H, Ar-H); MS (m/z): 353 (M+); Anal. 
Calcd for C21H18ClFN2: C, 71.49; H, 5.14; N, 7.94; Found: C, 71.43; H, 5.17; N, 7.97. 
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5-((E)-(4-nitrostyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (AW-
02). Yellow solid; Rf 0.72 (8:2 hexane-EtOAc); mp 110-112°C; IR (KBr): 3077, 3065, 
3031, 2932, 2856, 1664, 1450, 1430, 1368, 830 cm-1; 1H NMR (300 MHz, CDCl3): δ 
1.34-1.36 (d, 6H, 2 x iprCH3), 3.44-3.49 (m, 1H, iprCH), 6.55-6.61 (d, 1H, j=16.5Hz, 
ethylene-H), 7.08-7.17 (m, 3H, Ar-H & ethylene-H), 7.48-7.51 (d, 2H, Ar-H), 7.64-
7.68 (t, 2H, Ar-H), 8.19-8.22 (d, 2H, Ar-H); 13C NMR (DEPT):(75 MHz, CDCl3): 
21.73, 32.38, 115.48, 115.77, 124.29, 126.16, 127.09, 132.00, 132.11, 135.01; MS 
(m/z): 398 (M+); Anal. Calcd for C21H17ClFN3O2: C, 63.40; H, 4.31; N, 10.56; Found: 
C, 63.43; H, 4.37; N, 10.50. 
 
5-((E)-(4-chlorostyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (AW-
03). White solid; Rf 0.65 (8:2 hexane-EtOAc); mp 56-58°C; IR (KBr): 3095, 3084, 
3035, 2938, 2850, 1668, 1434, 1434, 1373, 830 cm-1; 1H NMR (300 MHz, CDCl3): δ 
1.32-1.34 (d, 6H, 2 x iprCH3), 3.45-3.50 (m, 1H, iprCH), 6.43-6.49 (d, 1H, j=16.5Hz, 
ethylene-H), 6.88-6.93 (d, 1H, j=16.5Hz, ethylene-H), 7.05 -7.11 (t, 2H, Ar-H), 7.26-
7.38 (q, 4H, Ar-H), 7.64-7.69 (t, 2H, Ar-H); 13C NMR(DEPT):(75 MHz, CDCl3): 
21.47, 32.19, 115.33, 115.62, 122.00, 127.71, 129.09, 132.01, 132.12, 136.01;MS 
(m/z): 388 (M+); Anal. Calcd for C21H17Cl2FN2: C, 65.13; H, 4.42; N, 7.23; Found: C, 
65.23; H, 4.37; N, 7.35. 
 
2-Choloro-4-(4-flurophenyl)-6-isopropyl-5-[(E)-2-(thiophene-2-yl)vinyl]-
pyrimidine (AW-04). White solid; Rf 0.79 (8:2 hexane-EtOAc); mp 114-116°C; IR 
(KBr): 3093, 3086, 3016, 2942, 2834, 1658, 1445, 1403, 1368, 830 cm-1; 1H NMR 
(300 MHz, CDCl3): δ 1.34-1.36 (d, 6H, 2 x iprCH3), 3.52 (m, 1H, iprCH), 6.67-6.73 
(dd, 2H, j=17.4Hz), 6.98-7.02 (d, 2H, Thiophene-H), 7.08-7.14 (t, 2H, Ar-H), 7.27-
7.26 (d, 1H, Thiophene-H), 7.69-7.74 (t, 2H, Ar-H); 13C NMR (DEPT):(75 MHz, 
CDCl3): 21.76, 32.14, 115.35, 115.63, 120.59, 125.77, 127.23, 127.88, 130.22, 
132.05, 132.16; MS (m/z): 359 (M+); Anal. Calcd for C19H17ClFN2S: C, 63.59; H, 
4.49; N, 7.81; Found: C, 63.43; H, 4.37; N, 7.70. 
 
2-Choloro-4-(4-flurophenyl)-5-[(E)-2-(furan-2-yl)vinyl]-6-isopropylpyrimidine 
(AW-05). White solid; Rf 0.82 (8:2 hexane-EtOAc); mp 119-121°C; IR (KBr): 3113, 
2972, 1730, 1683, 1070, 881, 796, 744 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.34-1.36 
(d, 6H, 2 x iprCH3), 3.44-3.49 (m, 1H, iprCH), 6.44-6.55 (d, 2H, Furan), 6.93-6.99  
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(d, 1H, j=16.2Hz, ethylene-H), 7.19-7.25 (d, 1H, j=16.2Hz, ethylene-H), 7.51-7.78 (t, 
3H, Ar-H & Furan), 8.19-8.22 (t, 2H, Ar-H), MS (m/z): 343 (M+); Anal. Calcd for 
C19H16ClFN2O: C, 65.67; H, 4.70; N, 8.17; Found: C, 65.70; H, 4.77; N, 8.07. 
 
3-((E)-2(2-chloro-4-(4-flurophenyl)-6-isopropylpyrimidyl-5-yl)vinyl-1H-indole 
(AW-06). Yellow solid; Rf 0.87 (8:2 hexane-EtOAc); mp 134-136°C;IR (KBr): 3063, 
3015, 2957, 2834, 1670, 1445, 1368, 830, 750  cm-1; MS (m/z): 392 (M+); Anal. Calcd 
for C23H19ClFN3: C, 70.49; H, 4.89; N, 10.72; Found: C, 70.59; H, 4.92; N, 10.77. 
 
5-((E)-(2-nitrostyryl))-2-chloro-4-(4-flurophenyl)-6-isopropylpyrimidine(AW-07) 
Yellow solid; Rf 0.69 (8:2 hexane-EtOAc); mp 96-98°C; IR (KBr): 3037, 3016, 2952, 
2822, 1657, 1453, 1403, 1368, 835, 753 cm-1; MS (m/z): 398 (M+); Anal. Calcd for 
C21H17ClFN3O2: C, 63.40; H, 4.31; N, 10.56; Found: C, 63.39; H, 4.32; N, 10.57. 
 
5-((E)-(2-chlorostyryl))-2-chloro-4-(4-flurophenyl)-6-isopropylpyrimidine (AW-
08). Yellow solid; Rf 0.73 (8:2 hexane-EtOAc); mp 64-65°C; IR (KBr): 3067, 3013, 
2947, 2830, 1652, 1453, 1403, 1376, 838, 748 cm-1; MS (m/z): 388 (M+); Anal. Calcd 
for C21H17Cl2FN2: C, 65.13; H, 4.42; N, 7.23; Found: C, 65.23; H, 4.37; N, 7.35. 
 
4-((E)-2-(2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl)vinyl)-2-
methoxyphenol (AW-09). Yellow solid; Rf 0.79 (8:2 hexane-EtOAc); mp 88-89°C; 
IR (KBr): 3442, 3093, 3086, 3016, 2942, 2834, 1658, 1445, 1403, 1368, 830, 783, 
708, cm-1; MS (m/z): 399 (M+); Anal. Calcd for C22H20ClFN2O2: C, 66.25; H, 5.05; N, 
7.02; Found: C, 66.25; H, 5.06; N, 7.07. 
 
5-((E)-(3,4-dimethoxystyryl)-2-chloro-4-(4-flurophenyl)-6-isopropylpyrimidine 
(AW-10). White solid; Rf 0.83 (8:2 hexane-EtOAc); mp 78-80°C; IR (KBr): 3028, 
2999, 2964, 2839, 1728, 1638, 1558, 1444, 1026, 842, 758, 702  cm-1; 1H NMR (300 
MHz, CDCl3): δ 1.25-1.34 (d, 6H, 2 x iprCH3), 3.51-3.55 (m, 1H, iprCH), 3.90 (S, 6H, 
2 x OCH3), 6.42-6.48 (d, 1H, j=16.5Hz, ethylene-H), 6.71-6.93 (m, 4H, Ar-H 
&ethylene-H), 7.06 -7.12 (t, 2H, Ar-H), 7.70 (s, 2H, Ar-H); 13C NMR (DEPT):(75 
MHz, CDCl3): 21.80, 32.03, 55.96, 56.01, 108.83, 111.22, 115.24, 115.52, 119.27, 
119.89, 132.05, 132.16, 136.96; MS (m/z): 413 (M+); Anal. Calcd for 
C23H22ClFN2O2: C, 66.91; H, 5.37; N, 6.78; Found: C, 66.93; H, 5.37; N, 6.75. 
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4-((E)-2-(2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl)vinyl)-N,N-
dimethylbenzenamine (AW-11). Yellow solid; Rf 0.75 (8:2 hexane-EtOAc); mp 118-
120°C; IR (KBr): 3092, 3028, 2966, 2823, 1660, 1428, 1368, 835, cm-1; MS (m/z): 
396 (M+); Anal. Calcd for C23H23ClFN3: C, 69.78; H, 5.86; N, 8.96; Found: C, 69.75; 
H, 5.76; N, 8.77 
 
5-((E)-(4-fluorostyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (AW-
12). White solid; Rf 0.73 (8:2 hexane-EtOAc); mp 54-56°C; IR (KBr): 3096, 3065, 
2952, 2869, 1675, 1468, 1442, 1353, 836, cm-1; 1H NMR (400 MHz, CDCl3): δ 1.15-
1.26 (d, 6H, 2 x iprCH3), 3.36-3.43 (m, 1H, iprCH), 6.35-6.39 (d, 1H, j=16.6Hz, 
ethylene-H), 6.73-6.77 (dd, 1H, j=16.6Hz, ethylene-H), 6.91-7.00 (m, 4H, Ar-H), 7.21 
-7.24 (m, 2H, Ar-H), 7.55-7.60 (m, 2H, Ar-H); 13C NMR (100 MHz, CDCl3): 21.72, 
32.17, 115.53, 115.54, 115.80, 116.01, 121.11, 121.13, 125.99, 126.39, 128.13, 
128.21, 128.49, 128.61, 132.04, 132.12,132.35, 132.39, 133.28, 133.31, 133.38, 
133.41, 136.10, 150.98, 159.22, 161.62, 162.30, 164.10, 164.79, 165.66, 165.86, 
177.22, 177.44; MS (m/z): 372 (M+); Anal. Calcd for C21H17ClF2N2: C, 68.02; H, 
4.62; N, 7.55; Found: C, 68.05; H, 4.66; N, 7.77 
 
5-((E)-(3-nitrostyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (AW-
13). White solid; Rf 0.72 (8:2 hexane-EtOAc); mp 63-65°C; IR (KBr): 3130, 3083, 
2932, 2856, 1652, 1428, 1426, 1375, 833, 780 cm-1; 1H NMR (300 MHz, CDCl3): δ 
1.34-1.36 (d, 6H, 2 x iprCH3), 3.45-3.49 (m, 1H, iprCH), 6.53-6.59 (d, 1H, j=16.5Hz, 
ethylene-H), 7.08-7.15 (m, 3H, Ar-H & ethylene-H), 7.52 -7.70 (m, 4H, Ar-H), 8.14-
8.22 (s d, 2H, Ar-H); 13C NMR (DEPT):(75 MHz, CDCl3): 21.71, 32.37, 115.46, 
115.75, 121.01, 123.08, 124.68, 129.95 131.97, 132.09, 132.29, 134.90; MS (m/z): 
398 (M+); Anal. Calcd for C21H17ClFN3O2: C, 63.40; H, 4.31; N, 10.56; Found: C, 
63.43; H, 4.37; N, 10.55 
 
5-((E)-(4-bromostyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine(AW-
14). White solid; Rf 0.75 (8:2 hexane-EtOAc); mp 96-98°C; IR (KBr): 3082, 3057, 
2933, 1643, 1449, 1403, 1368, 835 cm-1; 1H NMR (400 MHz, CDCl3): δ 1.23-1.25 (d, 
6H, 2 x iprCH3), 3.35-3.40 (m, 1H, iprCH), 6.34-6.38 (d, 1H, j=16.6Hz, ethylene-H), 
6.82-6.86 (dd, 1H, j=16.6Hz, ethylene-H), 6.97-7.02 (t, 2H, Ar-H), 7.12-7.17 (d, 2H, 
Ar-H), 7.37-7.39 (d, 2H, Ar-H), 7.55-7.59 (m, 2H, Ar-H); 13C NMR (100 MHz,  
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CDCl3): 21.74, 32.20, 115.38, 115.60, 121.12, 122.58, 125.80, 126.20, 127.99, 
132.02, 132.05, 132.10, 133.19, 133.29, 133.32, 135.02, 136.08, 151.11, 159.34, 
162.33, 164.83, 165.66, 165.87, 177.15, 177.38; MS (m/z): 431 (M+); Anal. Calcd for 
C21H17BrClF2N2: C, 58.42; H, 3.97; N, 6.49; Found: C, 58.55; H, 3.96; N, 6.47 
 
2-((E)-2-(2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl)vinyl)phenol 
(AW-15) White solid; Rf 0.64 (8:2 hexane-EtOAc); mp 52-54°C; IR (KBr): 3452, 
3048, 2942, 1648, 1441, 1408, 1359, 835 ,785 cm-1; MS (m/z): 369 (M+); Anal. Calcd 
for C21H18ClF2N2O: C, 68.38; H, 4.92; N, 7.60; Found: C, 68.35; H, 4.96; N, 7.57  
 
5-((E)-(4-methoxystyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine 
(AW-16). Yellow solid; Rf 0.71 (8:2 hexane-EtOAc); mp 67-69°C; IR (KBr): 3052, 
3042, 2948, 1638, 1449, 1401, 1348, 835 ,782 cm-1; MS (m/z): 384 (M+); Anal. Calcd 
for C22H20ClFN2O: C, 69.02; H, 5.27; N, 7.32; Found: C, 69.05; H, 5.26; N, 7.27 
 
5-((E)-(2,5-dimethoxystyryl)-2-chloro-4-(4-flurophenyl)-6-isopropylpyrimidine 
(AW-17). White solid; Rf 0.81 (8:2 hexane-EtOAc); mp 78-80°C; IR (KBr): 3048, 
3046, 2939, 1641, 1438, 1412, 1378, 838, 754, 779 cm-1; MS (m/z): 414 (M+); Anal. 
Calcd for C23H22ClFN2O2: C, 66.91; H, 5.37; N, 6.78; Found: C, 66.93; H, 5.37; N, 
6.75. 
 
5-((E)-(3-bromostyryl))-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (AW-
18). White solid; Rf 0.78 (8:2 hexane-EtOAc); mp 87-88°C; IR (KBr): 3043, 3051, 
2942, 1652, 1431, 1422, 1371, 831 ,786 cm-1; MS (m/z): 432 (M+); Anal. Calcd for 
C21H17BrClF2N2: C, 58.42; H, 3.97; N, 6.49; Found: C, 58.55; H, 3.96; N, 6.47.  
 
5-((E)-(3-chlorostyryl))-2-chloro-4-(4-flurophenyl)-6-isopropylpyrimidine (AW-
19). Yellow solid; Rf 0.73 (8:2 hexane-EtOAc); mp 50-52°C; IR (KBr): 3052, 3061, 
2936, 1648, 1438, 1428, 1364, 838, 778 cm-1; MS (m/z): 373 (M+); Anal. Calcd for 
C21H17Cl2FN2: C, 65.13; H, 4.42; N, 7.23; Found: C, 65.23; H, 4.37; N, 7.35. 
 
3-((E)-2-(2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl)vinyl)phenol 
(AW-20). White solid; Rf 0.83 (8:2 hexane-EtOAc); mp 59-61°C; IR (KBr): 3468, 
3058, 2932, 1641, 1442, 1432, 1357, 832, 781 cm-1; MS (m/z): 369 (M+); Anal. Calcd 
for C21H18ClF2N2O: C, 68.38; H, 4.92; N, 7.60; Found: C, 68.35; H, 4.96; N, 7.57. 
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1H NMR spectrum of compound AW-02 
 
 
Expanded 1H NMR spectrum of compound AW-02 
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1H NMR spectrum of compound AW-03 
 
 
Expanded 1H NMR spectrum of compound AW-03 
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1H NMR spectrum of compound AW-05 
 
 
Expanded 1H NMR spectrum of compound AW-05 
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1H NMR spectrum of compound AW-14 
 
 
Expanded 1H NMR spectrum of compound AW-14 
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13C NMR spectrum of compound AW-12 
 
 
Expanded 13C NMR spectrum of compound AW-12 
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MASS spectrum of compound AW-01 
  
 
MASS spectrum of compound AW-06 
 
N
NCl
F
m/z-352
N
NCl
F
NH
m/z-392
 
Chapter 2                                               Synthesis of substituted pyrimidines via Wittig  
Department of Chemistry, Saurashtra university, Rajkot-360005   77 
 
 
MASS spectrum of compound AW-09 
 
 
MASS spectrum of compound AW-20 
 
N
NCl
F
O
OH
m/z-398
N
NCl
F
OH
m/z-368
 
Chapter 2                                               Synthesis of substituted pyrimidines via Wittig  
Department of Chemistry, Saurashtra university, Rajkot-360005   78 
 
 
IR spectrum of compound AW-05 
 
 
IR spectrum of compound AW-10 
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Chapter - 3
Rapid Synthesis and Characterization of
Novel Tri-substituted Pyrazoles/Isoxazoles
Library Using Ketene Dithioacetals
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3.1 Introduction  
 
 The development of new methods for the synthesis of five member 
heterocyclic compound libraries, both in solution and on solid phase, is an ever-
expanding area in combinatorial chemistry. Specifically, those containing the 
pyrazole and isoxazole nucleus have been widely used as key building blocks for 
pharmaceutical agents. Its derivatives are endowed with high pharmacological 
properties, for example, hypoglycemic, analgesic, anti-inflammatory, antibacterial, 
anti-HIV, and anticancer activity,1 as well as useful activities in conditions like 
schizophrenia, hypertension, and Alzheimer’s disease.2 In addition, they also have 
agrochemical properties including herbicidal and soil fungicidal activity, thus they 
have been used as pesticides and insecticides.3 Recently, pyrazoles containing aryl 
substituted emerged as p38 Kinase inhibitors, antiparasitic activities.4 
Pyrazoles and isoxazoles are well known five member heterocyclic 
compounds and several procedures for its synthesis have been extensively studied. 
The pyrazole ring system consists of a doubly unsaturated five member ring 
containing two adjacent nitrogen atoms. Isoxazole ring system consist two hetero 
atoms oxygen at position 1 and nitrogen at position 2 (Figure-1). 
 
Figure-1 
Pyrazoles and isoxazoles bearing sulfone and carboxamide moieties 
demonstrated to have significant pharmacological applications. For examples, 
cyclooxygenase-2 (COX-2) selective inhibitors, celecoxib5, rofecoxib6 and 
valdecoxib7 are currently prescribed for the treatment of arthritis and inflammatory 
diseases. These COX-2 inhibitors exhibited anti-inflammatory activity with reduced 
gastrointestinal side effects. Oxacillin and its derivatives are useful compounds due to 
their narrow spectrum antibiotic properties8. Recently, pyrrolyl aryl sulfones have 
been reported by Silvestri et al.9 and Artico et al.10 as a new class of human 
immunodeficiency virus type 1 (HIV-1) RT inhibitors acting at the non-nucleoside 
binding site of this enzyme. Haruna et al.11 have been synthesized the propargylic 
sulfones with various planar molecules and evaluated for their DNA binding 
properties and DNA cleavage activity.  
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Moreover, the 1-(4-methylsulfonyl)benzene and 4-(4-methylsulfonyl)benzene 
substituted pyrazole compound containing a nitric oxide donating group at the 3-
position of the pyrazole ring, respectively, have been synthesized and evaluated for its 
ability to inhibit COX isoenzymes in human whole blood.12 Pyrazoles containing 
sulfone group at N position have been exhibited promising antimicrobial activity.13 
Further more, amide group linked with isoxazole derivatives found to have combined 
α2-adrenoceptor antagonistic and serotonine reuptake inhibiting activities.14 The 
Isoxazoles containing aryl and carboxamide were also shown to have potent in vivo 
antithrombotic efficacy.15 
 
3.2 Biological activity associated with pyrazoles and isoxazoles 
 
 As mentioned above, pyrazoles and isoxazoles nucleus have been widely used 
as key building blocks for pharmaceutical agents. Its derivatives are endowed with 
high pharmacological properties, for example, hypoglycemic, GABAA antagonist’s 
analgesic, anti-inflammatory, anti-HIV, and anticancer activity as well as useful 
activities in conditions like schizophrenia, hypertension, and Alzheimer’s disease.  
 Thomas D. Penning et al.16 has described a series of pyrazole and isoxazole 
analogs (Figure-2) as antagonists of the αvβ3 receptor. These compounds showed low 
to sub-nanomolar potency against αvβ3, as well as good selectivity against αIIbβ3. In 
HT29 cells, most analogs also demonstrated significant selectivity against αvβ6. 
Several compounds showed good pharmacokinetic properties in rats, in addition to 
anti-angiogenic activity in a mouse corneal micro pocket model. Compounds were 
synthesized in a straightforward manner from readily available glutarate precursors. 
 
Figure-2 
 Ebraheem Abdu Musad et al.17 has synthesized pyrazoles and isoxazoles 
(Figure-3) were screened for antioxidant and anti-microbial activities. Among that 
some of compounds showed higher antioxidant activity at 10μg/ml and some 
compounds exhibited better anti-microbial activity at 100μg/ml compared with 
standard vitamin C and ciprofloxacin, respectively. 
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Figure-3 
 Annamaria Lilienkampf et al.18 has developed isoxazole-based anti-TB 
compounds by applying rational drug design approach (Figure-4). The biological 
activity and the structure-activity relationships (SAR) for a designed series of 5-
phenyl-3-isoxazolecarboxylic acid ethyl ester derived anti-TB compounds were 
investigated. Several compounds were found to exhibit nanomolar activity against the 
replicating bacteria (R-TB) and low micromolar activity against the non replicating 
bacteria (NRP-TB). The series showed excellent selectivity toward Mtb, and in 
general, no cytotoxicity was observed in Vero cells (IC50>128 μM). Notably, selected 
compounds also retained their activity against isoniazid (INH), rifampin (RMP), and 
streptomycin (SM) resistant Mtb strains. Hence, benzyloxy, benzylamino, and 
phenoxy derivatives of5-phenyl-3-isoxazolecarboxylic acid ethyl esters represent a 
highly potent, selective, and versatile series of anti-TB compounds and as such 
present attractive lead compounds for further TB drug development. 
O
O N O
O
R1
R5
R4
R3
R2
R1=H, CF3, Cl, F, NO2
R2=OCF3, CH3, NH2, OCH3, CON(CH2CH2)2O, H,Cl, F,
R3=H, CF3, Cl, F,
R4= R5= H, F  
Figure-4 
 Recently, biological evaluation of novel potent HDAC3 and HDAC8 
isoxazole and pyrazole-based diazide probes (Figure-5) suitable for binding ensemble 
profiling with photo affinity labeling (BEProFL) experiments in cells is described. 
Both the isoxazole and pyrazole-based probes exhibit low nanomolar inhibitory 
activity against HDAC3 and HDAC8, respectively. The pyrazole-based one of the 
most active HDAC8 inhibitors reported in the literature with an IC50 of 17 nM.  
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 Docking studies suggest that unlike the isoxazole-based ligands the pyrazole-
based ligands are flexible enough to occupy the second binding site of HDAC8. 
Probes/inhibitors some compounds exerted the antiproliferative and neuroprotective 
activities at micromolar concentrations through inhibition of nuclear HDACs, 
indicating that they are cell permeable and the presence of an azide or a diazide group 
does not interfere with the neuroprotection properties, orenhance cellular cytotoxicity, 
or affect cell permeability.19 
 Figure-5 
 Maria Barceló et al.20 has described synthesis of binding affinities on D2, 5-
HT2A and 5-HT2C receptors of 6-aminomethyl-6,7-dihydro-1H-indazol-4(5H)-ones 
and 6-aminomethyl-6,7-dihydro-3-methyl-benzo[d]isoxazol-4(5H)-ones, as 
conformationallly constrained butyrophenone analogues. One of the new compounds 
(Figure-6) showed good in vitro binding features, and a Meltzer’s ratio characteristic 
of an atypical antipsychotic profile. 
 
Figure-6 
 Celecoxib and rofecoxib analogues (Figure-7), in which the respective 
SO2NH2 and SO2Me hydrogen-bonding pharmacophores were replaced by dipolar 
azido bioisosteric substituents, were investigated. Molecular modeling (docking) 
studies showed that the azido substituent of these two analogues was inserted deep 
into the secondary pocket of the human COX-2 binding site where it undergoes 
electrostatic interaction with Arg513. The azido analogue of rofecoxib is the most 
potent and selective inhibitor of COX-2 (COX-1 IC50= 159.7 µM; COX-2 IC50= 0.196 
µM; COX-2 selectivity index = 812), exhibited good oral anti-inflammatory and 
analgesic activity. 
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Figure-7 
 Amgad G. Habeeb et al.21 also reported a 4,5-diphenyl-4-isoxazolines 
(Figure-8) possessing a variety of substituents (H, F, MeS, MeSO2) at the para 
position of one of the phenyl rings were synthesized for evaluation as analgesic and 
selective cyclooxygenase-2 (COX-2) inhibitory anti-inflammatory (AI) agents. 
Although the 4,5-phenyl-4-isoxazolines (Figure-8), which do not have a C-3 Me 
substituent, exhibited potent analgesic and AI activities, those compounds evaluated  
were not selective inhibitors of COX-2. In contrast, 2,3-dimethyl-5-(4-
methylsulfonylphenyl)-4-phenyl-4-isoxazoline exhibited excellent analgesic and AI 
activities, and it was a potent and selective COX-2 inhibitor (COX-1, IC50) 258 μM; 
COX-2, IC50) 0.004 μM). 
O
N Me
R1
R2
R3
R1= H, Me
R2, R3=H, F, SMe, SO2Me  
Figure-8 
 A related compound (Figure-8) having a F substituent at the para position of 
the 4-phenyl ring was also a selective (SI =3162) but less potent (IC50 =0.0316 μM) 
inhibitor of COX-2 than 2,3-dihydro-2,3-dimethyl-5-(4-(methylsulfonyl)phenyl)-4-
phenyl isoxazole. A molecular modeling (docking study) for 4-(4-fluorophenyl)-2,3-
dihydro-2,3-dimethyl-5-(4-(methylsulfonyl)phenyl)-4-phenylisoxazole showed that 
the S atom of the MeSO2 substituent is positioned about 6.46 Å  inside the entrance to 
the COX-2 secondary pocket (Val523) and that a C-3 Me (2,3-dihydro-2,3-dimethyl-5-
(4-(methylsulfonyl)phenyl)-4-phenylisoxazole,4-(4-fluorophenyl)-2,3-dihydro-2,3di-
methyl-5-(4-(methylsulfonyl)phenyl)-4-phenylisoxazole) central isoxazoline ring 
substituent is crucial to selective inhibition of COX-2 for this class of compounds.  
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 Chih Y. Ho et al.22 have repoted a series of (6,7-dimethoxy-2,4-
dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines (Figure-9) has been optimized to 
preserve both potent kinase inhibition activity against the angiogenesis target, the 
receptor tyrosine kinase of Platelet-Derived Growth Factor-BB (PDGF-BB), and to 
improve the broad tumor cell antiproliferative activity of these compounds. This 
series culminates in the discovery of (JNJ-10198409), a compound with anti-PDGFR-
α kinase activity (IC50 = 0.0042 µM) and potent antiproliferative activity in six of 
eight human tumor cell lines (IC50 = 0.033 µM). 
 
Figure-9 
 Chih Y. Ho has developed antiangiogenic compounds with an additional 
antiproliferative activity capable of inhibiting tumor progression by controlling both 
the vascularization and proliferation of the tumor mass. Tumors may be regarded as a 
two-compartment system consisting of the vasculature supporting tumor growth 
composed of ‘normal’ homogeneous vascular endothelial cells, smooth muscle cells, 
and pericytes that are surrounded by colonies of neoplastic cancer cells. To find 
molecules that would affect both the vascular and transformed compartments, we 
identified several compounds with the potential to inhibit the PDGFR-β kinase-
mediated angiogenic effect and then assayed them for collateral antiproliferative 
activity against a panel of human tumor cell lines. 
 Christian Peifer et al.23 have been reported on the discovery of isoxazole 
(Figure-10) as a potent dual inhibitor of p38α (IC50= 0.45 μM) and CK1δ (IC50= 0.23 
μM). Because only a few effective small molecule inhibitors of CK1 have been 
described so far, we aimed to develop this structural class toward specific agents. 
Molecular modeling studies comparing p38α/CK1δ suggested an optimization 
strategy leading to design, synthesis, biological characterization, and SAR of highly 
potent compounds including possessing differentiated specificity. Selected 
compounds were profiled over 76 kinases and evaluation of their cellular efficacy 
showed 18 (CKP138) to be a highly potent and dual-specific inhibitor of CK1δ and 
p38α. 
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Figure-10 
 Small molecule inhibitors of various protein kinases are utilized extensively in 
research and drug development. The human kineme consists of more than 500 protein 
kinases, and kinase inhibitors typically bind in the highly conserved ATP pocket of 
these enzymes.24 Thus the specificity of ATP competitive kinase inhibitors is of 
significant interest and represents a crucial factor for their use in, e.g., signal 
transduction research or therapeutic applications. 
 A series of 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists have been 
synthesized and pharmacologically characterized.25 The meta-phenyl-substituted 
compounds and the para-phenoxy-substituted compound (Figure 11) all display high 
affinities (Ki = 10-70 nM) and antagonist potencies in the low nanomolar range (Ki = 
9-10 nM). These potencies are significantly higher than those of previously reported 
4-PIOL antagonists and considerably higher than that of the standard GABAA 
antagonist SR 95531. 
 
Figure 11 
 In contrast to the all osteric modulatory sites, the GABA binding site has very 
distinct and specific structural requirements for recognition and activation. Thus, very 
few different classes of structures have been reported. Within the series of compounds 
showing agonist activity at the GABAA receptor site are the selective GABAA 
agonists muscimol26 and 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol,26-27which 
have been used for the characterization of the GABAA receptors (Figure 11).28  
 Recently, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol has been shown to be 
functionally selective for a subpopulation of GABAA receptors and is currently in 
clinical trials as a therapeutic for the regulation of sleep. 
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3.3 Synthetic methods for the pyrazole and isoxazole derivatives 
 There are several methods reported in the literature for the preparation of 
pyrazoles and isoxazoles described as under. 
 Pranab K. Mahata et al.29 has synthesized 3-dimethoxymethyl-5-(methylthio) 
pyrazole/ isoxazole derivative (Figure-12) shown to be useful three carbon synthon 
for efficient regiospecific synthesis of a variety of five (pyrazole/isoxazole) with mask 
or unmask aldehyde functionality by cyclocondensation with bifunctional 
nucleophiles such as hydrazine and hydroxylamine respectively. 
Figure-12 
 Sabine Kuettel et al.30 has synthesized 4-(3-phenylpyrazole/isoxazol-5-
yl)morpholine derivatives (Figure-13) by two synthetic routes, in which substituted 
acetophenones were reacted with carbon disulfide and methyl iodide in the presence 
of sodium hydride to give 4-phenoxyphenyl-2,2-bis(methylthio)vinylketones, 
followed by in situ cyclization of the resulting N,S-acetals with hydrazine 
hydrate/hydroxylamine. 
 
Figure-13 
 Scott R. Tweedie et al.31 has synthesized a pyrazole and isoxazole derivatives 
via palladium-catalyzed couplings of heteroaryl amines with aryl halides using 
sodium phenolate as the stoichiometric base (Figure-14). 
 
Figure-14 
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 Kewei Wang et al.32 has reported an efficient and divergent one-pot synthesis 
of fully substituted 1H-pyrazoles and isoxazole derivatives. Substituted 1H-pyrazoles 
were synthesized from 1-carbamoyl, 1-oximyl cyclopropanes via sequential ring-
opening, chlorovinylation, and intramolecular aza-cyclization under Vilsmeier 
conditions (POCl3/DMF). Isoxazoles were synthesized from the cyclopropyl oximes 
via ring-opening and intramolecular nucleophilic vinylic substitution (SNV) reactions 
in the presence of POCl3/CH2Cl2 (Figure-15). 
 
Figure-15 
 Ebraheem Abdu Musad et al.33 has prepared a new 3,5-(substituted) pyrazoles 
and isoxazoles by reaction of (N’¹E , N’³E)- N’¹, N’³-bis(3,4,5-substituted- 
benzylidene)malonohydrazide with hydrazine hydrate and hydroxylamine 
hydrochloride respectively under solvothermal conditions involving an ecofriendly 
method without any environmental pollution (Figure-16). 
 Figure-16 
 Ch brajakishor singh et al.34 have been synthesized a steroidal pyrazole and 
isoxazole derivatives form 2-ethoxymethelene-4-androsten-3-one and 2-
bis(methylthio)methelene-4-androsten-3-one (Figure-17). 
Figure-17 
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 Alex F. C. Flores et al.35 have been synthesized a new series of hydroxyl 
pyrazoles and 2-methyl-3-isoxazolones from the cyclocondensation reaction of 
trichloromethyl-substituted 1,3-dielectrophiles with dry hydrazine and N-methyl 
hydroxylamine respectively (Figure-18). 
 
Figure-18 
 Sarvesh Kumar et al.36 has synthesized pyrazole and isoxazole derivatives via 
hetero annulations of 10,11-Dihydro-11-[bis(methylthio)methylene]dibenzoxepin-10-
one (α-oxoketene dithioacetal) (Figure-19). 
Figure-19 
 Valentina Molteni et al.37 have been developed an extremely simple one pot 
reaction for transforming diketones into the corresponding pyrazoles and isoxazoles 
promoted by microwave irradiation (Figure-20). 
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Figure-20 
 Thomas Kurz et al.38 has synthesized novel fluorinated ketene N,S-acetals 
were readily prepared by the reaction of fluorosubstituted cyanoacetamide derivatives 
with arylisothiocyanate in the presence of potassium hydroxide, followed by the 
alkylation of the produced salts with methyl iodide. The reaction of fluorinated ketene 
N,S-acetals with hydrazine afforded different fluorosubstituted pyrazole (Figure-21). 
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Figure-21 
 Galal H. Elgemeie et al.39 have been synthesized a variety of novel α-
cyanoketene S,S-acetals, readily prepared by the reaction of cyanoacetanilides or 
cyanothioacetamide with carbon disulfide, followed by alkylation, react smoothly 
with nucleophile to afford variously substituted methylthio derivatives of pyrazole 
(Figure-22). 
CN
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Figure-22 
 Jesse P. Waldo et al.40 have been synthesized of isoxazoles (Figure-23) via 
electrophilic cyclization under mild reaction conditions by the reaction of 2-alkyn-1-
one O-methyl oximes with ICl, I2, Br2, or PhSeBr. 
 
Figure-23 
 David J. Burkhart et al.41 have been synthesized ethyl 4-acetyl-5-methyl-3-
isoxazoyl carboxylate (Figure-24) was smoothly lithiated at the 5-methyl position. 
The anion was quenched with a variety of electrophiles such as alkyl halides, 
aldehyde, TMSCl and Me3SnCl in good to excellent yields. 
 
Figure-24 
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 V. P. Kislyi et al.42 were prepared 4-amino-5-benzoyl (acetyl) isoxazole-3-
carboxamides (Figure 25) by cyclization of α-hydroxyimino nitriles O-alkylated with 
bromoacetophenones (bromoacetone). The purity of the target 4-aminoisoxazoles can 
be substantially increased by treating O-alkylated oximes with LiClO4 before 
cyclization. 
 
Figure 25 
 Wenli Ma et al.43 have been developed an efficient three-component, two-step 
“catch and release” solid-phase synthesis of 3,4,5-trisubstituted pyrazoles and 
isoxazoles (Figure-26). The first step involves a base-promoted condensation of a 2-
sulfonyl- or a 2-carbonyl-acetonitrile derivative (1 or 7) with an isothiocyanate 2 and 
in situ immobilization of the resulting thiolate anion on Merrifield resin. Reaction of 
the resin-bound sulfonyl intermediate 4 with hydrazine or hydroxylamine, followed 
by release from the resin and intramolecular cyclization, affords 3,5-diamino-4-
(arylsulfonyl)-1H-pyrazoles 5 or isoxazoles 6, respectively. Reaction of the resin-
bound carbonyl intermediate 9 with hydrazine, on the other hand, leads to 3-
(arylamino)-5-aryl-1H-pyrazole-4-carbonitriles 10. 
 Figure-26 
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3.4 Some pharmaceutical molecules related to pyrazoles and
 isoxazoles 
 
 Pyrazole and isoxazole nucleus have been widely used as key building blocks 
for pharmaceutical agents. Its derivatives are endowed with high pharmacological 
properties, for example, hypoglycemic, analgesic, anti-inflammatory, antibacterial, 
anti-HIV, and anticancer activity,3 as well as useful activities in conditions like 
schizophrenia, hypertension, and Alzheimer’s disease.4 
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3.5 Current research work  
 
 α-Oxoketene dithioacetals especially the dimethylthioacetals have recently 
received considerable attention due to their synthetic importance for the construction 
of a variety of alicyclic, aromatic and heterocyclic compounds.44,45 Ketene 
dithioacetals, in the presence of various regents, undergo different types of reactions 
to yield other heterocyclic compounds, e.g., isoxazole, pyrazole, thiophenes, 
pyrimidines, pyridines, etc. Consequently we were interested in surveying the 
synthetic utility of ketene dithioacetals. 
 Recently, we have reported solution-phase library of pyrazoles and isoxazoles 
functionalized with methyl, sulfone and carboxamide moieties in two steps with 
excellent yield and chemical purity for medicinally interesting molecules. Water was 
emerged as an efficient and green solvent in the condensation reaction of various 
ketene dithioacetals with hydrazine hydrate or hydroxyl amine hydrochloride.46 
 
Figure-27 
 In an extension to this work, we describe here a novel synthesis of solvent free 
library of trisubstituted pyrazoles (B) and isoxazoles (C) (Figure-27) by the reaction 
of ketene dithioacetals with hydrazine hydrate and hydroxylamine hydrochloride 
under microwave irradiations Thus, it has been found that reaction of substituted 
acetoacetanilide derivatives with carbon disulfide in the presence of potassium 
carbonate followed by the alkylation with methyl iodide gives the novel ketene 
dithioacetals (A) (Figure 27), the structures of which have been established on the 
basis of their elemental analysis and spectral data.  
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3.6 Results and discussion 
Scheme: Synthesis of novel trisubstitited pyrazoles and isoxazoles from ketene   
dithioacetals 
Scheme-1 
 
Scheme-2 
N
H
O O
SS
R
N
H
O OR
3a-o 4a-o
1) CS2/K2CO3/DMF
2) CH3I
 
Scheme-3 
 
Where R=CH3, OCH3, F, NO2, Cl 
 
 Various substituted 3-cyclopropyl-3-oxo-N-arylpropanamide (3a-o) were 
prepared by reacting substituted amines (1a-h) and methyl 3-cyclopropyl-3-
oxopropanoate (2) in toluene with a catalytic amount of NaOH or KOH (Scheme 1). 
The reaction mixture was refluxed for 15-20 h. Fifteen different acetoacetanilide were 
synthesized bearing various electron donating and electron withdrawing groups such 
as 2,3-diCH3; 3,4-diCH3; 4-CH3; H; 2,5-diCH3; 2,4-diCH3; 3-Cl-4-F; 4-F; 4-Cl; 2-Cl; 
2-F; 4-OCH3; 2,5-diCl and 3-NO2 on the phenyl ring. The reaction of substituted 
acetoacetanilide 3a-o derivatives with carbon disulfide in the presence of potassium 
carbonate followed by the alkylation with methyl iodide (Scheme 2) gave the novel 
ketene dithioacetals 4a-o. Further treatment of 4a-o with hydrazine hydrate or 
hydroxyl amine hydrochloride in the presence of potassium hydroxide (Scheme-3) to 
furnish pyrazoles 5a-o and isoxazoles 6a-o in excellent yield. As a part of ‘green 
chemistry’ approaches, we have done all reaction in solvent free reaction condition and 
under microwave irradiation. Comparative study of reaction time and yield in 
conventional and microwave irradiation methods are summarized in Table-1. 
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Table-1: 3-cyclopropyl, 5-methylthio, 4-carboxamide substituted pyrazoles and  
isoxazoles. 
Entry R 
Reaction time 
Conventional
(hrs) 
Yield
(%) 
MW  
(min.) 
Yield 
(%) 
5a 4-CH3Ph 2.0 85 13.0 88 
5b 4-ClPh 1.5 88 12.5 90 
5c 4-FPh 1.5 87 10.0 92 
5d 4-OCH3Ph 2.0 83 12.0 90 
5e 3,4-diClPh 2.0 90 13.0 95 
5f 3,Cl,4-FPh 1.5 85 12.5 88 
5g 2,3-diCH3Ph 2.0 87 14.0 90 
5h 4-NO2Ph 2.5 82 17.0 95 
5i 2-OCH3Ph 1.5 85 14.5 97 
5j 2-CH3Ph 2.0 83 13.0 93 
5k 4-CH2CH3Ph 2.5 80 12.5 91 
5l 5,Cl,2-OCH3Ph 2.0 82 13.5 95 
5m 2,5-diClPh 1.0 87 12.0 90 
5n 2,5-diCH3Ph 2.0 80 13.0 88 
5o 3,4-diFPh 2.5 81 14.0 87 
6a 4-CH3Ph 2.5 79 12.5 85 
6b 4-ClPh 2.0 83 15.0 93 
6c 4-FPh 3.0 82 14.5 90 
6d 4-OCH3Ph 1.5 87 13.0 92 
6e 3,4-diClPh 2.0 85 14.0 91 
6f 3,Cl,4-FPh 2.5 82 13.0 87 
6g 2,3-diCH3Ph 3.0 81 13.5 89 
6h 4-NO2Ph 2.5 90 14.0 95 
6i 2-OCH3Ph 3.0 89 15.0 94 
6j 2-CH3Ph 2.5 87 17.5 92 
6k 4-CH2CH3Ph 3.0 85 15.0 90 
6l 5,Cl,2-OCH3Ph 1.5 80 12.5 84 
6m 2,5-diClPh 1.0 88 13.0 96 
6n 2,5-diCH3Ph 2.5 87 15.5 94 
6o 3,4-diFPh 3.0 85 14.0 92 
  
 The structures of 4a-o were established on the basis of their elemental analysis 
and spectral data (MS, IR, and 1H NMR). The analytical data for 4b revealed a 
molecular formula C15H16ClNO2S2 (m/z 342). The 1H NMR spectrum revealed a two 
multiplet at δ = 1.02-1.06 and 1.21-1.24 ppm assigned two –CH2 groups in 
cyclopropane ring, a multiplet at δ = 2.37-2.43 ppm assigned to the –CH protons,  
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a singlet at δ = 2.47 ppm assigned to (2 × SCH3), a multiplet at δ = 7.26–7.59 ppm 
assigned to the aromatic protons, and one broad singlet at δ = 8.69 ppm assigned to -
CONH groups. 
 The structures of 5a-o were established on the basis of their elemental analysis 
and spectral data (MS, IR, 1H NMR and 13C NMR).Structure 5a was supported by its 
mass (m/z 287), which agrees with its molecular formula C15H17N3OS; its 1H NMR 
spectrum had signals at δ = 0.81-0.82 and 0.96-0.99 (m, 2x CH2) in cyclopropane 
ring, a multiplet at δ = 2.24 ppm assigned to the cyclopropyl-CH protons, a singlet at 
δ=2.40 assigned to -CH3 protons, a singlet at δ=2.48 ppm assigned to (SCH3), a 
multiplet signal at δ = 7.09-7.53 ppm related to the aromatic protons, 9.36 (broad, -
CONH) and 12.84 (broad,  pyrazole NH). 
 The structures of 6a-o were established on the basis of their elemental analysis 
and spectral data (MS, IR, 1H NMR and 13C NMR).The analytical data for 6b 
revealed a molecular formula C15H16ClNO2S2 (m/z 342). The 1H NMR spectrum 
revealed a two multiplets at δ = 1.14-1.06 and 1.21-1.16 ppm assigned two –CH2 
groups in cyclopropane ring, a multiplet at δ = 2.16-2.20 ppm assigned to the –CH 
protons, a singlet at δ = 2.68 ppm assigned to (SCH3), a multiplet at δ = 7.26–7.56 
ppm assigned to the aromatic protons, and one broad singlet at δ = 8.19 ppm assigned 
to -CONH groups. 
 The proposed mechanism for the formation of 5a-o and isoxazoles 6a-o from 
the corresponding 3-cyclopropyl-3-oxo-N-arylpropanamide (3a-o) is shown in Figure 
28 & 29. In the ketene dithioacetal system the carbonyl carbon and β-carbon atoms 
regarded as hard and soft electrophilic centers, since the carbonyl carbon is adjacent 
to the hard-base oxygen while the β-carbon is flanked by the soft-base methylthio 
groups. Thus, the nucleophile hydrazine hydrate or hydroxyl amine hydrochloride 
may attack on β-carbon of systems and formed heterocyclic product by removal of 
methylthio and group as good leaving group and water molecule.  
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? Mechanism 
 
 
Figure 28: Proposed mechanism for the formation of pyrazole 
 
 
 
Figure 29: Proposed mechanism for the formation of isoxazole 
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3.7 Conclusion 
 
 In summary, we have synthesized a library of pyrazoles and isoxazoles 
functionalized with cyclopropyl, thiomethyl and carboxamide moieties in single steps 
with excellent yield under microwave irradiation. As a part of ‘green chemistry’ 
approach condensation reaction of various ketene dithioacetals with hydrazine hydrate 
or hydroxyl amine hydrochloride in solvent free condition under microwave 
irradiation. The present procedure is significant over the existing methods to develop 
this class of molecules with excellent yield, purity and simple isolation of products.  
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3.8 Experimental section 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (300 MHz), 1H (400 MHz), 13C (75 MHz) and 13C (100 MHz)  
NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl3 and 
DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal 
standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 
mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were measured in open capillaries and are uncorrected. 
 
? General synthesis of 3-cyclopropyl-3-oxo-N-arylpropanamide (3a-o). 
 A mixture containing the primary amine (1a-h, 10 mmol), methyl 3-
cyclopropyl-3-oxopropanoate (2, 10 mmol), and catalytic amount of sodium or 
potassium hydroxide (10 %) in toluene (50 mL) was reflux at 110 oC for the 
approximately 12-15 h. The reaction was monitored by TLC. After completion of 
reaction, the solvent was removed under vaccuo and the solid or oil was crystallized 
from methanol which afforded pure products. 
 
? General synthesis of ketene dithioacetals (4a-o). 
           A 100mL conical flask equipped with magnetic stirrer and septum was charged 
with a solution of 3-cyclopropyl-3-oxo-N-arylpropanamide (3a-o, 10 mmol) in DMF 
(10 mL). Dried K2CO3 (20 mmol) was added and the mixture was stirred for 2 h at 
room temperature. CS2 (10 mmol) was added and the mixture was stirred for an 
additional 2 h at room temperature. Methyl iodide (20 mmol) was added at 0-5 oC and 
the mixture was stirred for 4 h at room temperature. The reaction was monitored by 
TLC. After completion, the mixture poured into water (40 mL). The precipitated 
crude product was purified by filtration followed by crystallization from EtOH. When 
the product was oil, the organic phase was extracted with Et2O (3 × 10 mL). The 
combined organic extracts were washed with H2O (2 × 10 mL), dried (MgSO4), and 
concentrated in vaccuo to afford ketene dithioacetals directly used for the next step. 
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? General procedure for the synthesis of trisubstituted pyrazoles5a-o. 
? Conventional method: 
A 25mL conical flask equipped with magnetic stirrer and septum was charged 
hydrazine hydrate (15 mmol) and various ketene dithioacetals (3a-o, 10 mmol) and 
heated up to 75-85 oC for appropriate times (Table-1). After completion of the 
reaction, the reaction mixture was allowed to come to room temperature and add cold 
water (50 mL). The separated suspension was filtered, washed with water, dried and 
crystallized from methanol to afford analytically pure products with 80-90% yield. 
? Microwave assisted method: 
 A one neck flat bottom flask charged with the hydrazine hydrate (15 mmol), 
and various ketene dithioacetals 3a-o (10 mmol), was heated at 90 oC under 
microwave irradiation for appropriate time (Table-1). After completion of the 
reaction, the reaction mixture was allowed to attain room temperature and added cold 
water (50 mL). The suspension was filtered, washed with water, dried and crystallized 
from methanol to afford analytically pure products with 85-95% yield. 
 
? General procedure for the synthesis of trisubstituted isoxazoles6a-o. 
? Conventional method: 
A 25mL conical flask equipped with magnetic stirrer and septum was charged 
with hydroxyl amine hydrochloride (15 mmol), potassium hydroxide (15 mmol) and 
various ketene dithioacetals (3a-o, 10mmol) and heated up to 75-85 oC for appropriate 
times (Table-1). After completion of the reaction, the reaction mixtures were cooled 
to room temperature and add cold water (50 mL). The separated solid was filtered, 
washed with water, dried and crystallized from methanol to afford analytically pure 
products with 80-90% yield. 
? Microwave assisted method: 
 A one neck flat bottom flask charged with hydroxyl amine hydrochloride (15 
mmol), potassium hydroxide (15 mmol) and various ketene dithioacetals 3a-o (10 
mmol) and reaction mixture heated at 90 oC under microwave irradiation for 
appropriate time (Table-1). After completion of the reaction, the reaction mixture was 
allowed to come to room temperature and add cold water (50 mL). The separated 
solid was filtered, washed with water, dried and crystallized from methanol to afford 
analytically pure products with 85-95% yield. 
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? Spectral data of the synthesized compounds 
3-Cyclopropyl-N-(4-fluorophenyl)-3-oxopropanamide 3c.White solid; Rf 0.42 (8:2 
hexane-EtOAc); IR (KBr): 3364, 2927, 1674, 1533, 1462, 1281, 1112, 873 cm-1; 1H 
NMR (300 MHz, CDCl3): δ 1.07-1.13 (q, 2H, CH2), 1.14-1.20 (q, 2H, CH2), 2.00-
2.06 (m, 1H, CH), 3.71 (s,  2H, CH2), 6.97-7.03 (m, 2H, Ar-H), 7.48-7.53 (m, 2H, Ar-
H), 9.43 (s, 1H, NH); MS (m/z): 221 (M+); Anal. Calcd for C12H12FNO2: C, 65.15; H, 
5.47; N, 6.33; Found: C, 65.17; H, 5.45; N, 6.34. 
 
N-(4-chlorophenyl)-2-(cyclopropylcarbonyl)-3,3-bis(methylsulfanyl)prop-2-
enamide 4b. Yellow solid; Rf 0.48 (8:2 hexane-EtOAc); IR (KBr): 3033, 2927, 1674, 
1533, 1462, 1281, 1112, 873 cm-1; 1H NMR (400 MHz, CDCl3): δ 1.02-1.06 (m, 2H, 
CH2), 1.21-1.24 (m, 2H, CH2), 2.37-2.43 (m, 1H, CH), 2.47 (s,  6H, 2xSCH3), 7.26-
7.29 (d, 2H, j=9.6Hz, Ar-H), 7.53-7.59 (d, 2H, j=8.7Hz, Ar-H), 8.69 (s, 1H, NH); MS 
(m/z): 342 (M+); Anal. Calcd for C15H16ClNO2S2: C, 52.70; H, 4.72; N, 4.10; Found: 
C, 52.72; H, 4.75; N, 4.12. 
 
2-(Cyclopropylcarbonyl)-N-(4-methoxyphenyl)-3,3-bis(methylsulfanyl)prop-2-
enamide 4d. Yellow solid; Rf  0.42 (9:1 Chloroform: Methanol); IR (KBr): 3364, 
2927, 1674, 1533, 1462, 1281, 1112, 873 cm-1; 1H NMR (400 MHz, CDCl3): δ 1.02-
1.04 (m, 2H, CH2), 1.22 (m, 2H, CH2), 2.39-2.42 (m, 1H, CH), 2.47 (s,  6H, 2x 
SCH3), 3.84 (s, 3H, OCH3), 6.85-6.88 (d, 2H, j=8.7Hz,Ar-H), 7.48-7.51 (d, 2H, 
j=8.7Hz,Ar-H), 8.35 (s, 1H, NH); MS (m/z): 337 (M+); Anal. Calcd for C16H19NO3S2: 
C, 56.95; H, 5.68; N, 4.15; Found: C, 56.92; H, 5.65; N, 4.12. 
 
3-Cyclopropyl-5-(methylthio)-N-p-tolyl-1H-pyrazole-4-carboxamide 5a.  White 
solid; Rf 0.71 (9:1 Chloroform: Methanol); mp 155-157 oC; IR (KBr): 3284, 3151, 
3083, 3031, 2968, 2841, 1628, 1586, 1408, 1238, 1037, 887, 834 cm-1; 1H NMR (300 
MHz, CDCl3): δ 0.81-0.82 (m, 2H, CH2), 0.96-0.99 (m, 2H, CH2), 2.24 (m, 1H, CH), 
2.40 (s, 3H, CH3),  2.48 (s, 3H, SCH3), 7.09-7.11 (d, 2H, j=8.1Hz, Ar-H), 7.51-7.53 
(d, 2H, j=8.1Hz, Ar-H), 9.36 (s, 1H, NH), 12.84 (s, 1H, NH); MS (m/z): 287 (M+); 
Anal. Calcd for C15H17N3OS: C, 62.69; H, 5.96; N, 14.62; Found: C, 62.68; H, 5.95; 
N, 14.62. 
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N-(4-chlorophenyl)-3-cyclopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 
5b. White solid; Rf 0.68 (9:1 Chloroform: Methanol); mp 133-135 oC; IR (KBr): 3294, 
3259, 3153, 3020, 2953, 2895, 1681, 1589, 1485, 1251, 1006, 898, 821, 759, 732, 690 
cm-1; 13C NMR (100 MHz, CDCl3): 7.52, 120.82, 127.03, 128.23, 137.74, 161.69; MS 
(m/z): 307 (M+); Anal. Calcd for C14H14ClN3OS: C, 54.63; H, 4.58; N, 13.65; Found: 
C, 54.62; H, 4.55; N, 13.62. 
 
3-Cyclopropyl-N-(4-fluorophenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 
5c. White solid; Rf 0.71 (9:1 Chloroform: Methanol); mp 122-124 oC; IR (KBr): 3287, 
3136, 3081, 3014, 2968, 2833, 1641, 1584, 1251, 1024, 882, 832  cm-1; 1H NMR (300 
MHz, CDCl3): δ 0.82-0.83 (m, 2H, CH2), 0.96-1.03 (m, 2H, CH2), 2.26 (m, 1H, CH), 
2.40 (s, 3H, SCH3), 7.11-7.17 (m, 2H, Ar-H), 7.63-7.67 (d, 2H, j=13.2Hz, Ar-H), 9.53 
(s, 1H, NH), 12.88 (s, 1H, NH); MS (m/z): 291 (M+); Anal. Calcd for C14H14ClN3OS: 
C, 57.72; H, 4.84; N, 14.42; Found: C, 57.74; H, 4.85; N, 14.46. 
 
3-Cyclopropyl-N-(4-methoxyphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 
5d. White solid; Rf 0.42 (9:1 Chloroform: Methanol); mp 141-143 oC; IR (KBr): 3292, 
3147, 3090, 2962, 2835, 1635, 1031, 896, 830 cm-1; MS (m/z): 303 (M+); Anal. Calcd 
for C15H17N3O2S: C, 59.38; H, 5.65; N, 13.85; Found: C, 59.36; H, 5.65; N, 13.82. 
 
N-(3,4-dichlorophenyl)-3-cyclopropyl-5-(methylthio)-1H-pyrazole-4-carboxami-
de 5e. White solid; Rf 0.69 (9:1 Chloroform: Methanol); mp 179-181 oC; IR (KBr): 
3298, 3142, 3086, 3001, 2956, 2829, 1631, 1415, 1245, 1023, 828, 782 cm-1; MS 
(m/z): 342 (M+); Anal. Calcd for C14H13Cl2N3OS: C, 49.13; H, 3.83; N, 12.28; Found: 
C, 49.15; H, 3.85; N, 12.26. 
 
N-(3-chloro-4-fluorophenyl)-3-cyclopropyl-5-(methylthio)-1H-pyrazole-4-carbo-
xamide 5f. White solid; Rf  0.65 (9:1 Chloroform: Methanol); mp 179-181 oC; IR 
(KBr): 3287, 3082, 2961, 1628, 1041, 835, 789 cm-1; 1H NMR (300 MHz, CDCl3): δ 
0.80-0.82 (m, 2H, CH2), 0.95-1.03 (m, 2H, CH2), 2.24 (m, 1H, CH), 2.41 (s, 3H, 
SCH3), 7.33-7.39 (m, 1H, Ar-H), 7.55-7.58 (d, 1H, j=4.2Hz, Ar-H), 7.93-7.96 (d, 1H, 
j=6.9Hz, Ar-H), 9.71 (s, 1H, NH), 12.90 (s, 1H, NH); MS (m/z): 325 (M+); Anal. 
Calcd for C14H13ClFN3OS: C, 51.61; H, 4.02;  N, 12.90; Found: C, 51.64; H, 4.05; N, 
12.96. 
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3-Cyclopropyl-N-(2,3-dimethylphenyl)-5-(methylthio)-1H-pyrazole-4-carboxa-
mide 5g. White solid; Rf  0.81 (9:1 Chloroform: Methanol); mp 183-185 oC; IR (KBr): 
3289, 3136, 3094, 3013, 2958, 2826, 1638, 1587, 1418, 1239, 1028, 758, 785 cm-1;  
MS (m/z): 301 (M+); Anal. Calcd for C16H19N3O2S: C, 63.76; H, 6.35; N, 13.94; 
Found: C, 63.76; H, 6.35; N, 13.93. 
 
3-Cyclopropyl-5-(methylthio)-N-(4-nitrophenyl)-1H-pyrazole-4-carboxamide 5h. 
White solid; Rf  0.86 (9:1 Chloroform: Methanol); mp 212-215 oC; IR (KBr): 3278, 
3145, 3097, 3015, 2947, 2832, 1641, 1584, 1408, 1233, 1021, 834 cm-1; MS (m/z): 
318 (M+); Anal. Calcd for C14H14N4O3S: C, 52.82; H, 4.43; N, 17.60; Found: C, 
52.86; H, 4.45; N, 17.63. 
 
3-Cyclopropyl-N-(2-methoxyphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 
5i. White solid; Rf 0.76 (9:1 Chloroform: Methanol); mp 111-113 oC; IR (KBr): 3287, 
3139, 3085, 3011, 2955, 2824, 1631, 1587, 1417, 1241, 1026, 744 cm-1; MS (m/z): 
303 (M+); Anal. Calcd for C15H17N3O2S: C, 59.38; H, 5.65; N, 13.85; Found: C, 
59.36; H, 5.65; N, 13.82. 
 
3-Cyclopropyl-5-(methylthio)-N-o-tolyl-1H-pyrazole-4-carboxamide 5j. White 
solid; Rf 0.63 (9:1 Chloroform: Methanol); mp 142-144 oC; IR (KBr): 3283, 3141, 
3088, 3016, 2967, 2836, 1641, 1593, 1412, 1231, 1037, 755 cm-1; MS (m/z): 287 
(M+); Anal. Calcd for C15H17N3OS: C, 62.69; H, 5.96; N, 14.62; Found: C, 62.68; H, 
5.95; N, 14.62. 
 
3-Cyclopropyl-N-(4-ethylphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 
5k.White solid; Rf  0.71 (9:1 Chloroform: Methanol);  mp 187-189 oC; IR (KBr): 
3287, 3147, 3091, 3008, 2958, 2828, 1638, 1584, 1410, 1248, 1028, 837 cm-1; MS 
(m/z): 301 (M+); Anal. Calcd for C16H19N3O2S: C, 63.76; H, 6.35; N, 13.94; Found: C, 
63.76; H, 6.35; N, 13.93 
 
N-(5-Chloro-2-methoxyphenyl)-3-cyclopropyl-5-(methylthio)-1H-pyrazole-4-car-
boxamide 5l. White solid; Rf  0.69 (9:1 Chloroform: Methanol); mp 205-207 oC; IR 
(KBr): 3285, 3141, 3088, 3013, 2964, 2838, 1634, 1587, 1415, 1238, 1034, 878, 748 
cm-1; MS (m/z): 338 (M+); Anal. Calcd for C15H16ClN3O2S: C, 53.33; H, 4.77; N, 
12.44; Found: C, 53.36; H, 4.75; N, 12.43 
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N-(2,5-dichlorophenyl)-3-cyclopropyl-5-(methylthio)-1H-pyrazole-4-carboxami-
de 5m. White solid; Rf 0.62 (9:1 Chloroform: Methanol); mp 188-187 oC;  IR (KBr):  
3279, 3136, 3079, 3021, 2959, 2831, 1628, 1581, 1422, 1242, 1039, 892, 761 cm-1; 
MS (m/z): 342 (M+); Anal. Calcd for C14H13Cl2N3OS: C, 49.13; H, 3.83; N, 12.28; 
Found: C, 49.15; H, 3.85; N, 12.26. 
 
3-Cyclopropyl-N-(2,5-dimethylphenyl)-5-(methylthio)-1H-pyrazole-4-carboxa-
mide 5n. White solid; Rf  0.78 (9:1 Chloroform: Methanol); mp 177-178 oC; IR (KBr): 
3281, 3087, 2955, 2841, 1631, 1591, 886, 748 cm-1; MS (m/z): 301 (M+); Anal. Calcd 
for C16H19N3O2S: C, 63.76; H, 6.35; N, 13.94; Found: C, 63.76; H, 6.35; N, 13.93. 
 
3-Cyclopropyl-N-(3,4-difluorophenyl)-5-(methylthio)-1H-pyrazole-4-carboxa-
mide 5o. White solid; Rf  0.63 (9:1 Chloroform: Methanol); mp 202-204 oC; IR (KBr): 
3287, 3142, 3093, 3014, 2969, 2838, 1628, 1587, 1410, 1248, 1034, 833, 786 cm-1; 
MS (m/z): 309 (M+); Anal. Calcd for C14H13F2N3OS: C, 54.36; H, 4.24; N, 13.58; 
Found: C, 54.36; H, 4.25; N, 13.59. 
 
3-Cyclopropyl-5-(methylthio)-N-p-tolylisoxazole-4-carboxamide 6a. White solid; 
Rf 0.61 (8:2 hexane-EtOAc); mp 144-146 oC; IR (KBr): 3282, 3149, 3081, 3033, 2978, 
2839, 1630, 1584, 1410, 1236, 1039, 883, 837 cm-1; MS (m/z): 288 (M+); Anal. Calcd 
for C14H13F2N3OS: C, 62.48; H, 5.59; N, 9.71; Found: C, 62.49; H, 5.57; N, 9.72. 
 
N-(4-Chlorophenyl)-3-cyclopropyl-5-(methylthio)isoxazole-4-carboxamide 6b. 
White solid; Rf 0.70 (8:2 hexane-EtOAc); mp 125-127 oC; IR (KBr): 3294, 3149, 
3018, 2895, 1695, 1591, 1496, 1253, 1058, 810, 759, 715, 690 cm-1; 1H NMR (300 
MHz, CDCl3): δ 1.14-1.16 (m, 2H, CH2), 1.25 (m, 2H, CH2), 2.16-2.20 (m, 1H, CH), 
2.68 (s, 3H, SCH3), 7.26-7.33 (m, 1H, Ar-H), 7.53-7.56 (d, 1H, j=8.7Hz, Ar-H), 8.19 
(broad, 1H, CONH); 13C NMR (100 MHz, CDCl3): 6.85, 13.66, 22.72, 29.18, 110.84, 
121.05, 129.13, 136.09, 159.32, 162.66, 172.03; MS (m/z): 308 (M+); Anal. Calcd for 
C14H13ClFN2OS: C, 54.46; H, 4.24;  N, 9.07; Found: C, 54.44; H, 4.25; N, 9.06. 
 
3-Cyclopropyl-N-(4-fluorophenyl)-5-(methylthio)isoxazole-4-carboxamide 6c. 
White solid; Rf 0.59 (8:2 hexane-EtOAc); mp 133-138 oC; IR (KBr): 3289, 3139, 
3083, 3017, 2966, 1643, 1410, 1249, 885, 836  cm-1; MS (m/z): 292 (M+); Anal. Calcd 
for C14H13FN2OS: C, 57.52; H, 4.48; N, 9.58;  Found: C, 57.49; H, 4.47; N, 9.52. 
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3-Cyclopropyl-N-(4-methoxyphenyl)-5-(methylthio)isoxazole-4-carboxamide 6d. 
White solid; Rf 0.67 (8:2 hexane-EtOAc); mp 120-123 oC; IR (KBr): 3288, 3147, 
3095, 3031, 2965, 2837, 1637, 1592, 1409, 1247, 1036, 891, 833 cm-1; MS (m/z): 304 
(M+); Anal. Calcd for C15H16N2O3S: C, 59.19; H, 5.30; N, 9.20;  Found: C, 59.19; H, 
5.31; N, 9.22. 
 
N-(3,4-dichlorophenyl)-3-cyclopropyl-5-(methylthio)isoxazole-4-carboxamide 6e. 
White solid; Rf 0.62 (8:2 hexane-EtOAc); mp 180-182 oC; IR (KBr): 3295, 3148, 
3091, 3011, 2951, 2831, 1625, 1587, 1418, 1241, 1029, 832, 779  cm-1; MS (m/z): 343 
(M+); Anal. Calcd for C14H12Cl2N2O2S: C, 48.99; H, 3.52; N, 8.16;  Found: C, 48.97; 
H, 3.53; N, 8.12. 
 
N-(3-chloro-4-fluorophenyl)-3-cyclopropyl-5-(methylthio)isoxazole-4-carboxa-
mide 6f. White solid; Rf 0.69 (8:2 hexane-EtOAc); mp 197-199 oC; IR (KBr): 3288, 
3139, 3072, 3017, 2969, 2834, 1631, 1587, 1417, 1237, 1046, 839, 791 cm-1; MS 
(m/z): 327 (M+); Anal. Calcd for C14H12ClFN2O2S: C, 51.46; H, 3.70; N, 8.57;  
Found: C, 51.47; H, 3.73; N, 8.54. 
 
3-Cyclopropyl-N-(2,3-dimethylphenyl)-5-(methylthio)isoxazole-4-carboxamide 
6g. White solid Rf 0.72 (8:2 hexane-EtOAc); mp 181-183 oC; IR (KBr): 3297, 3138, 
3089, 3015, 2952, 2823, 1631, 1591, 1421, 1237, 1025, 754, 787;MS (m/z): 302 (M+); 
Anal. Calcd for C16H18N2O2S: C, 63.55; H, 6.00; N, 9.26;  Found: C, 63.57; H, 6.03; 
N, 9.24. 
 
3-Cyclopropyl-5-(methylthio)-N-(4-nitrophenyl)isoxazole-4-carboxamide 6h. 
White solid Rf 0.58 (8:2 hexane-EtOAc); IR mp 177-179 oC; IR (KBr): 3277, 3148, 
3091, 3004, 2942, 2839, 1636, 1591, 1419, 1241, 1033, 837 cm-1;MS (m/z): 319 (M+); 
Anal. Calcd for C14H13N3O4S: C, 52.66; H, 4.10; N, 13.16;  Found: C, 52.65; H, 4.13; 
N, 13.14. 
 
3-Cyclopropyl-N-(2-methoxyphenyl)-5-(methylthio)isoxazole-4-carboxamide 6i. 
White solid Rf 0.63 (8:2 hexane-EtOAc); mp 131-133 oC; IR (KBr): 3285, 3142, 3083, 
3013, 2964, 2833, 1637, 1591, 1414, 1246, 1028, 746 cm-1;MS (m/z): 304 (M+); Anal. 
Calcd for C15H16N2O3S: C, 59.19; H, 5.30; N, 9.20;  Found: C, 59.19; H, 5.31; N, 
9.22. 
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3-Cyclopropyl-5-(methylthio)-N-o-tolylisoxazole-4-carboxamide 6j. White solid; 
Rf 0.67 (8:2 hexane-EtOAc);  mp 155-157 oC; IR (KBr): 3285, 3145, 3091, 3003, 
2964, 2831, 1639, 1589, 1413, 1237, 1029, 761 cm-1; MS (m/z): 288 (M+); Anal. 
Calcd for C14H13F2N3OS: C, 62.48; H, 5.59; N, 9.71;  Found: C, 62.49; H, 5.57; N, 
9.72. 
 
3-Cyclopropyl-N-(4-ethylphenyl)-5-(methylthio)isoxazole-4-carboxamide 6k. 
White solid; Rf 0.72 (8:2 hexane-EtOAc); mp 160-162 oC; IR (KBr): 3282, 3143, 
3093, 3013, 2952, 2822, 1631, 1586, 1418, 1241, 1031, 839 cm-1; MS (m/z): 302 
(M+); Anal. Calcd for C16H18N2O2S: C, 63.55; H, 6.00; N, 9.26;  Found: C, 63.57; H, 
6.03; N, 9.24. 
 
N-(5-chloro-2-methoxyphenyl)-3-cyclopropyl-5-(methylthio)isoxazole-4-carboxa- 
mide 6l. White solid; Rf 0.65 (8:2 hexane-EtOAc); mp 220-222 oC; IR (KBr): 3291, 
3139, 3092, 3005, 2968, 2842, 1639, 1582, 1425, 1231, 1029, 872, 739  cm-1; MS 
(m/z): 338 (M+); Anal. Calcd for C15H15ClN2O3S: C, 53.17; H, 4.46; N, 8.27;  Found: 
C, 53.19; H, 4.43; N, 8.29. 
 
N-(2,5-dichlorophenyl)-3-cyclopropyl-5-(methylthio)isoxazole-4-carboxamide 
6m. White solid; Rf 0.73 (8:2 hexane-EtOAc); mp 202-204 oC;  IR (KBr): 3281, 3139, 
3081, 3019, 2951, 2829, 1632, 1584, 1426, 1238, 1037, 894, 763 cm-1; MS (m/z): 343 
(M+); Anal. Calcd for C14H12Cl2N2O2S: C, 48.99; H, 3.52; N, 8.16;  Found: C, 48.97; 
H, 3.53; N, 8.12. 
 
3-Cyclopropyl-N-(2,5-dimethylphenyl)-5-(methylthio)isoxazole-4-carboxamide 
6n. White solid; Rf 0.58 (8:2 hexane-EtOAc); mp 208-210 oC; IR (KBr): 3287, 3139, 
3091, 3007, 2959, 2839, 1634, 1594, 1419, 1243, 1029, 882, 742 cm-1; MS (m/z): 302 
(M+); Anal. Calcd for C16H18N2O2S: C, 63.55; H, 6.00; N, 9.26;  Found: C, 63.57; H, 
6.03; N, 9.24. 
 
3-Cyclopropyl-N-(3,4-difluorophenyl)-5-(methylthio)isoxazole-4-carboxamide 6o.  
White solid; Rf 0.67 (8:2 hexane-EtOAc); mp 223-225 oC; IR (KBr): 3292, 3139, 
3089, 3008, 2964, 2842, 1632, 1591, 1417, 1239, 1041, 839, 779 cm-1; MS (m/z): 310 
(M+); Anal. Calcd for C14H12Cl2N2O2S: C, 54.19; H, 3.90; N, 9.03;  Found: C, 54.17; 
H, 3.93; N, 9.02. 
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1H NMR spectrum of compound 4b 
  
 
1H NMR spectrum of compound 4d 
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1H NMR spectrum of compound 5b 
 
 
Expanded 1H NMR spectrum of compound 5b 
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1H NMR spectrum of compound 5e 
 
 
Expanded 1H NMR spectrum of compound 5e 
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1H NMR spectrum of compound 5c 
 
 
1H NMR spectrum of compound 6b 
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13C NMR spectrum of compound 5b 
 
 
Expanded 13C NMR spectrum of compound 5b 
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13C NMR spectrum of compound 6b 
 
 
Expanded 13C NMR spectrum of compound 6b 
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MASS spectrum of compound 5a 
 
 
MASS spectrum of compound 5d 
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 MASS spectrum of compound 6c 
 
 
MASS spectrum of compound 6d 
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IR spectrum of compound 5b 
 
 
IR spectrum of compound 6b 
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4.1 Introduction 
 
 Biaryls and heterobiaryls have attracted significant attention from the 
scientific community because of their relevance in medicinal chemistry. Heterobiaryls 
frequently can be observed in numerous bioactive small molecules, and in particular, 
heterobiaryls fused with various heterocycles, such as pyrazole, pyridine, and 
pyrimidine, have been used as key pharmacophores.1 Pyrazolo[1,5-a]pyrimidines have 
attracted considerable interest because of their biological activity. For instance, this 
heterocyclic system is found as purine analogues and has useful properties as 
antimetabolites in purine biochemical reactions.2 Several compounds of this class 
display interesting antitrypanosomal3 and antischistosomal activities.4 They are used 
as HMG-CoA reductaseinhibitors,5 COX-2 selective inhibitors,6 30,50-cyclic-AMP 
phosphodiesteraseinhibitors,7 CRF1 antagonists,8a-d selective peripheral 
benzodiazepine receptor ligands,9a-c potassium channel10 and histamine-3 receptor 
ligands11 and antianxiety agents.12  
 Some pyrazolopyrimidines serve as efficient sedative-hypnotic and anxiolytic 
drugs like zaleplon (Sonata, hypnotic),13 indiplon (hypnotic),14 and ocinaplon 
(anxiolytic),15 fasiplon (anxiolytic),16 (Figure-1) these drugs are related to the class of 
nonbenzodiazepines, and their therapeutic effect is due to allosteric enhancement of 
the action of the inhibitory neurotransmitter GABA at the GABAA receptor.13-14 These 
examples emphasize the importance of pyrazol-fused heterobiaryls, as well as 
pyrazolopyridines, as key pharmacophores in bioactive small molecules. 
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4.2 Biological activity related to pyrazolopyrimidine derivatives 
 
 Pyrazolopyrimidines have multiple pharmacological activities including 
hypnotic, anti-inflammatory, anti-tumor, antimycobacterial, antidiabetic, 
antiphlogistic agents, antidepressants, analgesics and anti-viral. Several diverse 
biological activities have been reported for pyrazolopyrimidine ring systems which 
are described as below. 
 Ivashchenko et al.17 reported that substituted 3-(arylsulfonyl)pyrazolo[1,5-a] 
pyrimidines (Figure-2) are claimed as antagonists of serotonin 5-HT6 receptors for 
treating and preventing pathol. states and diseases of the central nervous system in 
humans and warm-blooded animals, the pathogenesis of which is caused by disorder 
in the serotonin 5-HT6 receptor activation. 
 
Figure-2 
 Alexandre V. Ivachtchenko et al.18 has described structure activity 
relationships for a series of novel 2-substituted 3-benzenesulfonyl-5,6-dimethyl-
pyrazolo[1,5-a]pyrimidines. In spite of a wide, four orders of magnitude, SAR range 
(Ki varied from 260 pM to 2.96 mM), no significant correlation of 5-HT6R 
antagonistic potency was observed with major physiochemical characteristics, such as 
molecular weight, surface polar area, cLogP, or number of rotatable bonds. 
Statistically significant trend was only observed for size of substitute group, which 
was not enough to explain the deep SAR trend. Besides with the substitute group size, 
another factor that presumably plays a role in defining the compound potencies isa 
relative position of the heterocycle and sulfophenyl moieties. Among all synthesized 
derivatives, (3 benzenesulfonyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-
amine (Figure-3) is the most potent(Ki ¼ 260 pM) and extremely selective, 5000 to 
>50,000-fold relative to 55 therapeutic targets, antagonist of the 5-HT6 receptor. 
 
Figure-3 
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 Silvia Selleri et al.19 have been developed a new class of N,N-diethyl-(2-
arylpyrazolo[1,5-a]pyrimidin-3-yl)acetamides, (Figure-4)  as azaisosters of Alpidem, 
and their affinities for both the peripheral (PBR) and the central (CBR) 
benzodiazepine receptors were evaluated. Binding assays were carried out using both 
[3H]PK 11195 and [3H]Ro 5-4864 as radio ligands for PBR, whereas [3H]Ro 15-1788 
was used for CBR, in rat kidney and rat cortex, respectively. The tested compounds 
exhibited a broad range of binding affinities from as low as 0.76 nM to inactivity and 
most of them proved to be high selective ligands for PBR. The preliminary SAR 
studies suggested some of the structural features required for high affinity and 
selectivity; particularly the substituent on the pyrimidine moiety seemed to play an 
important role in PBR versus CBR selectivity. A subset of the highest affinity 
compounds was also tested for their ability to stimulate steroid biosynthesis in C6 
glioma rat cells and some of these were found to increase pregnenolone formation 
with potency similar to RO 5-4864 and PK 11195.  
 
Figure-4 
 John E. Tellew et al.20 has discovered an antagonist of the corticotropin-
releasing factor (CRF) neuropeptide may prove effective in treating stress and anxiety 
related disorders. In an effort to identify antagonists with improved physico-chemical 
properties a new series of CRF1 antagonists were designed to substitute the propyl 
groups at the C7 position of the pyrazolo[1,5-a]pyrimidine core with heterocycles. 
Compound (Figure-5) was identified as a high affinity ligand with a pKi value of 8.2 
and a functional CRF1 antagonist with IC50 value of 7.0 in the in vitro CRF ACTH 
production assay. 
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Figure-5 
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 Song Qing Wang et al.21 have been designed some new 5-methyl-7-
substituted–pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives on the basis of the 
Zaleplon structure for studies on their hypnotic activity. The preliminary 
pharmacological evaluations indicated that some compounds showed hypnotic 
activity, among that one compound (Figure-6) was the most potent one. 
 
Figure-6 
 Robert H. Springer et al.22 has prepared a number of 3,7-disubstituted 6-
carbethoxypyrazolo[ 1,5-a]pyrimidines and 3,7-disubstituted 6-ethoxypyrazolo-[1,5-
a]pyrimidines (Figure-7) have been and evaluated as adenosine cyclic 3’,5’-
phosphate (cAMP) phosphodiesterase (PDE) inhibitors vs. the low K, enzyme isolated 
from beef heart, rabbit lung, and kidney preparations. The results were found to be 
between 0.5 to 13 times as potent as theophylline as inhibitors of PDE, depending on 
the tissue source. A number of these PDE inhibitors exhibited significant 
physiological effects in different animal systems, suggesting it should be possible to 
obtain selective PDE inhibition in various tissues. Several of these heterocycles were 
found superior to adenosine in inhibiting ADP-induced platelet aggregation in vitro. 
N
N
N
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R2
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N
N
N
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O
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R1=H, C2H5, NO2, Br, COOEt
R2=OH, NH2,OC2H5, SH, SC2H5  
Figure-7 
 Robin R. Frey et al.23 have discovered 7-aminopyrazolo[1,5-a]pyrimidine urea 
receptor tyrosine kinase inhibitors. Investigation of structure-activity relationships of 
the pyrazolo[1,5-a]pyrimidine nucleus led to a series of 6-(4-N,N′-diphenyl)ureas that 
potently inhibited a panel of vascular endothelial growth factor receptor (VEGFR) 
and platelet-derived growth factor receptor (PDGFR) kinases. Several of these 
compounds are potent inhibitors of kinase insert domain-containing receptor tyrosine 
kinase (KDR) both enzymatically(<10 nM) and cellularly (<10 nM).  
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In addition, compound (Figure-8) possesses a favorable pharmacokinetic profile and 
demonstrates efficacy in the estradiol-induced murine uterine edema (UE) model 
(ED50) 1.4mg/kg). 
 
Figure-8 
 Rui Ding et al.24 has synthesized compound 5-((2-aminoethylamino)methyl)-
7-(4-bromoanilino)-3-cyanopyrazolo[1,5-a]pyrimidine (ABCPP) via conjugated with 
N-mercaptoacetylglycine (MAG), N-mercaptoacetylphenylalanine (MAF) and N-
mercaptoacetylvaline (MAA), (Figure-9) respectively. These three compounds were 
labeled successfully with [99mTcN]2+intermediate in high radiochemical purities. 
Biodistribution in tumor-bearing mice demonstrated that the three new complexes 
showed tumor accumulation, high tumor-to muscle (T/M) ratios and fast clearance 
from blood and muscle. Among them, the 99mTcNMAG-ABCPP showed the most 
favorable characteristics, with tumor/blood and tumor/muscle ratios reaching 1.51 and 
2.97 at 30 min post-injection, 1.84 and 2.49 at 60 min post-injection, suggesting it 
could be further studied as potential tumor imaging agent for single photon emission 
computed tomography (SPECT). 
 
Figure-9 
 Osama M. Ahmed et al.25 has synthesized some new pyrazolo[1,5-
a]pyrimidine derivatives, (Figure-10) which showed potent anti-tumor cytotoxic 
activity in vitro using different human cancer cell linesHepG2 (hepatocellular 
carcinoma cell line), MCF7 (breastcarcinoma cell line), HCT116 (colon carcinoma 
cell line), HeLa (cervix carcinoma cell line). 
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Figure-10 
 Naveen Mulakayala et al.26 has synthesized some new 7-trifluoromethyl 
substituted pyrazolo[1,5-a]pyrimidines (Figure-11) with potent antitumor agents. The 
cytotoxic effects of the newly synthesized pyrazolo[1,5-a]pyrimidines against 
leukemiacells, K562 and human colon carcinoma cells, Colo-205 were evaluated. 
N
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R1=H, R2=H, Cl, Br, F, Me  
Figure-11 
 
4.3 Various synthetic approaches for substituted 
 pyrazolopyrimidine derivatives 
 
 As mention previously, pyrazolopyrimidine ring system is present in a variety 
of biologically active compounds (both naturally-occurring and synthetic). Although a 
large number of methods for their synthesis have been documented in the literature, 
many of them require multistep procedures using intermediates which are not readily 
available. Among them, few methods are discussed here.  
 Abbas-Temirek, H. H. synthesized some new bridged nitrogen pyrazolo[1,5-
a]pyrimidines from 5-amino-3-methylthio-1H-pyrazole-4-carboxylate (Figure-12) 
under refluxing with acetic acid.27 
 
Figure-12 
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 Yan-Chao Wu et al.28 were established an efficient, fast and facile 
pyrazolo[1,5-a]pyrimidine (Figure-13) synthetic protocol for the condensation of 
aminopyrazoles with 1,3-dicarbonyl components in AcOH/H2SO4 system. 
 
Figure-13 
 G. G. Danagulyan et al.29 have described condensation of ethyl 3-
aminopyrazole-4-carboxylate (1) with ethyl ethoxymethylenecyanoacetate (2) was 
carried out with the aim of preparing diethyl 7-aminopyrazolo[1,5-a]pyrimidine-3,6-
dicarboxylate (3) and subsequent study of its C–C recyclization to the isomeric 6-
carbamoyl-7-hydroxypyrazolopyrimidine but the reaction did not go to completion, 
on the basis of NMR it was clear that a mixture of compounds including both the 
cyclization product (3)and the uncyclized condensation adduct ethyl 3-[(2-cyano-3-
ethoxy-3-oxoprop-1-en-1-yl)amino]-1H-pyrazole-4-carboxylate (4) had been 
obtained. However, in basic medium both the condensed pyrazolopyrimidine (3) and 
the cyano derivative (4) were converted in high yield to the 6-carbamoyl-7-
hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylic acid (5) (Figure-14).  
 
Figure-14 
 Li Ming et al.30 was reported a convenient, rapid, and highly selective method 
for synthesis of new Pyrazolo[1,5-a]pyrimidines (Figure-15) via the Reaction of 
enaminones and5-amino-1H-pyrazoles under Microwave Irradiation. 
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Figure-15 
 Abraham Thomas et al.31 has described a facile highly regioselective general 
route to substituted and fused pyrazolo[a]pyrimidines via cyclocondensation of 
oxoketene dithioacetals with 3-aminopyrazoles (Figure-16). 
 Figure-16 
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 Pushpak Mizar et al.32 have been described a facile method for the synthesis of 
pyrazolo[1,5-a]pyrimidine (Figure-17) by reacting N-substituted or unsubstituted-
pyrazol-5(4H)-one, aryl-oxoketene dithioacetals and alkyl amide. 
 
Figure-17 
 Recently, Ibtissam  Bassoude et al.33 described one step condensation reaction 
of of 5(3)-amino-3(5)-arylpyrazoles with 4-hydroxy-6-methylpyran-2-one leading to 
new  pyrazolo[1,5-a]pyrimidines(Figure-18). 
 Figure-18 
 V. N. Britsun was reported cyclocondensation products of N-aryl-3-
oxobutanethioamides with 5-amino-3-R-4-R1-pyrazoles are 4-(arylamino)-2-methyl-
7-R-8-R1-pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a]pyrimidine-4-thione 
derivatives (Figure-19), the ratio of which depends on the nucleophilicity of the 
starting 5-amino-3-R-4-R1- pyrazoles and the presence of a proton donor solvent.34 
 Figure-19 
 D. V. Kryl’skii et al.35 has described Three-component condensation of 3-
methyl(or methoxymethyl)-4-phenyl-1H-pyrazol-5-amine with triethylorthoformate 
and carbonyl compounds or nitriles containing an activated methylene group 
(cyclohexane-1,3-diones, acetoacetanilides, benzoylacetone, ethyl cyanoacetate, 
malononitrile, 1H-benzimidazol-2-yl-acetonitrile) gave substituted 
pyrazolopyrimidines (Figure-20). 
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Figure-20 
 Sayed A. Ahmed et al.36 have synthesized pyrazolo[1,5-a]pyrimidines from 
the appropriate 3-aminopyrazoles with the appropriate sodium (3-oxocycloalkylidene) 
methenolate, β-diketone, β-keto esters or 1,2-disubstitutedacrylonitrile (Figure-21). 
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Figure-21 
 Mohamed R. Shaaban et al.37 have described a simple, facile, efficient and one 
pot three-component procedure for the synthesis of pyrazolo[1,5-a]pyrimidine ring 
systems incorporating phenylsulfonyl moiety was developed via the reaction of 1-
aryl-2-(phenylsulfonyl)ethanone derivatives with the appropriate heterocyclic amine 
and triethylorthoformate (Figure-22). 
Figure-22 
Baseer M. Shaikh et al.38 has prepared pyrazolo [1, 5-a] pyrimidines derivative by the 
condensation of substituted of α, β- unsaturated carbonyl compounds (chalcones) with  
substituted 5-aminopyrazole as an alternative polyethylene glycol (PEG-400) as green 
reaction medium (Figure-23). 
 Figure-23 
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4.4 Current research work 
 
 The pyrazolopyrimidine derivatives have considerable chemical and 
pharmacological importance because of a broad range of biological activities 
displayed by these classes of molecules. As we demonstrated, the tremendous 
biological potential of pyrazolopyrimidine derivatives encouraged us to synthesize 
some new highly functionalized pyrazolopyrimidine derivatives. Various 
methodologies have been described for the synthesis of pyrazolopyrimidine 
derivatives. However, the existing methods are suffer with some drawbacks, such as; 
yield, time, product isolation, isomer formation.  
 As a part of our ongoing interest on the synthesis of various heterocyclic 
compounds using ketene dithioacetals, we have demonstrated that ketene dithioacetals 
are versatile intermediate for the synthesis of pyrazolopyrimidine derivatives. Thus, to 
explore further, we sought that the reaction of various ketene dithioacetals with 5-
amino-N-cyclohexyl-3-(methylthio)-1H-pyrazole-4-carboxamide in the presence of 
base in isopropyl alcohol could be an effective strategy to furnish the novel 
pyrazolopyrimidine derivatives. Here we describe the novel synthetic methodology 
for the fused pyrazolopyrimidines. 
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4.5 Results and discussion 
Scheme: Synthesis of novel substituted Pyrazolo[1,5-a]pyrimidines derivatives. 
Scheme-01 
 
Scheme-02 
 
Scheme-03 
 
Where R= CH3, CH(CH3)2, (CH2)3 , R1= CH3, OCH3 NO2,Cl 
 
 Preparation of the target compounds was initiated by the reaction of 
ethylcynoacetate (1) with cyclohexyl amines (2) in toluene at reflux temperature to 
afford the cyanoacetamides (3) in 90% yields. This product undergoes reaction with 
carbon disulfide in the presence of base in DMF followed by methylation to afford 
corresponding 2-cyano-3,3-bis(methylthio)-N-phenylacrylamide (4). Which on 
reaction with hydrazine hydrate undergoes cyclization to form 5-amino-N-cyclohexyl-
3-(methylthio)-1H-pyrazole-4-carboxamide (5) (Scheme-1).   
 Various acetoacetanilide (8a-x) were synthesized by reacting substituted 
amine (7a-h) with various β-keto esters (6a-c) in toluene in the presence of catalytic 
amount of KOH at reflux temperature for 15-20 h.  
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 Twenty four different acetoacetanilide were synthesized bearing various 
electron donating and electron withdrawing groups such as 2,3-diCH3; 3,4-diCH3; 4-
CH3; H; 2,5-diCH3; 2,4-diCH3; 3-Cl-4-F; 4-F; 4-Cl; 2-Cl; 2-F; 4-OCH3; 2,5-diCl and 
3-NO2 on the phenyl ring. Thus, it has been found that reaction of substituted 
acetoacetanilide 8a-x derivatives with carbon disulfide in the presence of potassium 
carbonate followed by the alkylation with methyl iodide (Scheme-2) gave the novel 
ketene dithioacetals 9a-x. The resulting various ketene dithioacetals (9a-x) were 
reacted with 5-amino-N-cyclohexyl-3-(methylthio)-1H-pyrazole-4-carboxamide (5) in 
the presence of NaHCO3 and methanol as a solvent to afford highly substituted 
pyrazolo[1,5-a]pyrimidines (10a-x)  in low yield  (Table-1 and 2). To optimize the 
reaction condition for the synthesis of compound 10a, various solvents and various 
bases were utilized. As a result, we found the reaction of 9a with 5 was faster and 
afforded the pyrazolo[1,5-a]pyrimidine10a in good yield in the presence of K2CO3 as 
a base and isopropyl alcohol (Scheme-3). 
Table-1: Reaction of 9a with various solvents in the presence of base. 
Entry Solvent Base Time hrs Yield % 
1 Methanol NaHCO3 20 65 
2 Ethanol NaHCO3 18 68 
3 Isopropyl alcohol NaHCO3 16 70 
4 Dioxane NaHCO3 15 58 
5 DMF NaHCO3 10 60 
6 Methanol Na2CO3 14 70 
7 Ethanol Na2CO3 13 72 
8 Isopropyl alcohol Na2CO3 10 78 
9 Dioxane Na2CO3 10 75 
10 DMF Na2CO3 8 68 
11 Methanol K2CO3 10 75 
12 Ethanol K2CO3 10 80 
12 Isopropyl alcohol K2CO3 8 94 
14 Dioxane K2CO3 8 82 
15 DMF K2CO3 7 78 
16 AcOH CH3COONa 8 65 
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Table-2: synthesis of novel substituted and fused pyrazolopyrimidine derivatives.  
Entry R R1 Time hrs Yield (%) 
10a CH3 4-CH3 8.0 94 
10b CH3 3-Cl 7.5 92 
10c CH3 3-Cl, 4-F 7.5 90 
10d CH3 4-Cl 7.0 88 
10e CH3 4-F 7.0 92 
10f CH3 4-NO2 9.0 95 
10g CH3 4-OCH3 8.0 90 
10h CH3 2,5diCH3 8.5 89 
10i (CH3)2CH 4-CH3 8.0 93 
10j (CH3)2CH 3-Cl 7.0 87 
10k (CH3)2CH 3-Cl, 4-F 7.5 95 
10l (CH3)2CH 4-Cl 7.0 94 
10m (CH3)2CH 4-F 7.5 92 
10n (CH3)2CH 4-NO2 8.5 97 
10o (CH3)2CH 4-OCH3 8.0 94 
10p (CH3)2CH 2,5diCH3 8.5 90 
10q (CH2)2CH 4-CH3 8.5 88 
10r (CH2)2CH 3-Cl 7.5 92 
10s (CH2)2CH 3-Cl, 4-F 7.0 87 
10t (CH2)2CH 4-Cl 7.5 90 
10u (CH2)2CH 4-F 8.0 93 
10v (CH2)2CH 4-NO2 8.5 96 
10w (CH2)2CH 4-OCH3 7.5 90 
10x (CH2)2CH 2,5diCH3 8.0 87 
 
 The structures of compound 5 were established on the basis of their elemental 
analysis and spectral data (MS, IR, and 1H NMR). The analytical data for 5 revealed a 
molecular formula C11H18N4OS (m/z 254). The 1H NMR spectrum revealed a 
multiplets at δ = 1.20-1.98 assigned to 10 protons of (5x CH2) groups in cyclohexane 
ring, a singlet at δ = 2.48 ppm assigned to - SCH3, a multiplet at δ = 3.96-3.99 ppm 
assigned to the –CH protons of cyclohexane ring,  
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one broad singlet at δ = 5.57 ppm assigned to –NH2 groups, one singlet at δ = 7.28 
ppm assigned to –CONH groups and one broad singlet observed at δ = 11.9 ppm 
assigned to pyrazole -NH. 
 The structures of 9a-x were established on the basis of their elemental analysis 
and spectral data (MS, IR, and 1H NMR). The analytical data for 9i revealed a 
molecular formula C16H21NO2S2 (m/z 323). The 1H NMR spectrum revealed a singlet 
at δ = 1.18-1.20 ppm assigned to isopropyl-CH3, a singlet at δ = 1.57 ppm assigned to 
the –CH3 protons, a singlet at δ = 2.44 ppm assigned to (2 × SCH3), a multiplet at δ = 
3.17-3.24 ppm assigned to the isopropyl -CH protons, a multiplets at δ = 6.99–7.54 
ppm assigned to the aromatic protons, and one broad singlet at δ = 8.38 ppm assigned 
to -CONH groups.  
 The structures of 10a-x were established on the basis of their elemental 
analysis and spectral data (MS, IR, 1H NMR and 13C NMR). The analytical data for 
10b revealed a molecular formula C23H26ClN5O2S2 (m/z 503). The 1H NMR spectrum 
revealed a multiplets at δ = 1.35-1.81 assigned to 10 protons of (5x CH2) groups in 
cyclohexane ring, a singlet at δ = 2.45 ppm assigned to - SCH3,a singlet at δ = 2.70 
ppm assigned to - CH3, a multiplet at δ = 3.79 ppm assigned to the –CH protons of 
cyclohexane ring, a multiplet at δ = 7.05–8.00 ppm assigned to the aromatic protons, 
one singlet at δ = 8.56 ppm assigned to –CONH groups attached with cyclohexane 
ring, and one singlet observed at δ = 12.56 ppm assigned to –CONH group attached 
with phenyl ring. 
 The proposed mechanism for the cyclization is shown in Figure-24. The 
endocyclic-NH in compound A is the most nucleophilic center it is also the most 
sterically hindered site. Therefore, addition takes place at the exocyclic-NH2 groups. 
The nucleophilic amino group attacks on the double bond via a Michael addition 
reaction, followed by loss of the thiomethane group. The intermediate D then cyclizes 
with subsequent dehydration E to afford the pyrazolopyrimidine derivative F. 
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? Mechanism:- 
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Figure 24: Proposed mechanism for the formation of pyrazolopyrimidine. 
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4.6 Conclusion 
 
 In summary, the heterocyclizations of various ketene dithioacetals with 5-
aminopyrazole derivative were studied in details, and the influence of the reaction 
parameters and the aminoazole structure on the direction of the reaction was 
established. We found that the reaction of various ketene dithioacetal 9a-x with 5-
aminopyrazole derivative 5 were faster and afforded the pyrazolo[1,5-a]pyrimidine 
10a-x in good yield in the presence of K2CO3 as a base and isopropyl alcohol. The 
results of the study described above have led to the development of a simple approach 
for synthesis of pyrazolo[1,5-a]pyrimidines, substances that potentially interesting 
biological and medicinal properties.  
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4.7 Experimental section 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (300 MHz), 1H (400 MHz), 13C (75 MHz) and 13C (100 MHz)  
NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl3 and 
DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal 
standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 
mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were measured in open capillaries and are uncorrected. 
 
? Synthesis of 2-cyano-N-cyclohexylacetamide (3). 
 In a 250mL round bottom flask equipped with magnetic stirrer and 
thermometer was placed ethyl 2-cyanoacetate (0.25mol), cyclohexyl amine (0.25mol) 
and toluene (100 mL). The reaction mixture was heated up to 110-115 oC for 8 h. The 
progress of reaction was monitored by thin layer chromatography. The reaction 
mixture was cooled to room temperature and the solid product was filtered, washed 
with toluene to afford 90% yield.  
 
? Synthesis of 2-cyano-N-cyclohexyl-3,3-bis(methylthio)acrylamide (4). 
 A 100mL conical flask equipped with magnetic stirrer and septum was 
charged with a solution of 2-cyano-N-cyclohexylacetamide (3), (10 mmol) in DMF 
(10 mL). Dry K2CO3 (10 mmol) was added and the mixture was stirred at room 
temperature for 2 h.  CS2 (30 mmol) was added and the mixture was stirred for an 
additional 2 h at room temperature. Then, methyl iodide (20 mmol) was added at 0-5 
oC and the mixture was stirred for 4 h at room temperature. The progress of the 
reaction was monitored by thin layer chromatography. After completion of the 
reaction, it was poured into 50ml cold water. The precipitated crude product was 
purified by filtration followed by crystallization from EtOH. 
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? Synthesis of 5-amino-N-cyclohexyl-3-(methylthio)-1H-pyrazole-4-
carboxamide (5). 
 
 A 100mL conical flask equipped with magnetic stirrer and septum was 
charged 2-cyano-N-cyclohexyl-3,3-bis(methylthio)acrylamide (4) (0.1mol) in  
isopropyl alcohol (100 mL) and hydrazine hydrate (0.1mol). The Reaction mixture 
was heated to reflux for 2 h. After completion of the reaction, it was poured into 
50mL cold water. The precipitated crude product was purified by filtration followed 
by crystallization from EtOH. 
 
? General synthesis of Acetoacetanilide derivatives (AAA) (8a-x). 
 A mixture containing the primary amine (7a-h) (10 mmol), β-keto esters (6a-
c) (10 mmol), and catalytic amount of sodium or potassium hydroxide (10 %) in 
toluene (50 mL) was refluxed at 110 oC for 12-15 h. The reaction was monitored by 
TLC. After completion of reaction, the solvent was removed under vaccuo and the 
residue was crystallized from methanol. 
 
? General synthesis of ketene dithioacetals (9a-x). 
 A 100mL conical flask equipped with magnetic stirrer and septum was 
charged with a solution of acetoacetanilide derivatives (8a-x) (10 mmol) in DMF (10 
mL). Dry K2CO3 (20 mmol) was added and the mixture was stirred for 2 h at room 
temperature. CS2 (10 mmol) was then added and the mixture was stirred for an 
additional 2 h at room temperature. Methyl iodide (20 mmol) was added at 0-5 oC and 
the mixture was stirred for 4 h at room temperature. The reaction was monitored by 
TLC. After completion, reaction mixture poured into water (50 mL). The precipitated 
crude product was purified by filtration followed by crystallization from EtOH.  
 
? General synthesis of substituted and fused pyrazolopyrimidines (10a-x). 
 A mixture of 5-amino-N-cyclohexyl-3-(methylthio)-1H-pyrazole-4-
carboxamide (5) (3.0mmol), potassium carbonate (6.0mmol) and ketene dithioacetals 
(9a-x) (3.0mmol) in isopropyl alcohol (10 mL) was heated to reflux for 7-10 h. The 
progress of reaction mixture was monitored by TLC. After completion of reaction, the 
mixture was cooled to room temperature and solid residue was filtered and washed 
with 10mL of isopropyl alcohol followed by 50 ml of water. The product was 
crystallized from MeOH to give 10a-x in 87-97% yield. 
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? Spectral data of newly synthesized compounds 
 
2-(bis(methylthio) methylene)-4-methyl-3-oxo-N-p-tolylpentanamide 9i. yellow 
solid; mp 155-158°C; Rf 0.54 (8:2 hexane-EtOAc); IR (KBr): 3373, 3072, 2895, 2828, 
1694, 1635, 1482, 1343, 1298 cm-1; 1H NMR (400 MHz, DMSO): δ 1.18-1.20 (m, 
6H, 2 × iprCH3), 1.57 (s, 3H, CH3), 2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 
6.99–7.54 (m, 4H, Ar), 8.38  (br, s, 1H, -CONH); MS (m/z):323 [M+];Anal. Calcd for 
C16H21NO2S2: C, 59.41; H, 6.54; N, 4.33; Found: C, 59.33; H, 6.45; N, 4.23. 
 
2-(bis(methylthio)methylene)-N-(4-methoxyphenyl)-4-methyl-3-oxopentanamide 
9o. yellow solid; mp 169-171°C; Rf 0.57 (8:2 hexane-EtOAc); IR (KBr): 3439, 3007, 
2928, 2808, 1599, 1462, 1327, 1255 cm-1; 1H NMR (400 MHz, DMSO): δ 1.18-1.20 
(m, 6H, 2 × iprCH3), 2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 3.75 (s, 3H, 
OCH3), 6.99–7.54 (m, 4H, Ar), 8.38  (br, s, 1H, -CONH); MS (m/z):339 [M+];Anal. 
Calcd for C16H21NO3S2: C, 56.61; H, 6.24; N, 4.13; Found: C, 56.53; H, 6.14; N, 4.06. 
 
N-(4-chlorophenyl)-2-(cyclopropylcarbonyl)-3,3-bis(methylsulfanyl)prop-2-
enamide 9t. Yello solid; mp 138-140°C, Rf 0.52 (8:2 hexane-EtOAc); IR (KBr): 3364, 
2927, 1674, 1533, 1462, 1281, 1112, 873 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.02-
1.06 (m, 2H, CH2), 1.21-1.24 (m, 2H, CH2), 2.37-2.43 (m, 1H, CH), 2.47 (s,  6H, 2x 
SCH3), 7.26-7.29 (d, 2H, j=9.6Hz, Ar-H), 7.53-7.55 (d, 2H, j=8.7Hz, Ar-H), 8.69 (s, 
1H, NH); MS (m/z): 342 (M+); Anal. Calcd for C15H16ClNO2S2: C, 52.70; H, 4.72; N, 
4.10; Found: C, 52.72; H, 4.75; N, 4.12. 
 
2-(Cyclopropylcarbonyl)-N-(4-methoxyphenyl)-3,3-bis(methylsulfanyl)prop-2-
ena- mide 9w. Yello solid; mp 154-156°C, Rf 0.61 (8:2 hexane-EtOAc); IR (KBr): 
3354, 2925, 1684, 1525, 1450, 1285, 1112, 880, 753 cm-1; 1H NMR (300 MHz, 
CDCl3): δ 1.02-1.04 (m, 2H, CH2), 1.22 (m, 2H, CH2), 2.39-2.42 (m, 1H, CH), 2.47 
(s,  6H, 2x SCH3), 3.84 (s, 3H, OCH3), 6.85-6.88 (d, 2H, j=8.7Hz, Ar-H), 7.48-7.51 
(d, 2H, j=8.7Hz, Ar-H), 8.35 (s, 1H, NH); MS (m/z): 337 (M+); Anal. Calcd for 
C16H19NO3S2: C, 56.95; H, 5.68; N, 4.15; Found: C, 56.92; H, 5.65; N, 4.12. 
 
N3-cyclohexyl-7-methyl-2,5-bis(methylthio)-N6-p-tolylpyrazolo[1,5-a]pyrimidine-
3,6-dicarboxamide 10a. White solid; mp >320 oC, Rf 0.31 (9:1Chloroform: 
Methanol); IR (KBr): 3309, 3254, 3016, 2925, 1671, 1473, 831, 807, 758 cm-1; 
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MS (m/z): 484 (M+); Anal. Calcd for C24H29N5O2S2: C, 59.60; H, 6.04; N, 14.48; 
Found: C, 59.56; H, 6.03; N, 14.45. 
 
N6-(3-chlorophenyl)-N3-cyclohexyl-7-methyl-2,5-bis(methylthio)pyrazolo[1,5-a] 
pyrimidine-3,6-dicarboxamide 10b. Creamish solid; mp >320 oC, Rf 0.40 
(9:1Chloroform : Methanol); IR (KBr): 3379, 3024, 2902, 1651, 1516,1483, 1332, 
845, 800, 756, 695 cm-1; 1H NMR (300 MHz, DMSO): δ 1.35-1.81 (m, 10H,CH2), 
2.45 (s, 6H, SCH3), 2.70 (s, 3H, CH3), 3.79 (m,  1H, CH), 7.05 (s, 1H, Ar-H), 7.31-
7.35 (m, 2H, Ar-H), 8.0 (s, 1H, AR-H), 8.56 (s, 1H, CONH), 12.56 (s, 1H, CONH); 
13C NMR (100 MHz, DMSO): 12.40, 23.86, 25.34, 27.54, 30.54, 32.55, 45.86, 98.23, 
98.89, 117.29, 118.69, 121.70, 129.88, 133.31, 141.26, 148.07, 154.00, 158.20, 
161.85, 163.79, 165.67; MS (m/z): 503 (M+); Anal. Calcd for C23H26ClN5O2S2: C, 
54.80; H, 5.20; N, 13.89; Found: C, 54.81; H, 5.24; N, 13.89. 
 
N6-(3-chloro-4-fluorophenyl)-N3-cyclohexyl-7-methyl-2,5-bis(methylthio) 
pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide 10c. White solid; mp >320 °C, Rf 
0.48 (9:1Chloroform: Methanol); IR (KBr): 3323, 3026, 2908, 2856, 1674, 1630, 
1563, 1473, 1246, 927, 843, 798, 732, cm-1; MS (m/z): 522 (M+); Anal. Calcd for 
C23H25ClFN5O2S2: C, 52.91; H, 4.83; N, 13.41; Found: C, 52.96; H, 4.83; N, 13.45. 
 
N6-(4-chlorophenyl)-N3-cyclohexyl-7-methyl-2,5-bis(methylthio)pyrazolo[1,5-a] 
pyrimidine-3,6-dicarboxamide 10d. Creamish solid; mp >320 °C, Rf 0.35 
(9:1Chloroform: Methanol); IR (KBr): 3379, 3024, 2902, 1651, 1516, 1483, 1332, 
1166, 954, 852, 822, 748, 709  cm-1; MS (m/z): 503 (M+); Anal. Calcd for 
C23H26ClN5O2S2: C, 54.80; H, 5.20; N, 13.89; Found: C, 54.81; H, 5.24; N, 13.89. 
 
N3-cyclohexyl-N6-(4-fluorophenyl)-7-methyl-2,5-bis(methylthio)pyrazolo[1,5-a]  
pyrimidine-3,6-dicarboxamide 10e. White solid; mp >320 °C, Rf 0.28 
(9:1Chloroform: Methanol); IR (KBr): 3430, 3133, 3051, 2922, 1651, 1516, 1483, 
1232, 1166, 954, 883, 780, 743, 698 cm-1; MS (m/z): 487 (M+); Anal. Calcd for 
C23H26FN5O2S2: C, 56.65; H, 5.37; N, 14.36; Found: C, 56.61; H, 5.34; N, 14.39. 
 
N3-cyclohexyl-7-methyl-2,5-bis(methylthio)-N6-(4-nitrophenyl)pyrazolo[1,5-a] 
pyrimidine-3,6-dicarboxamide 10f. Yellow solid; mp >320 °C, Rf 0.29 (9:1 
Chloroform: Methanol); IR (KBr): 3421, 3122, 3088, 2922, 1651, 1516, 1483, 1232,  
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1166, 954, 883, 780, 743, 698 cm-1; MS (m/z): 514 (M+); Anal. Calcd for 
C23H26N6O4S2: C, 53.68; H, 5.09; N, 16.33; Found: C, 53.67; H, 5.04; N, 16.36. 
 
N3-cyclohexyl-N6-(4-methoxyphenyl)-7-methyl-2,5-bis(methylthio)pyrazolo[1,5-a] 
pyrimidine-3,6-dicarboxamide 10g. Creamish solid; mp >320 °C, Rf 0.36 (9:1 
Chloroform: Methanol); IR (KBr): 3422, 3127, 3085, 2942, 1628, 1483, 1237, 1158, 
883, 780, 743 cm-1; MS (m/z): 499 (M+); Anal. Calcd for C24H29N5O3S2: C, 57.69; H, 
5.85; N, 14.02; Found: C, 57.67; H, 5.84; N, 14.03. 
 
N3-cyclohexyl-7-methyl-N6-(2,5-dimethylphenyl)-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide 10h. Creamish solid; mp >320 °C, Rf 0.41 
(9:1Chloroform: Methanol); IR (KBr): 3430, 3133, 3051, 2922, 1651, 1516, 1483, 
1232, 1166, 954, 883, 780, 743, 698 cm-1; MS (m/z): 497 (M+); Anal. Calcd for 
C25H31N5O2S2: C, 60.33; H, 6.28; N, 14.07; Found: C, 60.35; H, 6.25; N, 14.03. 
 
N3-cyclohexyl-7-isopropyl-2,5-bis(methylthio)-N6-p-tolylpyrazolo[1,5-a] 
pyrimidine-3,6-dicarboxamide 10i. White solid; mp >320 °C, Rf  0.35 
(9:1Chloroform: Methanol); IR (KBr): 3279, 3254, 3016, 2928, 2850, 1730, 1681, 
1566, 1313, 1246, 835, 810, 748, 667 cm-1; 1H NM R(300 MHz, DMSO): δ 1.17-
1.21(d, 6H, 2 ×iprCH3), 1.27-1.89 (m, 10H,CH2), 2.48 (s, 6H, SCH3), 2.54 (s, 3H, 
CH3), 3.79 (m,  1H, CH), 4.10-4.18 (m, 1H, iprCH), 7.09-7.19 (dd, 1H, Ar-H), 7.53-
7.56 (d, 2H, Ar-H, J=8.1Hz), 8.21-8.23 (d, 1H, CONH), 11.94 (s, 1H, CONH); MS 
(m/z): 512 (M+); Anal. Calcd for C26H33N5O2S2: C, 61.03; H, 6.50; N, 13.69; Found: 
C, 61.05; H, 6.53; N, 13.66. 
 
N6-(3-chlorophenyl)-N3-cyclohexyl-7-isopropyl-2,5-bis(methylthio)pyrazolo[1,5-
a] pyrimidine-3,6-dicarboxamide 10j. White solid; mp >320 °C, Rf 0.44 
(9:1Chloroform: Methanol); IR (KBr): 3198, 3157, 3042, 2942, 2832, 1734, 1668, 
1654, 1257, 832, 806, 742 cm-1; MS (m/z): 532 (M+); Anal. Calcd for 
C25H30ClN5O2S2: C, 56.43; H, 5.68; N, 13.16; Found: C, 56.45; H, 5.67; N, 13.16. 
 
N6-(3-chloro-4-fluorophenyl)-N3-cyclohexyl-7-isopropyl-2,5-bis(methylthio) 
pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide 10k. Creamish solid; mp >320 °C, Rf 
0.41 (9:1Chloroform: Methanol); IR (KBr): 3398, 3227, 3150, 2902, 2865, 1651, 
1516, 1452, 1326, 880, 828, 750, 697 cm-1; 1H NMR(300 MHz, DMSO):  
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δ 1.27-1.30 (d, 6H, 2 ×iprCH3), 1.34-1.89 (m, 10H,CH2), 2.49 (s, 6H, SCH3), 3.74 (m,  
1H, CH), 4.10-4.18 (m, 1H, iprCH), 7.31-7.37 (m, 1H, Ar-H), 7.43-7.46 (m, 1H, Ar-
H), 8.10-8.12 (m, 1H, Ar-H), 8.54-8.57 (d, 1H, CONH), 12.02(s, 1H, CONH); MS 
(m/z): 550 (M+); Anal. Calcd for C25H29ClFN5O2S2: C, 54.58; H, 5.31; N, 12.73; 
Found: C, 54.59; H, 5.33; N, 12.76. 
 
N6-(4-chlorophenyl)-N3-cyclohexyl-7-isopropyl-2,5-bis(methylthio)pyrazolo[1,5-
a]pyrimidine-3,6-dicarboxamide 10l. White solid; mp >320 °C, Rf  0.38 
(9:1Chloroform: Methanol); IR (KBr): 3425, 3258, 3124, 2998, 2847, 1661, 1532, 
1425, 1318, 867, 817, 753, 689  cm-1; 1H NMR (300 MHz, DMSO): δ 1.17-1.19(d, 
6H, 2 ×iprCH3), 1.27-1.38 (m, 4H,CH2), 1.66-1.89 (m, 6H,CH2), 2.48 (s, 6H, SCH3), 
3.79 (m,  1H, CH), 4.10-4.18 (m, 1H, iprCH), 7.32-7.35 (d, 2H, Ar-H, J=8.1Hz), 7.67-
7.70 (d, 1H, Ar-H, J=8.4Hz), 8.53-8.57 (d, 1H, CONH), 11.96(s, 1H, CONH); MS 
(m/z): 532 (M+); Anal. Calcd for C25H30ClN5O2S2: C, 56.43; H, 5.68; N, 13.16; 
Found: C, 56.45; H, 5.67; N, 13.16. 
 
N3-cyclohexyl-N6-(4-fluorophenyl)-7-isopropyl-2,5-bis(methylthio)pyrazolo[1,5-
a]pyrimidine-3,6-dicarboxamide 10m. Creamish solid; mp >320 °C, Rf 0.45 (9:1 
Chloroform: Methanol); IR (KBr): 3454, 3260, 3142, 2978, 2850, 1645, 1542, 1425, 
1318, 867, 750 cm-1; MS (m/z): 515 (M+); Anal. Calcd for C25H30FN5O2S2: C, 58.23; 
H, 5.86; N, 13.58; Found: C, 58.25; H, 5.87; N, 13.56. 
 
N3-cyclohexyl-7-isopropyl-2,5-bis(methylthio)-N6-(4-nitrophenyl)pyrazolo[1,5-
a]pyrimidine-3,6-dicarboxamide 10n. Creamishsolid; mp >320°C, Rf 0.34 
(9:1Chloroform: Methanol); IR (KBr): 3460, 3367, 3242, 2956, 2845, 1647, 1538, 
1420, 1318, 867, 750, 700  cm-1; MS (m/z): 542 (M+); Anal. Calcd for C25H30N6O4S2: 
C, 55.33; H, 5.57; N, 15.49; Found: C, 55.35; H, 5.57; N, 15.46. 
 
N3-cyclohexyl-7-isopropyl-N6-(4-methoxyphenyl)-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide. 10o. White solid; mp >320 °C, Rf 0.23 
(9:1Chloroform: Methanol); IR (KBr): 3483, 3242, 3162, 3068, 2902, 1675, 1584, 
1425, 1332, 1066, 954, 820, 750 cm-1; MS (m/z): 528 (M+); Anal. Calcd for 
C26H33N5O3S2: C, 59.18; H, 6.30; N, 13.27; Found: C, 59.20; H, 6.32; N, 13.26. 
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N3-cyclohexyl-7-isopropyl-N6-(2,5-dimethylphenyl)-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide 10p. White solid; mp >320 °C, Rf 0.22 
(9:1Chloroform: Methanol); IR (KBr): 3503, 3450, 3206, 3068, 2908, 1628, 1548, 
1420, 1342, 1066, 825, 754 cm-1; MS (m/z): 525 (M+); Anal. Calcd for C27H35N5O3S2: 
C, 61.68; H, 6.71; N, 13.32; Found: C, 61.67; H, 6.72; N, 13.36. 
 
N3-cyclohexyl-7-cyclopropyl-2,5-bis(methylthio)-N6-p-tolylpyrazolo[1,5-a]pyrimi-
dine-3,6-dicarboxamide 10q. Creamish solid; mp >320 °C, Rf0.35 (9:1Chloroform: 
Methanol); IR (KBr): 3460, 3226, 3047, 2938, 1615, 1539, 1422, 1336, 1066, 834, 
757 cm-1; 1H NMR (300 MHz, DMSO): δ 0.98-1.01 (m, 4H, 2 ×CH2), 1.16-1.37 (m, 
4H, CH2), 1.55-1.89 (m, 6H, CH2), 2.25-2.27 (s, 3H, CH3), 2.43.2.77 (m,  6H, SCH3), 
3.64 (m, 2H, CH), 7.09-7.19 (dd, 2H, Ar-H, J=7.8Hz, J=8.4Hz), 7.67-7.70 (d, 1H, 
Ar-H, J=8.1Hz), 8.21-8.23 (d, 1H, CONH), 11.96 (s, 1H, CONH); MS (m/z): 509 
(M+); Anal. Calcd for C26H31N5O2S2: C, 61.27; H, 6.13; N, 13.74; Found: C, 61.25; H, 
6.17; N, 13.76. 
 
N6-(3-chlorophenyl)-N3-cyclohexyl-7-cyclopropyl-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide 10r. White solid; mp >320 °C, Rf 0.43 
(9:1Chloroform: Methanol); IR (KBr): 3457, 3345, 3147, 3038, 2952, 1615, 1539, 
1422, 1336, 1076, 828, 745 cm-1; MS (m/z): 530 (M+); Anal. Calcd for 
C25H28ClN5O2S2: C, 56.64; H, 5.32; N, 13.21; Found: C, 56.62; H, 5.32; N, 13.24. 
 
N6-(3-chloro-4-fluorophenyl)-N3-cyclohexyl-7-cyclopropyl-2,5-bis(methylthio)   
pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide 10s. Creamish solid; mp >320°C, Rf 
0.40 (9:1Chloroform: Methanol); IR (KBr): 3448, 3250, 3130, 2948, 2902, 1651, 
1516, 1483, 1332, 1166, 850, 772, 705 cm-1; MS (m/z): 548 (M+); Anal. Calcd for 
C25H27ClFN5O2S2: C, 54.78; H, 4.97; N, 12.78; Found: C, 54.76; H, 4.95; N, 12.74. 
 
N6-(4-chlorophenyl)-N3-cyclohexyl-7-cyclopropyl-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide 10t. Creamish solid; mp >320°C, Rf 0.46 
(9:1Chloroform: Methanol); IR (KBr): 3328, 3248, 3057, 2964, 2926, 1651, 1516, 
1483, 1328, 1158, 850, 772 cm-1; MS (m/z): 530 (M+); Anal. Calcd for 
C25H28ClN5O2S2: C, 56.64; H, 5.32; N, 13.21; Found: C, 56.62; H, 5.32; N, 13.24. 
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N3-cyclohexyl-7-cyclopropyl-N6-(4-fluorophenyl)-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide 10u. White solid; mp >320°C, Rf 0.23 
(9:1Chloroform: Methanol); IR (KBr): 3408, 3340, 3277, 3070, 2928, 2852, 1672, 
1556, 1481, 1354, 1251, 1058, 893, 833, 792, 750, 711 cm-1; 13C NMR (100 MHz, 
CDCl3): 10.96, 12.35, 13.76, 23.32, 25.29, 46.23, 98.07, 99.87, 114.93, 115.14, 
120.80, 120.88, 136.19, 148.46, 153.74, 156.37, 157.47, 158.75, 161.92, 165.71, 
166.89; MS (m/z): 513 (M+); Anal. Calcd for C25H28FN5O2S2: C, 58.46; H, 5.49; N, 
13.63; Found: C, 58.49; H, 5.47; N, 13.64. 
 
N3-cyclohexyl-7-cyclopropyl-2,5-bis(methylthio)-N6-(4-nitrophenyl)pyrazolo[1,5-
a]pyrimidine-3,6-dicarboxamide 10v. Creamish solid; mp >320°C, Rf 0.52 
(9:1Chloroform: Methanol); IR (KBr): 3422, 3205, 3169, 2964, 2856, 1658, 1522, 
1425, 1084, 838, 736  cm-1; MS (m/z): 540 (M+); Anal. Calcd for C25H28N6O4S2: C, 
55.54; H, 5.22; N, 15.54; Found: C, 55.55; H, 5.22; N, 15.54. 
 
N3-cyclohexyl-7-cyclopropyl-N6-(4-methoxyphenyl)-2,5-bis(methylthio)pyrazolo 
[1,5-a]pyrimidine-3,6-dicarboxamide 10w. Creamish solid; mp >320°C, Rf 0.48 
(9:1Chloroform: Methanol); IR (KBr): 3445, 3247, 3038, 2952, 1628, 1539,1422, 
1336, 1257, 838, 745 cm-1; MS (m/z): 525 (M+); Anal. Calcd for C26H31N5O3S2: C, 
59.40; H, 5.94; N, 13.32; Found: C, 59.44; H, 5.92; N, 13.34. 
 
N3-cyclohexyl-7-cyclopropyl-N6-(2,5-dimethylphenyl)-2,5-bis(methylthio) 
pyrazolo[1,5-a]pyrimidine-3,6-dicarboxamide 10x. Creamish solid; mp >320°C, Rf 
0.23 (9:1Chloroform: Methanol); IR (KBr): 3258, 3158, 3038, 2948, 1645, 1558,1426, 
1358, 1216, 835, 745,708  cm-1; MS (m/z): 523 (M+); Anal. Calcd for C27H33N5O2S2: 
C, 61.92; H, 6.35; N, 13.37; Found: C, 61.94; H, 6.32; N, 13.34. 
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1H NMR spectrum of compound 9i 
 
 
Expanded 1H NMR spectrum of compound 9i 
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1H NMR spectrum of compound 10b 
 
 
1H NMR spectrum of compound 10k 
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1H NMR spectrum of compound 10l 
 
 
Expanded 1H NMR spectrum of compound 10l 
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13C NMR spectrum of compound 10b 
 
 
Expanded 13C NMR spectrum of compound 10b 
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13C NMR spectrum of compound 10u 
 
 
Expanded 13C NMR spectrum of compound 10u 
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MASS spectrum of compound 10a 
 
 
MASS spectrum of compound 10d 
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MASS spectrum of compound 10o 
 
 
MASS spectrum of compound 10u 
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IR Spectrum of compound 10i 
 
 
IR Spectrum of compound 10u 
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5.1 Introduction 
 
Pyrrole is an important π-excessive aromatic heterocycle because this ring 
system is incorporated in as a basic structural unit in porphyrins;porphin (heam) and 
chlorine (chlorophyll) and corrins (vitamin B12) (Figure-1). More over the presence 
of pyrrole ring in system in porphobilinogen (intermediate in biosynthesis of 
porphyrins and vitamin B12), biliverdin and bilirubin (pyrrole-based bile pigments) 
and pyrrolnitrin (with antibiotic activity) has provided an impetus to the pyrrole 
chemistry. 
Figure-1 
 Pyrrole has a planar pentagonal structure with four carbon atoms and nitrogen 
sp2-hybridized. Each ring atom forms two sp2-sp2 σ -bonds to its neighbouring ring 
atoms and one sp2-sσ -bond to a hydrogen atom. The remaining unhybridized p-
orbitals, one on each ring atom (with one electron on each carbon and two electron on 
nitrogen), are perpendicular to the plane of σ–bonds and overlap form a π-molecular 
system with three bonding orbitals. The six π-electrons form an aromatic sextet which 
is responsible for aromaticity and renders stability to the pyrrole ring. The Cα-N and 
Cα-Cβ bonds are shorter than normal single bonds, where as Cα-Cβ bonds are normal 
than normal double bonds. The molecular dimentions of the pyrrole reflect cyclic 
delocalization with the environment of lone pair of electrons on the nitrogen atom. 
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 Pyrrole is extremely weak base because the lone pair of electrons on the 
nitrogen atom involved in the cyclic delocalization and is, therefore, less available for 
protonation. Moreover, pyrrole is a weaker base than pyridine and even than aniline in 
which lone pair on the nitrogen atom is involved in the resonance and not essentially 
contributes to the aromatic sexlet. The protonation of pyrrole at nitrogen or C2 or C3 
atom of the ring reduces its basicity and destroys its aromaticity. However, C- and N- 
alkyl substituents enhance the basicity of pyrrole but the electron withdrawing 
substituents on the ring make pyrrole a weaker base. 1-11 
 
5.2 Various synthetic approaches for highly substituted pyrroles. 
 
 Pyrroles are generally synthesized by the cyclization reactions involving 
nucleophilic-electrophilic interactions. This is the most widely used method and 
involves the cyclizative condensation of α-aminoketones or α-amino-β-keto 
esters(three atom fragment with nucleophilic nitrogen and electrophilic carbonyl 
carbon) with β-diketones or β-ketoesters (two atom fragment with electrophilic 
carbonyl carbon and a nucleophilic carbon) with the formation of N-C2 and C3-C4 
bonds (Figure-2). 
 
Figure-2 
 The reaction of α-aminoketones with alkynes proceeds with the nucleophilic 
addition of amino group to the electrophilic carbon of alkyne with the formation of 
enamine intermediate which on intramolecular cyclization provides pyrroles involving 
nucleophilc (β-carbon of the enamine intermediate)-electrophilic (carbonyl carbon) 
interaction with the formation of C3-C4 bond (Figure-3).12 
 Figure-3 
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 The reaction of β-amino-α,β-unsaturated esters 91(three atom fragment) with 
nitroalkenes (two atom fragment) provides substituted pyrrole involving (3+2) 
cyclization with N-C2 and C3-C4 bonds (Figure-4).13 
 Figure-4 
 Base catalyzed (3+2) cyclizative condensation of α-diketones with amines 
substituted with electron withdrawing substituents at α, α’-positions results in the 
corresponding pyrroles with the formation of C2-C3 and C4-C5 bonds (Figure-5).14 
 
Figure-5 
 The reaction of β-keto esters with α-halo ketones or aldehydes in the presence 
of ammonia or primary amine affords pyrroles involving (2+2+1) cyclization with the 
formation of N-C2, C3-C4 and N-C5 bonds. (Hantzsch Synthesis). The reaction 
proceeds via stabilized enamine intermediate which on C-alkylation and N-alkylation 
by α-haloketone leads to the formation of corresponding pyrrole (Figure-6). 
 Figure-6 
 The condensation of aliphatic aldehydes or ketones with hydrazine under 
strongly acidic conditions affords pyrroles involving (3+3) sigmatropic rearrangement 
and cyclization. (Piloty-Robinson Synthesis). This reaction can also be applied for the 
preparation of N-substituted pyrroles by condensing ketones with methyl hydrazine or 
N,N’-dimethyl hydrazine (Figure-7).15 
R
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Figure-7 
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 The reaction of benzoin with benzyl aryl ketones in the presence of 
ammonium acetate results in the formation of polyaryl substituted pyrroles involving 
(2+2+1) cyclization (Figure-8).16 
 
Figure-8 
 The condensation of alkyl isocyanoacetates with aldehydes in 2:1 ratio 
proceeds to involve an initial conjugated addition followed by an anionic cyclization 
with the formation of C2-C3, C3-C4 and C4-C5 bonds (Figure-9).17 
 
Figure-9 
 It is the most general method and involves (4+1)cyclizative condensation of 
1,4-dikitones (enolizable) with ammonia or its derivatives with the formation of N-C2 
and N-C5 bonds 1-6, 18-19. The reaction is considered to proceed with the successive 
attacks of nucleophilic nitrogen on the carbonyl carbon and finally followed by 
dehydration (aromatization) for which driving force is provided by the stability of the 
resulting pyrrole (Figure-10). 
 
Figure-10 
 Metal ion assisted amination of 1,4-dienes or diynes with primary amines 
followed by cyclization provides N-substituted pyrroles (Figure 11 & 12).20-21 
 
Figure 11 
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Figure 12 
 2-Acylaziridines undergo ring expansion reactions to provide pyrroles 
involving ring-opened dipolar intermediates (Figure-13).22 
 
Figure-13 
 Vinylazirines also undergo ring expansion reactions, but two isomeric pyrroles 
are obtained depending on the reaction conditions. Thermal reactions involve a 
nitrene intermediate, while photochemical reaction proceeds via a nitrile ylide 
intermediate (Figure-14).23 
 
Figure-14 
 The complex ring systems, formed by (3+2) cycloaddition of activated alkynes 
substituted with electron-withdrawing substituents, with mesoionic heterocycles, 
undergo extrusion reactions with the cleavage of larger ring leaving the pyrrole ring 
system intact (Figure-15).24-26 
 
Figure-15 
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 Ethyl-3-amino-5-phenyl-1H-pyrrol-2-carboxylate found to be a useful 
intermediate in the synthesis of other nitrogen heterocycles.27 However Elliott and co-
workers28-29 have described that condensation of aldehyde with aminomalonate gave 
3-substituted enamine, which was cyclized in the presence of sodium methoxide to 
give 3-amino-4-benzyl-1H-pyrrol-2-carboxylate (Figure-16).  
 
Figure-16 
 Using a similar approach toward the synthesis of pyrrole (Figure-17), Ning 
Chen, et al.30 were failed to synthesize 2-substituted enamine intermediate from 
benzoyl acetonitrile and diethyl aminomalonate using standard conditions such as 
azeotropic removal of water,31 dehydration with molecular sieves or Lawis acid 
catalysis(TiCl432, BF3.OEt2) 
CN
Ph
O
EtOOC
NH2
COOEt
NC
NEtOOC
EtOOC
Ph
H NH
H2N
EtOOC Ph
 
Figure-17 
 Considering the lower electrophilicity of the aryl ketone compared to the 
aldehyde, an alternative strategy for preparing enamine was examined. Since amines 
are known to undergo substitution reactions with chloro- and alkylthio-substituted 
olefins to yield enamines33, a similar approach was considered and the reaction of p-
toluenesulfonyl enol ester of α-cyano ketone with diethyl aminomalonate was 
investigated. Tosylate was prepared by reacting benzoyl acetonitrile with p-
toluenesulfonic anhydride (1.2 eq.) in dichloromethane and triethylamine (1.5 eq.) in 
99% yield. When a mixture of tosylate and diethyl aminomalonate hydrochloride (1.2 
eq.) were treated with an ethanolic solution of sodium ethoxide (0.2 M, 3.5 eq.),34 the 
pyrrole was directly obtained without isolation of enamine. Addition of the amine, 
cyclization and decarboxylation occurred in one-pot at room temperature to give a 
46% overall yield of from benzoyl acetonitrile (Figure-18). 
 
 
Chapter-5  Synthesis of highly substituted pyrroles 
Department of Chemistry, Saurashtra University, Rajkot-360005   164 
 
 
 Figure-18 
 In continuation with this study prior work at Saurashtra University on 1H-
pyrrole derrivatives clubed with substituted-1,3,4-Oxadiazoles, 1-[2,4-dimethyl-5-(5-
phenyl-1,3,4-oxadiazol-2-yl)-1H-pyrrol-3-yl]ethanone derivatives were synthesized. 
The synthetic stretagy follows starting with acid catalyzed cyclocondensation of ethyl 
ester derivative of 3-amino-2-butenoic acid (generated insitu from ethylacetoacetate 
upon oximenation followed by reduction) with acetylacetone to afford ethyl-3-acetyl-
2,4-dimethyl-1H-pyrrole-5-carboxylate, which was derivatized into corresponding 
hydrazide derivative on treatment with hydrazine hydrate. The hydrazide derivative 
on reaction with different aromatic and heteroaromatic acid, in the presence of 
phosphorous oxychloride affords 1-[2,4-dimethyl-5-(5-phenyl-1,3,4-oxadiazol-2-yl)-
1H-pyrrol-3-yl]ethanone derivatives (Figure-19).35-36 
 Figure-19 
 A range of 2,5-disubstituted and 2,4,5-trisubstituted pyrroles can be 
synthesized from dienyl azides at room temperature using ZnI2 or Rh2(O2CC3F7)4 as 
catalysts (Figure-20).37 
 
Figure-20 
 The CuI/N,N-dimethylglycine-catalyzed reaction of amines with γ-bromo-
substituted γ,δ-unsaturated ketones in the presence of K3PO4 and NH4OAc gave the 
corresponding polysubstituted pyrroles in very good yields (Figure-20).38 
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Figure-20 
 Two methods for the regioselective synthesis of tetra- and trisubstituted N-H 
pyrroles from starting vinyl azides have been developed: A thermal pyrrole formation 
via the 1,2-addition of 1,3-dicarbonyl compounds to 2H-azirine intermediates 
generated in situ from vinyl azides and a Cu(II)-catalyzed synthesis with ethyl 
acetoacetate through a 1,4-addition (Figure-21). 39 
 
Figure-21 
 An operationally simple, practical, and economical Paal-Knorr pyrrole 
condensation of 2,5-dimethoxytetrahydrofuran with various amines and sulfonamines 
in water in the presence of a catalytic amount of iron(III) chloride allows the synthesis 
of N-substituted pyrroles (Figure-22) under very mild reaction conditions in good to 
excellent yields. 40 
 
Figure-22 
 A new and efficient three-component reaction between dialkyl 
acetylenedicarboxylates, aromatic amines, triphenylphosphine, and arylglyoxals 
afforded polysubstituted pyrrole derivatives in high yields (Figure-23). The reactions 
were performed in dichloromethane at room temperature and under neutral 
conditions. 41 
 
Figure-23 
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 A three-component reactions of arylacyl bromides, amines, and dialkyl 
acetylene dicarboxylate in the presence of iron(III) chloride as a catalyst at room 
temperature afforded polysubstituted pyrroles in high yields (Figure-24). 42 
Ar
O
Br +
H2N R
+ CO2R1
R1O2C
NAr CO2R1
CO2R1
R
15 mol-% FeCl3
CH2Cl2, rt, 14-16 h
or
NH4OAc
 
Figure-24 
 A new and efficient three-component reaction between dialkyl acetylene 
dicarboxylates, aromatic amines, triphenylphosphine, and arylglyoxals afforded 
polysubstituted pyrrole derivatives in high yields (Figure-25). The reactions were 
performed in dichloromethane at room temperature and under neutral conditions. 43 
 
Figure-25 
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5.3 Biological activity associated with pyrrole derivatives 
Pyrrole has its own pharmaceutical importance and various activities of 
pyrrole include: 
? Selective Mono Amine Oxidase type A Inhibitors 44-57 
? Antitubercular activities 58-66 
? HIV-1 intigrase Inhibitors 67-69 
? Antiproliferative activity 70-71 
? Glycogen Synthase Kinase-3(GSK-3) Inhibitors 72-79 
? Analgesic and Antiinflammatory activity 80-81 
? Bactericidal activities 82-86 
? Fungicides and Plant Growth Regulators 87-89 
? Action on the Cardiovascular System 90-94 
? Neuronal L-type Calcium channel activator 95 
. 
5.4   Some drugs from pyrrole nucleus 44-95 
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5.5 Current research work 
 
` The above literature study reveled that pyrrole derivatives contacting 
heterocyclic molecules showed significant biological potential.44-95 One such highly 
functionalized pyrrole derivative is Atorvastatin.  It is a class of statins, which act by 
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the 
sterol by synthesis pathway; therefore, they are used in human therapy to reduce 
cholesterol in the level of blood. These compounds also have certain (pleiotropic) 
effects, e.g. decreasing inflammation and improving the endothelial functions.96 
Recently reports described their inhibitory effect of the growth of different pathogenic 
fungi.97-98 Sun and Singh reported that statins directly attenuate the virulence of 
microorganisms: modulate regulatory pathway of involved in the infection process.99 
There are also sporadic new reports on the combined application of statins and 
different antimycotics.100-106  
 
Figure-27 
 Thus, to investigate the potential biological effect of some new pyrrole 
derivatives (AS-01 to AS-30), we set to modify position 2 and 3 of the Atrovastatin 
intermediate (Figure-27). To achieve the targeted compounds, we have synthesized 
thirty novel 1,4-diketone from easily available b-keto esters, which was further 
condensed with amino side chain (tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-
dimethyl-1,3-dioxan-4-yl)acetate) using pivalic acid as a catalyst  under microwave 
irradiation. The newly synthesized compounds were characterized by IR, Mass, 1H 
NMR, 13C NMR spectroscopy and elemental analysis. All synthesized compounds 
were evaluated for their antimicrobial activity. 
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5.6   Results and discussion 
Scheme:Synthesis of highly substituted Atorvastatin analogs 
Scheme-01 
O
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Scheme-03 
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Where R=CH3, (CH3)2CH, (CH2)2CH,   R1=CH3, OCH3, Cl, NO2 
  
 Scheme 1 and 2 shows the synthetic route for the requisite starting materials. 
First, acid chloride of phenyl acetic acid (2) was prepared from phenylacetic acid (1) 
using thionyl chloride in MDC as described in literature.107 The fridle-craft reaction of 
Compound 2 with fluorobenzene in the presence of ZnO108 afforded 1-(4-
fluorophenyl)-2-phenylethanone (3) with good yield. The bromination of compound 3 
using Br2/AcOH provided 2-bromo-1-(4-fluorophenyl)-2-phenylethanone (4).109 
 Various acetoactanilide derivatives (AAA-01-30) were prepared as described 
in chapter-4. The condensation reaction of these acetoactanilide derivative (AAA-01-
30) with 2-bromo-1-(4-fluorophenyl)-2-phenylethanone (4) using potassium 
carbonate as a base in isopropyl alcohol afford the requisite 1,4-dicarbonyl 
compounds (ADD-01-30).  
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 The final coupling reaction of 1,4-dicarbonyl compounds with amino side 
chain (tert-butyl 2-((4R,6R)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate) 
(5) in the presence of acid catalyst under microwave irradiation afford pyrrole 
derivatives. For optimization of reaction condition 1,4-dicarbonyl compound (ADD-
01) was react with amino side chain (5) by using various acid catalyst in various 
solvents or binary mixture of solvents in conventional method and under microwave 
irradiation method. The require reaction time and obtained (%) of yield were 
summarized in table-1. 
Table-1: Optimization of reaction condition for synthesis of AS-01 in various 
conditions 
Entry Catalyst Solvents 
Reaction time and yield (%) 
Conventional MW 
Time 
h 
Yield 
(%) 
Time 
min 
Yield
(%) 
1 PTSA Toluene 38 68 120 88 
2 PTSA Cyclohexane  36 70 110 82 
3 PTSA Cyclohexane/THF (9:1) 31 78 90 86 
4 PTSA Toluene/THF (9:1) 32 76 96 85 
5 MSA Toluene 35 78 112 81 
6 MSA Cyclohexane  34 74 100 85 
7 MSA Cyclohexane/THF (9:1) 30 80 90 87 
8 MSA Toluene/THF (9:1) 30 77 88 82 
9 Sulfamic acid Toluene 40 74 140 78 
10 Sulfamic acid Cyclohexane  42 76 148 80 
11 Sulfamic acid Cyclohexane/THF (9:1) 36 72 125 75 
12 Sulfamic acid Toluene/THF (9:1) 35 70 130 75 
13 Pivalic acid Toluene 32 85 120 82 
14 Pivalic acid Cyclohexane  36 83 105 90 
15 Pivalic acid Cyclohexane/THF (9:1) 28 90 75 95 
16 Pivalic acid Toluene/THF (9:1) 30 84 82 88 
On the basis of our study we found that using pivalic acid and binary solvent 
Cyclohexane/THF (9:1) gave an excellent yield in short time (Table-1). Having 
optimized condition in our hand,  
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we carried out the reaction of various 1,4-dicarbonyl compounds (ADD-01 to 30) 
with amino side chain (5) in the presence of pivalic acid and cyclohexane/THF (9:1) 
under microwave irradiation afford pyrroles with excellent yield (Table-2). 
Table-2: Synthesis of highly functionalized pyrroles as atorvastatin analogs 
under microwave irridiation. 
Entry R R1 Time (min) Yield (%) 
AS-01 CH3 4-CH3 75 95 
AS-02 CH3 4-OCH3 78 91 
AS-03 CH3 4-Cl 70 94 
AS-04 CH3 4-F 72 92 
AS-05 CH3 4-CH2CH3 80 88 
AS-06 CH3 4-NO2 82 85 
AS-07 CH3 2,5diCH3 85 86 
AS-08 CH3 3-Cl,4-F 70 94 
AS-09 CH3 3,4diCl 72 87 
AS-10 CH3 2,3diCH3 82 90 
AS-11 (CH3)2CH 4-CH3 78 94 
AS-12 (CH3)2CH 4-OCH3 80 90 
AS-13 (CH3)2CH 4-Cl 75 95 
AS-14 (CH3)2CH 4-F 73 94 
AS-15 (CH3)2CH 4-CH2CH3 82 90 
AS-16 (CH3)2CH 4-NO2 88 87 
AS-17 (CH3)2CH 2,5diCH3 80 92 
AS-18 (CH3)2CH 3-Cl,4-F 72 94 
AS-19 (CH3)2CH 3,4diCl 78 91 
AS-20 (CH3)2CH 2,3diCH3 80 85 
AS-21 (CH2)2CH 4-CH3 90 90 
AS-22 (CH2)2CH 4-OCH3 91 89 
AS-23 (CH2)2CH 4-Cl 83 95 
AS-24 (CH2)2CH 4-F 85 94 
AS-25 (CH2)2CH 4-CH2CH3 88 88 
AS-26 (CH2)2CH 4-NO2 87 95 
AS-27 (CH2)2CH 2,5diCH3 90 95 
AS-28 (CH2)2CH 3-Cl,4-F 87 90 
AS-29 (CH2)2CH 3,4diCl 83 94 
AS-30 (CH2)2CH 2,3diCH3 85 88 
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 The structures of ADD-01-30 were established on the basis of their elemental 
analysis and spectral data (MS, IR, and 1H NMR). The analytical data for (ADD-05) 
revealed a molecular formula C26H24FNO3 (m/z 417). The 1H NMR spectrum revealed 
a triplet at δ = 1.06-1.11 ppm assigned to isopropyl-CH3, a singlet at δ = 2.22 ppm 
assigned to the –CH3 protons, a quartet at δ = 2.44-2.47 ppm assigned to-CH2 protons, 
two doublets at δ = 4.70-4.73 ppm (j=10.8Hz) and 5.36-5.39 ppm (j=10.8Hz) 
assigned to the -CH protons, two multiplets at δ = 7.03-7.35 ppm and triplet at δ = 
8.09-8.13 ppm assigned to the aromatic protons, and one broad singlet at δ = 10.16 
ppm assigned to -CONH groups.  
 The structures of AS-01-30 were established on the basis of their elemental 
analysis and spectral data (MS, IR, 1H NMR and 13C NMR). The analytical data for 
(AS-04) revealed a molecular formula C38H42F2N2O5 (m/z 644). The 1H NMR 
spectrum revealed a signals at δ ppm 1.03-1.07 (m, 1H, CH), 1.30-1.63 (m, 18H,  
CH2, CH & 5 x CH3), 2.24-2.37 (m, 2H,  CH2), 2.71 (s, 3H, CH3), 3.66 (m, 1H, CH), 
3.86-3.99 (m, 2H, CH2), 4.14-4.17 (m, 1H, CH),  6.83-7.00 (m, 7H, Ar) and  7.12-
7.28  (m, 7H, Ar & NH). 
 The mechanism for the synthesis of the pyrrole proceeds via Paal-Knorr 
reaction,110 in which protonated carbonyl (B) is attacked by the amine to form the 
hemiaminal (C). The amine attacks the other carbonyl to form a 2,5-
dihydroxytetrahydropyrrole (D) derivative which undergoes dehydration in two steps 
give the corresponding substituted pyrrole (F). 
 
Figure 28: Proposed mechanism for the formation of pyrroles 
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5.7 Antimicrobial sensitivity testing 
 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
 In vitro effectivity of antimicrobial agents can be demonstrated by observing 
their capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective then many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive then using disk method. 
 
Principle  
 
 When antimicrobial substance is added in agar cup (made in a medium 
previously inoculated with test organism) the redial diffusion of an antimicrobial 
agent through the agar, produces a concentration gradient. The test organism is 
inhibited at the minimum inhibitory concentration (MIC), giving rise to a clear zone 
of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
 Inoculum was prepared by selecting 4-5 colonies from slope of stock culture 
of the indicator organism and emulsifying them in a suitable broth. The inoculated 
broth was incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This 
happens in 2-8 h. 
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Procedure 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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? Antimicrobial Sensitivity Assay 
   (Concentration 250/500/1000 µg/ml) 
Sr. 
No. 
CODE 
No. 
Pseudomonas 
aeruginosa 
Proteus vulgaris Escherichia  
coli 
Staphylococcus 
aureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  AS-01 R R R R R R R R R R R R R R R 
2.  AS-02 1.5 1.7 2.0 1.4 1.6 2.0 R R R R R R R R R 
3.  AS-03 R R R R R R R R R R R R R 1.4 2.0
4.  AS-04 R 1.0 1.3 R R R R R R R R R R R R 
5.  AS-05 R R 1.0 R R R R R R 1.1 1.4 2.0 1.1 1.5 2.0
6.  AS-06 R R R R R R 1.3 1.6 1.8 1.5 1.8 2.0 R R R 
7.  AS-07 1.2 1.4 1.6 1.6 1.8 2.0 1.1 1.4 2.0 1.0 1.3 2.0 R R R 
8.  AS-08 R R R R R R R 1.2 1.8 1.1 1.4 2.0 R R R 
9.  AS-09 R R R R R R R R 1.2 R 1.3 2.0 R R R 
10.  AS-10 1.0 1.3 1.7 R 1.0 1.5 R R 1.2 R R 1.2 1.3 1.8 2.0
11.  AS-11 R R R R R R R R R R R 1.2 R R R 
12.  AS-12 R R R R R R 1.0 1.3 1.8 1.1 1.5 2.0 R R R 
13.  AS-13 R R R R R R 1.6 1.8 2.0 1.4 1.6 2.0 1.0 1.4 2.0
14.  AS-14 R R R R R R R 1.2 1.8 1.1 1.4 2.0 1.1 1.5 2.0
15.  AS-15 R R R R R R R 1.1 1.7 R 1.3 2.0 1.5 1.8 2.0
16.  AS-16 1.6 1.8 2.0 1.0 1.2 1.6 R 1.1 1.6 1.2 1.5 1.7 R 1.1 1.8
17.  AS-17 R 1.4 2.0 1.0 1.3 1.5 1.2 1.5 2.0 1.3 1.5 2.0 1.5 1.7 2.0
18.  AS-18 1.0 1.3 1.5 1.1 1.3 1.6 1.5 1.8 2.0 1.5 1.7 2.0 R 1.5 1.9
19.  AS-19 1.2 1.5 1.8 1.5 1.8 2.0 1 1.2 2.0 1.1 1.6 2.0 1.3 1.6 2.0
20.  AS-20 R 1.3 1.0 1.1 1.3 1.2 1.0 1.2 1.4 1.0 1.2 1.5 1.2 1.5 1.7
21.  AS-21 R 1.4 2.0 R R R R R R R R R R R R 
22.  AS-22 R 1.4 2.0 R R R 1.2 1.4 1.6 1.5 1.7 2.0 1.6 1.8 2.0
23.  AS-23 1.0 1.3 2.0 R R R R R R R R R R R R 
24.  AS-24 R 1.4 2.0 R R R R R R R 1.0 1.3 R R R 
25.  AS-25 R 1.3 2.0 R R R 1.1 1.4 2.0 R R 1.0 R R R 
26.  AS-26 R R 1.2 R R R 1.1 1.4 2.0 R R R R R R 
27.  AS-27 R R 1.2 1.5 1.8 2.0 1.0 1.3 2.0 R R 1.2 R 1.5 2.0
28.  AS-28 1.5 1.8 2.0 R 1.2 1.8 1.1 1.4 2.0 R R R R R R 
29.  AS-29 R 1.4 2.0 R R 1.2 R 1.3 2.0 R R R R R R 
30.  AS-30 R 1.4 2.0 R R 1.2 R R 1.2 R R R R R R 
31.  A 1.8 1.8 1.9 1.9 - 
32.  CPD 2.2 2.1 2.1 2.2 - 
33.  GF 1.8 1.9 2.0 2.0 - 
34.  GRF - - - - 2.6 
35.  FLC - - - - 2.8 
 Note: Zone of inhibition interpretation is as follows    STD Antibiotic Sensitivity Assay Concentration 40 µg/ml
1. Zone size < 1.0 cm- Resistent (R)  
2. Zone size  1.0 to 1.5 cm – Intermediate 
3. Zone size > 1.5 – Sensitive 
 
      A:    Ampicillin     
     CPD:   Cefpodoxime 
     GF:   Gatifloxacin 
GRF: Gresiofulvin 
 FLC: Fluconazole 
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5.8 Conclusion 
 
 In summary, we have synthesized a series of highly substituted pyrroles as a 
atorvastain analogs from novel 1,4-dicarbonyl compounds and amino side chain using 
pivalic acid as a catalyst and cyclohexane and THF as binary solvent under 
microwave irradiation technique. All the synthesized compounds were evaluated for 
their antimicrobial activity. The investigation of antibacterial and antifungal screening 
data revealed that all the tested compounds AS-01-30 showed that some of compound 
gave moderate to potent activity. The compounds AS-02, 07, 16, 19, 27, and 28 
showed comparatively good activity against gram (+ve) bacterial stains, AS-06, 13, 
18, and 22 showed comparatively good activity against gram (-ve) bacterial stains and 
AS-15, 17 and 22 showed comparatively good activity against fungal stains. 
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5.9 Experimental section 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (300 MHz), 1H (400 MHz), 13C (75 MHz) and 13C (100 MHz)  
NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl3 and 
DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal 
standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 
mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were measured in open capillaries and are uncorrected. 
 
? Synthesis of 2-phenylacetyl chloride107 (2). 
 In a 250mL round bottom flask equipped with magnetic stirrer and 
thermometer was placed phenylaceticacid (0.2mol) in MDC (100 mL). To this, slowly 
added a solution of thionyl chloride (0.25mol) in MDC (25 mL) under nitrogen 
atmosphere. The reaction mixture was stirred for 2 hrs. The progress of reaction was 
monitored by thin layer chromatography. After completion, the reaction mixture was 
evaporated to dryness under vacuum and the residue directly used for next step. 
 
? Synthesis of 1-(4-fluorophenyl)-2-phenylethanone (3). 
 In a 250mL round bottom flask equipped with magnetic stirrer and 
thermometer was placed 2-phenylacetyl chloride (2, 1 mmol) and ZnO (powder, 0.5 
mmol) under nitrogen atmosphere. Slowly added fluorobenzne (1 mmol) in to 
reaction mixture at room temperature. Color (usually pink, but in few cases green or 
blue) developed immediately and darkened with progress of the reaction. The reaction 
mixture was kept at room temperature with occasional stirring for 1 h to complete the 
reaction (monitored by TLC). The solid mass was then eluted with dichloromethane 
(20 mL) and the dichloromethane extract was then washed with an aqueous solution 
of sodium bicarbonate and dried over anhydrous sodium sulfate. Evaporation of 
solvent furnished practically pure the corresponding product with 90 % yield.108 
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? Synthesis of 2-bromo-1-(4-fluorophenyl)-2-phenylethanone (4). 
 In a 250mL round bottom flask equipped with magnetic stirrer and 
thermometer was placed 1-(4-fluorophenyl)-2-phenylethanone (3, 10 mmol) in 
methylene chloride (80 mL), slowly added Br2 solution (10 mmol Br2 in acetic acid 
(20 mL)) at below 10 oC. Stirred reaction mixture for 2-3 hrs at below 10 oC. After 
completion, reaction mixture poured in to ice water and extract in methylene chloride, 
separated organic layer wash with saturated sodium bicarbonate solution (2 x 50 mL) 
and brine solution (2 x 50 mL). The organic layer was separated, dried over 
anhydrous sodium sulfate and evaporated to dryness under reduce pressure.  The 
residue was crystallized from methanol to afford 87 % yield, which was directly used 
for next step.   
 
? General synthesis of acetoacetanilide derivatives (AAA-01-30). 
 Compounds AAA-01-30 were prepared by following the procedure described 
in chapter-4. 
  
? General synthesis of 1,4 dicarbonyl compounds (ADD-01-30). 
 In a 50mL round bottom flask equipped with magnetic stirrer and thermometer 
was placed acetoacetanilide (AAA-01-30, 10 mmol), 2-bromo-1-(4-fluorophenyl)-2-
phenylethanone (4, 10mmol), potassium carbonate (15mmol) and isopropyl alcohol 
(20 mL).  Reaction mixture was heated at 50-55 oC for 4-5 h. The progress of reaction 
was monitored by thin layer chromatography. After completion, the reaction mixture 
was cooled to rt. The precipitate was collected by filtration and washed excessively 
with water and dried. The recrystallized from methanol to give analytically pure 
products in 70-80% yield. 
 
? General synthesis of highly substituted pyrroles (AS-01-30). 
? Conventional method:  
 In a 100mL round bottom flask equipped with dean-stark apparatus, magnetic 
stirrer and thermometer was placed with 1,4 dicarbonyl compound (ADD-01-30, 2 
mmol), amino side chain (5, 2 mmol), pivalic acid (2 mmol), cyclohexane (18 mL) 
and THF (2 mL). The reaction mixture was heated to reflux temperature for 30-40 h. 
The progress of reaction was monitored by thin layer chromatography.  
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After completion, the reaction mixture was cooled to rt, washed with water and 5 (%) 
sodium bicarbonate solution.  The organic layer was separated, dried over anhydrous 
sodium sulfate and evaporated to dryness under reduce pressure.  The residue was 
crystallized from isopropyl alcohol/water (11:5) to obtain the desire product (68-85 % 
yield). 
 
? Microwave assisted method: 
 A flat bottom flask was charged with the 1,4 dicarbonyl compound (ADD-01-
30, 2 mmol), amino side chain (5, 2mmol), pivalic acid (2 mmol), cyclohexane (18 
mL) and THF (2 mL). The reaction mixture was irradiated under microwave for 
appropriate time (Table-2). The progress of reaction was monitored by thin layer 
chromatography. After completion, the reaction mixture was cooled to and washed 
with water, 5 % sodium bicarbonate solution.  The organic layer was separated, dried 
over anhydrous sodium sulfate and evaporated to dryness under reduce pressure.  The 
residue was crystallized from isopropyl alcohol/water (11:5) to obtain the desire 
product (85-95 % yield). 
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? Spectral data of synthesized compounds 
2-acetyl-N-(4-ethylphenyl)-4-(4-fluorophenyl)-4-oxo-3-phenylbutanamide ADD-
05. White solid, yield 82%, mp 190-192°C; Rf 0.42 (9:1 Chloroform: Methanol); IR 
(KBr): 3473, 3072, 2895, 2828, 1694, 1635, 1482, 850, 780 cm-1; 1H NMR (300 
MHz, DMSO): δ 1.06-1.11 (t, 3H, CH3), 2.22 (s, 3H, CH3), 2.44-2.47 (q, 2H CH2), 
4.70-4.73 (d, 1H, CH, j=10.8Hz), 5.36–5.39 (d, 1H, CH, j=10.8Hz), 7.03-7.15 (m, 
3H, Ar), 7.18-7.35 (m, 8H, Ar),  8.09-8.13  (t, 2H, Ar), 10.16  (s, 1H, NH); MS (m/z): 
417 [M+]; Anal. Calcd for C26H24FNO3: C, 74.80; H, 5.79; N, 3.36; Found: C, 74.82; 
H, 5.75; N, 3.33. 
 
N-(4-chlorophenyl)-2-(cyclopropanecarbonyl)-4-(4-fluorophenyl)-4-oxo-3-phenyl 
butanamide ADD-23. White solid, yield 85%, mp 220-222°C; Rf 0.42 (9:1 
Chloroform: Methanol); IR (KBr): 3430, 3045, 2895, 1635, 1482, 1343, 1298, 980, 
783, 732 cm-1; 1H NMR (400 MHz, CDCl3): δ 0.90-0.93 (m, 2H, CH2), 1.05-1.13 (m, 
2H, CH2), 2.18-2.23 (m, 1H,  CH), 4.77-4.80 (d, 1H, CH, j=10.84Hz), 4.49–5.51 (d, 
1H, CH, j=10.84Hz), 6.84-6.89 (m, 2H, Ar), 7.00-7.09 (m, 4H, Ar),  7.18-7.27  (m, 
3H, Ar), 7.34-7.40  (m, 2H, Ar); 13C NMR (100 MHz, CDCl3): δ 11.82, 13.12. 20.34, 
53.10, 66.10, 115.42, 115.90, 121.83, 122.56, 128.13, 128.70, 129.03, 129.25, 129.39, 
131.66, 131.75, 123.16, 132.19, 132.92, 132.95, 160.94, 167.04, 196.70, 205.50; MS 
(m/z): 449 [M+]; Anal. Calcd for C26H21ClFNO3: C, 69.41; H, 4.70; N, 3.11; Found: 
C, 69.43; H, 4.75; N, 3.13.  
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-methyl-3-phenyl-4-(p-tolylcarba- 
moyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-01. White 
solid, mp 167-169°C; Rf 0.42 (9:1 Chloroform: Methanol); IR (KBr): 3412, 3032, 
2977, 2872, 1731, 1659, 1479, 1029, 792, 737, 709 cm-1; MS (m/z): 625 [M+]; Anal. 
Calcd for C38H42FN2O5: C, 72.94; H, 6.77; N, 4.48; Found: C, 72.95; H, 6.78; N, 4.50. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-methoxyphenyl)carbamoyl)-
5-methyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-02. White solid, mp 153-155 °C; Rf 0.47 (9:1 Chloroform: Methanol); IR (KBr): 
3477, 3037, 2981, 2928, 2878, 1729, 1665, 1567, 1542, 1482, 1288, 1083, 1035, 837, 
789, 741, 711 cm-1; MS (m/z): 656 [M+]; Anal. Calcd for C38H42FN2O6: C, 71.32; H, 
6.91; N, 4.27; Found: C, 71.35; H, 6.92; N, 4.28. 
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tert-butyl 2-((4R,6R)-6-(2-(3-((4-chlorophenyl)carbamoyl)-5-(4-fluorophenyl)-2-
methyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-
03. White solid, mp 147-149 °C; Rf 0.47 (9:1 Chloroform: Methanol); IR (KBr): 3458, 
3035, 2988, 2932, 2881, 1731, 1675, 1564, 1547, 1486, 1291, 1087, 1037, 841 cm-1; 
MS (m/z): 660 [M+]; Anal. Calcd for C38H42ClFN2O5: C, 69.03; H, 6.40; N, 4.24; 
Found: C, 69.05; H, 6.42; N, 4.28. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-fluorophenyl)carbamoyl)-5-
methyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-
04. White solid, mp 153-155 °C; Rf  0.52 (9:1 Chloroform: Methanol); IR (KBr): 3411, 
3030, 2979, 2937, 2879, 1725, 1660, 1560, 1535, 1473, 1290, 1095, 1031, 833, 790, 
735, 705 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.03-1.07 (m, 1H, CH), 1.30-1.63 (m, 
18H,  CH2, CH & 5 x CH3), 2.24-2.37 (m, 2H,  CH2), 2.71 (s, 3H, CH3), 3.66 (m, 1H, 
CH), 3.86-3.99 (m, 2H, CH2), 4.14-4.17 (m, 1H, CH),  6.83-7.00 (m, 7H, Ar), 7.12-
7.28  (m, 7H, Ar & NH); 13C NMR (DEPT): (75 MHz, CDCl3): δ 11.61, 19.62. 28.09, 
29.96, 36.05, 37.16, 40.23, 42.46, 65.88, 65.96, 115.11, 115.26, 115.41, 115.54, 
120.66, 120.77, 127.31, 128.66, 131.16, 132.84, 132.95; MS (m/z): 644 [M+]; Anal. 
Calcd for C38H42F2N2O5: C, 70.79; H, 6.57; N, 4.34; Found: C, 70.75; H, 6.52; N, 
4.38. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((4-ethylphenyl)carbamoyl)-5-(4-fluorophenyl)-2-
methyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-
05. White solid, mp 172-174°C; Rf 0.54 (9:1 Chloroform: Methanol); IR (KBr): 3402, 
3063, 2995, 2974, 2875, 1724, 1660, 1533, 1255, 842, 734, 705 cm-1; 1H NMR (300 
MHz, CDCl3): δ ppm 1.16-1.18 (m, 4H, CH & CH3), 1.31-1.76 (m, 18H, CH, CH2 & 
5 x CH3), 2.21-2.36 (m, 2H,  CH2), 2.53-2.55 (m, 2H, CH2), 2.71 (s, 3H, CH3), 3.66 
(m, 1H, CH), 3.89-3.97 (m, 2H, CH2), 4.17 (m, 1H, CH),  6.91-6.99 (m, 7H, Ar), 
7.14-7.26  (m, 7H, Ar & NH); 13C NMR (DEPT): (75 MHz, CDCl3): δ 11.61, 15.72. 
19.62, 28.09, 28.25, 29.97, 36.05, 37.18, 40.20, 42.48, 65.89, 65.98, 115.23, 115.51, 
120.66, 119.30, 128.03, 128.62, 131.15, 132.87, 132.97; MS (m/z): 654 [M+]; Anal. 
Calcd for C40H47FN2O5: C, 73.37; H, 7.23; N, 4.28; Found: C, 73.35; H, 7.25; N, 4.28. 
 
 
 
 
 
Chapter-5  Synthesis of highly substituted pyrroles 
Department of Chemistry, Saurashtra University, Rajkot-360005   182 
 
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-methyl-4-((4-nitrophenyl)carba-
moyl)-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-
06. White solid, mp 183-185°C; Rf 0.44 (9:1 Chloroform: Methanol); IR (KBr): 3428, 
3036, 2979, 2945, 2887, 1723, 1659, 1567, 1541, 1471, 1287, 1095, 1038, 834, 792, 
746, 712 cm-1; MS (m/z): 671 [M+]; Anal. Calcd for C38H42FN3O7: C, 67.94; H, 6.30; 
N, 6.26; Found: C, 67.95; H, 6.25; N, 6.28. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((2,5-dimethylphenyl)carbamoyl)-5-(4-fluorophenyl) 
-2-methyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-07. White solid, mp 143-145°C; Rf 0.51 (9:1 Chloroform: Methanol); IR (KBr): 
3433, 3035, 2972, 2951, 2881, 1729, 1661, 1563, 1545, 1477, 1291, 1086, 1041, 882, 
839, 786, 751, 707 cm-1; MS (m/z): 654 [M+]; Anal. Calcd for C40H47FN2O5: C, 
73.37; H, 7.23; N, 4.28; Found: C, 73.35; H, 7.25; N, 4.28. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((3-chloro-4-fluorophenyl)carbamoyl)-5-(4-fluoro- 
phenyl)-2-methyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-08. White solid, mp 135-138°C; Rf 0.51 (9:1 Chloroform: Methanol); IR 
(KBr): 3405, 3043, 2985, 2972, 2863, 1739, 1675, 1555, 1565, 1464, 1287, 1074, 
1034, 839, 786, 758, 718 cm-1; MS (m/z): 678 [M+]; Anal. Calcd for C38H41ClF2N2O5: 
C, 67.20; H, 6.08; N, 4.12; Found: C, 67.25; H, 6.10; N, 4.13. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((3,4-dichlorophenyl)carbamoyl)-5-(4-fluorophenyl) 
-2-methyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-09. White solid, mp 157-159°C; Rf 0.44 (9:1 Chloroform: Methanol); IR (KBr): 
3447, 3024, 2956, 2964, 2878, 1746, 1661, 1569, 1545, 1447, 1278, 1064, 1049, 831, 
775, 767, 713 cm-1; MS (m/z): 694 [M+]; Anal. Calcd for C38H41Cl2FN2O5: C, 65.61; 
H, 5.94; N, 4.03; Found: C, 65.62; H, 5.95; N, 4.03. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((2,3-dimethylphenyl)carbamoyl)-5-(4-fluorophenyl) 
-2-methyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-10. White solid, mp 143-145°C; Rf 0.51 (9:1 Chloroform: Methanol); IR (KBr): 
3416, 3039, 2967, 2977, 2861, 1734, 1679, 1545, 1565, 1442, 1297, 1043, 1034, 842, 
787, 743, 719 cm-1; MS (m/z): 654 [M+]; Anal. Calcd for C40H47FN2O5: C, 73.37; H, 
7.23; N, 4.28; Found: C, 73.34; H, 7.26; N, 4.30. 
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tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(p-tolyl-
carbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-11. 
White solid, mp 158-160°C; Rf 0.47 (9:1 Chloroform: Methanol); IR (KBr): 3477, 
3037, 2987, 2939, 2878, 1735, 1651, 1567, 1529, 1474, 1291, 1082, 1037, 837, 798, 
731, 704 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.02-1.10 (m, 1H, CH), 1.30-1.66 (m, 
24H, CH, CH2 & 7 x CH3), 2.24-2.42 (m, 5H,  CH2 & CH3), 3.53-3.84 (m, 3H, CH & 
CH2), 4.07-4.16 (m, 2H, 2 x CH),  6.80 (s, 1H, NH), 6.98-7.26  (m, 13H, Ar); 13C 
NMR (DEPT): (75 MHz, CDCl3): δ 19.68, 20.83, 21.62, 21.80, 26.09, 28.09, 29.93, 
35.97, 38.09, 40.82, 42.46, 65.90, 66.41, 115.22, 115.51, 119.63, 126.48, 128.31, 
129.19, 130.47, 133.14, 133.25; MS (m/z): 668 [M+]; Anal. Calcd for C41H49FN2O5: 
C, 73.63; H, 7.38; N, 4.19; Found: C, 73.64; H, 7.36; N, 4.19. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-4-((4-methoxyphenyl)- 
carbamoyl)-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-12. White solid, mp 174-176°C; Rf 0.45 (9:1 Chloroform: Methanol); IR (KBr): 
3412, 3031, 2989, 2935, 2868, 1737, 1671, 1558, 1554, 1474, 1298, 1087, 1047, 845, 
775, 734, 703 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.06 (m, 1H, CH), 1.30-1.65 (m, 
24H, CH, CH2 & 7 x CH3), 2.25-2.37 (m, 2H,  CH2), 3.54 (m, 3H, CH), 3.73 (m, 5H, 
CH3 & 2 x CH), 4.14 (m, 2H, CH2), 6.72-6.75  (d, 3H, J=7.5Hz, Ar), 6.99 (s, 4H, Ar), 
7.16 (s, 7H, Ar & NH); 13C NMR (DEPT): (75 MHz, CDCl3): δ 19.68, 21.64, 21.82, 
26.10, 28.09, 29.92, 35.97, 38.09, 40.79, 42.46, 65.90, 66.41, 113.86, 115.22, 115.50, 
121.47, 126.45, 128.29, 130.46, 133.14, 133.25; MS (m/z): 684 [M+]; Anal. Calcd for 
C41H49FN2O6: C, 71.91; H, 7.21; N, 4.09; Found: C, 71.94; H, 7.26; N, 4.09. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((4-chlorophenyl)carbamoyl)-5-(4-fluorophenyl)-2-
isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate. 
AS-13. White solid, yield 94%, mp 184-186°C; Rf 0.46 (9:1 Chloroform: Methanol); 
IR (KBr): 3410, 3041, 2992, 2943, 2875, 1744, 1677, 1474, 1287, 1075, 1047, 846 
cm-1; 1H NMR (400 MHz, CDCl3): δ 0.92-1.01 (m, 1H, CH), 1.22 (s, 3H, CH3), 1.26-
1.28 (m, 4H,  CH & CH3), 1.35-137 (s, 9H, 3 x CH3), 1.43-1.45 (d, 6H, 2 x CH3), 
1.56-1.60 (m, 2H, CH2), 2.07-2.18 (dd, 1H, CH), 2.27-2.33 (dd, 1H, CH), 3.48-3.53 
(m, 1H, CH), 3.60-3.62 (m, 1H, CH), 3.73-3.76 (m, 1H, CH), 3.96-4.09 (m, 2H, CH2), 
6.76 (s, 1H, NH), 6.88-6.92 (m, 4H, Ar), 7.02-7.18 (m, 9H, Ar & NH);  
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13C NMR: (100 MHz, CDCl3): δ 19.68, 21.50, 21.67, 26.07, 28.09, 29.93, 35.96, 
38.07, 40.91, 42.45, 65.90, 66.39, 98.69, 114.88, 115.29, 115.50, 120.61, 121.77, 
126.70, 128.09, 128.12, 128.25, 128.43, 128.64, 128.93, 130.55, 133.14, 
133.22,134.62, 137.04, 141.93, 161.06, 163.52, 164.68, 170.20; MS (m/z): 688 [M+]; 
Anal. Calcd for C40H46ClFN2O5: C, 69.70; H, 6.73; N, 4.06; Found: C, 69.70; H, 6.74; 
N, 4.09. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-((4-fluorophenyl)carbamoyl)-5-
isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-14. White solid, mp 170-172°C; Rf 0.48 (9:1 Chloroform: Methanol); IR (KBr): 
3437, 3039, 2985, 2948, 2865, 1739, 1675, 1563, 1549, 1486, 1281, 1087, 1048, 837, 
787, 744, 716 cm-1; MS (m/z): 672 [M+]; Anal. Calcd for C40H46F2N2O5: C, 71.41; H, 
6.89; N, 4.16; Found: C, 71.41; H, 6.84; N, 4.19. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((4-ethylphenyl)carbamoyl)-5-(4-fluorophenyl)-2-
isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-15. White solid, mp 202-204°C; Rf 0.55 (9:1 Chloroform: Methanol); IR (KBr): 
3429, 3039, 2975, 2954, 2895, 1736, 1665, 1571, 1542, 1461, 1287, 1081, 1043, 831, 
784, 739, 713 cm-1; MS (m/z): 682 [M+]; Anal. Calcd for C42H51FN2O5: C, 73.87; H, 
7.53; N, 4.10; Found: C, 73.81; H, 7.54; N, 4.10. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-4-((4-nitrophenyl) 
carbamoyl)-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-16. White solid, mp 188-190°C; Rf 0.48 (9:1 Chloroform: Methanol); IR (KBr): 
3427, 3045, 2969, 2956, 2875, 1729, 1678, 1581, 1557, 1464, 1271, 1097, 1045, 839, 
781, 758, 721 cm-1; MS (m/z): 699 [M+]; Anal. Calcd for C40H46FN3O7: C, 68.65; H, 
6.63; N, 6.00; Found: C, 68.86; H, 6.64; N, 6.05. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((2,5-dimethylphenyl)carbamoyl)-5-(4-fluorophenyl) 
-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-17. White solid, mp 157-159°C; Rf 0.41 (9:1 Chloroform: Methanol); IR (KBr): 
3415, 3048, 2979, 2948, 2875, 1739, 1678, 1579, 1555, 1464, 1276, 1071, 1049, 876, 
849, 765, 749, 716 cm-1; MS (m/z): 682 [M+]; Anal. Calcd for C42H51FN2O5: C, 
73.87; H, 7.53; N, 4.10; Found: C, 73.84; H, 7.54; N, 4.12. 
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tert-butyl 2-((4R,6R)-6-(2-(3-((3-chloro-4-fluorophenyl)carbamoyl)-5-(4-fluoro-
phenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-18. White solid, mp 144-146°C; Rf 0.46 (9:1 Chloroform: Methanol); IR 
(KBr): 3399, 3053, 2975, 2982, 2875, 1736, 1684, 1564, 1573, 1475, 1283, 1062, 
1041, 833, 781, 752, 703 cm-1; MS (m/z): 706 [M+]; Anal. Calcd for C40H45ClF2N2O5: 
C, 67.93; H, 6.41; N, 3.96; Found: C, 67.94; H, 6.42; N, 3.97. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((3,4-dichlorophenyl)carbamoyl)-5-(4-fluorophenyl) 
-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-19. White solid, mp 136-138°C; Rf 0.38 (9:1 Chloroform: Methanol); IR (KBr):  
3425, 2964, 2974, 2863, 1756, 1672, 1575, 1549, 1457, 1288, 1068, 1053, 836, 764, 
772, 719 cm-1; MS (m/z): 722 [M+]; Anal. Calcd for C40H45Cl2FN2O5: C, 66.39; H, 
6.27; N, 3.87; Found: C, 66.40; H, 6.30; N, 3.88. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((2,3-dimethylphenyl)carbamoyl)-5-(4-fluorophenyl) 
-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-20. White solid, mp 180-182°C; Rf 0.41 (9:1 Chloroform: Methanol); IR (KBr): 
3417, 3048, 2957, 2985, 2875, 1748, 1663, 1557, 1579, 1457, 1285, 1052, 1038, 857, 
757, 763, 709 cm-1; MS (m/z): 682 [M+]; Anal. Calcd for C42H51FN2O5: C, 73.87; H, 
7.53; N, 4.10; Found: C, 73.84; H, 7.54; N, 4.12. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-5-(4-fluorophenyl)-4-phenyl-3-(p-tolyl-
carbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate AS-21. 
White solid, mp 163-165°C; Rf 0.35 (9:1 Chloroform: Methanol); IR (KBr): 3441, 
3228, 3101, 2978, 2941, 1730, 1643, 1491. 1247, 833, 738, 704 cm-1; 1H NMR (300 
MHz, CDCl3): δ 0.77 (m, 2H, CH2), 0.99-1.11 (m, 3H, CH2 & CH), 1.21-1.59 (m, 
19H, 2 x CH2 & 5 x CH3),  1.91 (m, 1H, CH), 2.20-2.37 (m, 5H, CH & 2 x CH2), 3.63 
(m, 1H, CH), 4.14 (m, 3H, CH & CH2), 6.84 (s, 1H, NH), 6.99-7.26 (m, 13H, Ar); 13C 
NMR (DEPT): (75 MHz, CDCl3): δ 6.81, 7.54, 7.63, 19.62, 20.84, 28.09, 29.96, 
36.01, 37.19, 40.38, 42.50, 65.91, 66.14, 115.32, 115.61, 119.50, 126.46, 128.27, 
129.25, 130.42, 132.80, 132.90; MS (m/z): 666 [M+]; Anal. Calcd for C41H47FN2O5: 
C, 73.85; H, 7.10; N, 4.20; Found: C, 73.84; H, 7.04; N, 4.22. 
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tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-5-(4-fluorophenyl)-3-((4-methoxy-
phenyl)carbamoyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-22. White solid, mp 163-165°C; Rf 0.35 (9:1 Chloroform: Methanol); IR 
(KBr): 3421, 3045, 2975, 2948, 2852, 1742, 1664, 1569, 1567, 1461, 1291, 1079, 
1041, 851, 781, 745, 714 cm-1; MS (m/z): 682 [M+]; Anal. Calcd for C41H47FN2O6: C, 
72.12; H, 6.94; N, 4.10; Found: C, 72.12; H, 6.95; N, 4.12. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((4-chlorophenyl)carbamoyl)-2-cyclopropyl-5-(4-
fluorophenyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-23. White solid, mp 193-194°C; Rf 0.45 (9:1 Chloroform: Methanol); IR 
(KBr): 3452, 3052, 2987, 2939, 2884, 1753, 1679, 1564, 1559, 1482, 1267, 1065, 
1039, 856 cm-1; MS (m/z): 686 [M+]; Anal. Calcd for C40H44ClFN2O5: C, 69.91; H, 
6.45; N, 4.08; Found: C, 69.95; H, 6.48; N, 4.12. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-5-(4-fluorophenyl)-3-((4-fluorophenyl) 
carbamoyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-24. White solid, mp 172-174°C; Rf 0.38 (9:1 Chloroform: Methanol); IR (KBr): 
3499, 3052, 2975, 2957, 2854, 1742, 1665, 1572, 1556, 1478, 1271, 1073, 1053, 831, 
782, 754, 726 cm-1; MS (m/z): 670 [M+]; Anal. Calcd for C40H44F2N2O5: C, 71.62; H, 
6.61; N, 4.18; Found: C, 71.63; H, 6.58; N, 4.12. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-3-((4-ethylphenyl)carbamoyl)-5-(4-
fluorophenyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-25. White solid, mp 112-115°C; Rf 0.45 (9:1 Chloroform: Methanol); IR 
(KBr): 3438, 3043, 2965, 2943, 2887, 1736, 1645, 1562, 1532, 1456, 1272, 1061, 
1031, 821, 774, 729, 703 cm-1; MS (m/z): 680 [M+]; Anal. Calcd for C42H49FN2O5: C, 
74.09; H, 7.25; N, 4.11; Found: C, 74.13; H, 7.28; N, 4.12. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-5-(4-fluorophenyl)-3-((4-nitrophenyl)-
carbamoyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
AS-26. White solid, mp 132-134°C; Rf 0.52 (9:1 Chloroform: Methanol); IR (KBr): 
3413, 3052, 2972, 2961, 2865, 1739, 1688, 1571, 1562, 1476, 1269, 1084, 1051, 842, 
778, 768, 728 cm-1 MS (m/z): 697 [M+]; Anal. Calcd for C40H44FN3O7: C, 68.85; H, 
6.36; N, 6.02; Found: C, 68.87; H, 6.38; N, 6.08. 
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tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-3-((2,5-dimethylphenyl)carbamoyl)-5-
(4-fluorophenyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-27. White solid, mp 210-212°C; Rf 0.38 (9:1 Chloroform: Methanol); IR 
(KBr): 3440, 3053, 2987, 2951, 2868, 1746, 1687, 1554, 1571, 1445, 1268, 1061, 
1067, 856, 859, 774, 752, 722 cm-1; MS (m/z): 680 [M+]; Anal. Calcd for 
C42H49FN2O5: C, 74.09; H, 7.25; N, 4.11; Found: C, 74.13; H, 7.28; N, 4.12. 
 
tert-butyl 2-((4R,6R)-6-(2-(3-((3-chloro-4-fluorophenyl)carbamoyl)-2-cyclopropyl 
-5-(4-fluorophenyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-28. White solid, mp 169-171°C; Rf 0.47 (9:1 Chloroform: Methanol); IR 
(KBr): 3428, 3041, 2965, 2997, 2885, 1726, 1675, 1566, 1587, 1464, 1278, 1072, 
1052, 836, 775, 759, 713 cm-1; MS (m/z): 680 [M+]; Anal. Calcd for C40H43ClF2N2O5: 
C, 68.12; H, 6.15; N, 3.97; Found: C, 68.13; H, 6.18; N, 4.01. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-3-((3,4-dichlorophenyl)carbamoyl)-5-(4-
fluorophenyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-29. White solid, mp 133-135°C; Rf 0.35 (9:1 Chloroform: Methanol); IR 
(KBr): 3472, 3120, 3073, 2975, 2985, 2879, 1763, 1665, 1581, 1553, 1468, 1276, 
1079, 1045, 842, 771, 768, 729 cm-1; MS (m/z): 720 [M+]; Anal. Calcd for 
C40H43Cl2FN2O5: C, 66.57; H, 6.01; N, 3.88; Found: C, 66.49; H, 6.10; N, 3.95. 
 
tert-butyl 2-((4R,6R)-6-(2-(2-cyclopropyl-3-((2,3-dimethylphenyl)carbamoyl)-5-
(4-fluorophenyl)-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl) 
acetate AS-30. White solid, mp 123-125°C; Rf 0.40 (9:1 Chloroform: Methanol); IR 
(KBr): 3423, 3039, 2948, 2981, 2865, 1769, 1678, 1547, 1587, 1443, 1278, 1064, 
1045, 864, 752, 768, 718 cm-1; MS (m/z): 680 [M+]; Anal. Calcd for C42H49FN2O5: C, 
74.09; H, 7.25; N, 4.11; Found: C, 74.13; H, 7.28; N, 4.12. 
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1H NMR spectrum of compound ADD-23 
 
 
Expanded 1H NMR spectrum of compound ADD-23 
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1H NMR spectrum of compound AS-04 
 
 
Expanded 1H NMR spectrum of compound AS-04 
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1H NMR spectrum of compound AS-13 
 
 
Expanded 1H NMR spectrum of compound AS-13 
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1H NMR spectrum of compound AS-21  
 
 
Expanded 1H NMR spectrum of compound AS-21 
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1H NMR spectrum of compound AS-11  
 
 
1H NMR spectrum of compound AS-12 
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13C NMR spectrum of compound AS-11 
 
 
13C NMR spectrum of compound AS-13 
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MASS spectrum of compound ADD-05 
 
 
MASS spectrum of compound ADD-11 
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MASS spectrum of compound AS-12 
 
 
MASS spectrum of compound AS-13 
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IR spectrum of compound AS-05 
 
 
IR spectrum of compound AS-21 
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6.1 Introduction 
 
 The clinical importance and commercial success associated with the 1,4-
benzodiazepine class of central nervous system (CNS)-active agents and the utility of 
1,4-diazepines as peptide mimetic scaffolds have led to their recognition by the 
medicinal chemistry community as privileged structures. This ring system has 
demonstrated considerable utility in drug design, with derivatives demonstrating a 
wide range of biological activities. 
 The ring numbering and accepted system of nomenclature for 1,4-diazepines 
are illustrated in the structures (Figure-1). These structures are representatives of the 
tautomeric forms that have been most studied. Examples of all the fully unsaturated 
monocyclic 1,4-diazepines have been described and all are very unstable. In the 
dihydro-1,4-diazepines, the 2,3-dihydro-1H compounds have been studied most. For 
benzo-analogues the 3H series are usually more stable than 1H and although the 
parent compounds of both series are unknown, there is an extensive chemistry on 
substituted analogous especially in 3H series. The benzodiazepine-2-ones have been 
widely studied as benefits their commercial importance.  
 
Figure-1 
 On the other hand, examples of the serendipitous discovery of new drugs 
based on an almost random screening of chemicals synthesized in the laboratory are 
striking. Since 1960, when chlordiazepoxide (Librium) entered in the market, efforts 
to discover new biologically active compounds with limited side effects in 
benzodiazepines are going on which are reflected by the important number of 
publication focused in this subject.1-5 
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 Diazepine derivatives constitute an important class of heterocyclic compounds 
which possess a wide range of therapeutic and pharmacological properties. 
Derivatives of benzodiazepines are widely used as anticonvulsant, antianxiety, 
analgesic, sedative, anti-depressive, and hypnotic agents6-7 as well as anti-
inflammatory agents.8 In the last decade, the area of biological interest of 1,5-
benzodiazepines has been extended to several diseases such as cancer, viral infection 
and cardiovascular disorders.9-10 In addition,1,5-benzodiazepines are key 
intermediates for the synthesis of various fused ring systems such astriazolo-, 
oxadiazolo-, oxazino- or furanobenzodiazepines.11-14 Besides, benzodiazepine 
derivatives are also of commercial importance as dyes for acrylic fibers in 
photography.15 Owing to their versatile applications various methods for the synthesis 
of benzodiazepines have been reported in the literature. These include condensation 
reactions of o-phenylenediamines with α,β-unsaturated carbonylcompounds,16 with 
ketones in the presence of BF3·Et2O, NaBH4 , polyphosphoric acid or SiO2, 
MgO/POCl3 , Yb(OTf)3, Al2O3/P2O5 or AcOH under microwave conditions, 
Amberlyst-15 in the ionic liquid 1-butyl-3-methylimidazoliumbromide ([bmim]Br), 
CeCl3·7H2O/NaI supported on silica gel,InBr3 , Sc(OTf)3 , sulfated zirconia, InCl3 , 
CAN, ZnCl2 under thermal conditions, AgNO3.17-32 
 Among all types of benzodiazepines (1,2-,1,3-, 1,4-, 1,5-, 2,3-, & 2,4- ) only 
1,4- and 1,5-benodiazepines have found wide applications in medicines, during one of 
the most important classes of the therapeutic agents with wide spread biological 
activities33 including hypnotics, sedatives, anxiolytics and antianxiety etc, effect range 
from their well-documented anticonvulsive or tranquilizing properties, through 
pesticidal34 or antitumor35 action and to their more recently described peptidomimetic 
activity.36 
 Recently, structural modification has been done in diazepine ring system to 
enhance biological activity. Diazepine ring system modified at N and 3-position has 
been studied extensively. They have been tested clinically as an antitrypanosomal 
activity,37 antiplasmodial falcipain-2 inhibitors,38 antileukemic agents,39 and 
endothelin Receptor Antagonists.40 V. I. Pavlovsky et al.41 has reported that 3-
arylideneand 3-hetarylidene 1,4-diazepinederivatives afford good affinity toward CNS 
benzodiazepine receptors. 
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6.2 Biological activities associated with diazepine derivatives 
 Buckle et al.42 has prepared 1H-benzo-1,5-diazepine-2,4-(3H,5H)-diones 
(Figure-2) from 4,2-R2(NH2)C6H3NH2 (R2= H, Cl, F, COOH) by refluxing with 
malonic acid in 4N HCl for half an hour followed by nitration with fuming HNO3 
which is antiallergic substance useful in the treatment of rhinitis, hay fever and certain 
type of asthma. 
 
Figure-2 
 K. S. Andronati et al.43 has prepared 3-Amino-1,2-dihydro-3h-1,4-
benzodiazepin-2-one derivatives (Figure-3) via interaction with 3-chloro 
benzodiazepines, diethylamine, 1,6-diaminohexane, or p-nitroaniline, which is exhibit 
a pronounced anticonvulsant activity and produce significant anorexigenic effect. 
N
H
N
O
R2
R1
Br
R2=N(C2H5)2, NH(CH2)6NH2
R1=H,Cl
 
Figure-3 
 More recent analogues of the Benzodiazepines have attracted interest as anti 
HIV compounds, such as the clinically used nevirapine and as anticancer compounds, 
such as the pyrrolo fused antitumor antibiotic DC-18 (Figure-4), analogues of which 
are in clinical development as anticancer agents.44 
 
Figure-4 
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 Rubin et al.45 have synthesized 4-phenyl-2-trichloromethyl-3H-1,5-
benzodiazepine hydrogen sulphate and examined its pharmacological effects in mice, 
keeping diazepam as reference. The data suggest that this recently synthesized 
compound possesses anxiolytic activity and produces motor in co-ordination similar 
to those observed with diazepam. 
 The synthesis of a new class of annulated 1,4-benzodiazepines with anti-
psychotic activity was exemplified by preparation of 10-fluoro-3-methy1-7-(2-
thieny1)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine(Figure-5). The 
influence of variations of the fluoro-substitution pattern and variations of the fused 
ring system on the biological activity of the structural analogues was evaluated.46 
 
Figure-5 
 3-Acetyl coumarins when allowed react with isatin gave corresponding 3-(3’-
hydroxy-2’-oxoindolo)acetylcoumarins, which on dehydration afforded the 
corresponding α,β-unsaturated ketones. Which on cyclocondensation with substituted 
o-phenylenediamines resulted in novel4-(2-oxo-2H-chromen-3-yl)-1,5-dihydrospiro 
[benzo[b][1,4]diazepine-2,3'-indolin]-2'-one (Figure-6). All the compounds have 
been screened for their antimicrobial and antianxiety activity in mice.47 
 
Figure-6 
 A library of compounds targeted to the vasopressin/oxytocin family of 
receptors was screened for activity at a cloned human oxytocin receptor using a 
reporter gene assay. Potency and selectivity were optimized to afford compound 
(Figure-7), EC50=33 nM. This series of compounds represents the first disclosed, 
non-peptide, low molecular weight agonists of the hormone oxytocin.48 
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Figure-7 
 A series of 2,3-dihydro-1,5-benzodiazepines were synthesized and evaluated 
for anti-inflammatory effects in microglia cells.49 Among the 1,5-benzodiazepines 
tested, compound (Figure-8) strongly inhibited LPS-induced nitric oxide (NO) 
production, with an IC50 value of 7.0 µM in the microglia cells.  
 
Figure-8 
 A series of 2,3-dihydro-1H-thieno[2,3-e][1,4]diazepine (Figure-9) was 
synthesized and evaluated for CNS activity. A new antianxiety screen for 
benzodiazepine-like drugs was used along with the standard anticonvulsant test. 
Structure activity relationships were discussed.50 
 
Figure-9 
 Walser A. et al.51 have prepared [1,2,4]triazolo[4,3-a][1,4]benzodiazepines 
bearing an ethynyl functionality at the 8-position and the isostericthieno[3,2-f] 
[1,2,4]triazolo[4,3-a][1,4]diazepines (Figure-10) and evaluated as antagonists of 
platelet activating factor. 
 
 
Chapter 6             Synthesis of benzodiazepines 
Department of Chemistry, Saurashtra University, Rajkot-360005   206 
 
 
 
Figure-10 
 Nakanishi et al.52 have reported the synthesis and pharmacological activity of 
tetrazolo, oxadiazolo and imidazothienodiazepines derivatives (Figure-11). Some of 
them were found as minor tranquilizers.  
 
Figure-11 
 Malcolm et al.53 have been synthesized acetamido-1,4-diazepine analogs 
(Figure-12) which worked as inhibitor of respiratory syncytial virus(RSV) and 
exhibited IC50 in the range of 10-20 íM over all three assays routinely used. This 
molecule also demonstrated excellent pharmacokinetic properties in the rat with a 
half-life of approximately 6 hand an oral bioavailability of 76%. This suggested that 
the core benzodiazepine was relatively stable to metabolism and a good starting point 
for lead optimization. 
 
Figure-12 
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6.3 Some pharmaceutical molecules related to benzodiazepines 
 Benzodiazepines enhance the effect of the neurotransmitter gamma-amino 
butyric acid (GABA), which results in sedative, hypnotic (sleep-inducing), anxiolytic 
(anti-anxiety), anticonvulsant, muscle relaxant and amnesic action. These properties 
make benzodiazepines useful in treating anxiety, insomnia, agitation, seizures, muscle 
spasms, alcohol withdrawal and as a premedication for medical or dental procedures. 
Benzodiazepines are categorized as either short-, intermediate- or long-acting. Short- 
and intermediate-acting benzodiazepines are preferred for the treatment of insomnia; 
longer-acting benzodiazepines are suggested for the treatment of anxiety. The detail 
of benzodiazepines related drugs is given below (Figure-13). 
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Figure-13 
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6.4 Synthetic methods for benzodiazepines derivatives 
 The most extensively used methods for preparing 1,4-benzodiazepines begins 
with an ortho-aminobenzophenone (1). The first method involves two-step synthesis. 
The first step involves treatment of the appropriate aminobenzophenone with 
haloacetyl halide to afford the amide (2), followed by the addition of ammonia to first 
displace the chlorine giving the glycinamide (3). Then cyclization by imine formation 
will give the benzodiazepine (4).54-55 The other method involves treating the o-amino-
ketone with an amino acid ester hydrochloride in pyridine to yield (4) (Figure-14). 
Generally, the first method gave a higher percent yield of clean product, while the 
second method facilitated the conversion of o-aminoketones to benzodiazepines in 
one step, with a variety of substituents.54-56 
Figure-14 
 Jin-Yuan Wang et al.57 have developed a new strategy for the synthesis of 1,4-
benzodiazepine from Methyl1-arylaziridine-2-carboxylates with N-[2-Bromo- 
methyl(phenyl)]trifluoroacetamides (Figure-15). The reaction proceeds through the 
N-benzylation and highly regioselective ring-opening reaction of aziridine by bromide 
anion followed by Et3N mediated intramolecular nucleophilic displacement of the 
bromide by the amide nitrogen. 
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Figure-15 
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 Recently, Joshua et al.58 has reported the synthesis of saturated 1,4-
benzodiazepines and 1,4-benzodiazepin-5-ones (Figure-16) via Pd-catalyzed 
carboamination reactions using sodium tert-butoxide base and xylene as a solvent at 
refluxing condition. 
 
Figure-16 
 Veena Yadav et al.59 has developed an efficient microwave assisted protocol 
for the exclusive one pot synthesis of N-amino-methyl substituted 1,4- 
benzodiazepine derivatives by the reaction of N-amino-methylsubstituted isatoic 
anhydride with glycine and L-proline respectively has been described (Figure-17). 
 
Figure-17 
 Line S. Laustsen et al.60 has developed an efficient solid-phase method has 
been for the parallel synthesis of 1,3-dihydro-1,4-benzodiazepine-2-one derivatives 
(Figure-18). A key step in this procedure involves catching crude 2-aminobenzoimine 
(1) products on an amino acid Wang resin (2). Mild acidic conditions then promote a 
ring closure and in the same step cleavage from the resin to give pure benzodiazepine 
products (3).These synthesis strategies involve catch and release phenomena. 
Figure-18 
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 New 2,4-disubstituted 1,5-benzodiazepine derivatives containing different 
functional groups have been synthesized and screened for their antibacterial activity. 
The 2,4-disubstituted 1,5-benzodiazepine derivatives were synthesized by reacting 
substituted chalcones synthesized using aldol condensation with o-phenylenediamine 
(Figure-19). QSAR studies of synthesized derivatives were performed.61 
 
Figure-19 
 A facile and efficient synthesis of 1,5-benzodiazepines with an aryl 
sulfonamido substituent at C(3) is described. 1,5-Benzodiazepine, derived from the 
condensation of benzene-1,2-diamine and diketene, reacts with an 
arylsulfonylisocyanate via an enamine intermediate to produce 1,5-benzodiazepines 
good yields (Figure-20).62 
 
Figure-20 
 Goswami and Das reports the organo catalyzed one-pot synthesis of 
substituted 1,5-benzodiazepinesby condensation of o-phenylenediamine, and 1,3-
dicarbonyl compounds at room temperature or under reflux in the presence of 
catalytic amount of L-proline as shown in (Figure-20).63 
 
Figure-20 
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6.5. Current research work 
 The chemistry of benzodiazepines and its derivatives has been studied for over 
a century due to their diverse biological activities. It has numerous pharmacological 
and medicinal applications viz, PAF antagonists, cardiovascular agents, CNS-active 
agent, hypnotic, anxiolytic, sedative and anticonvulsant. Therefore, we set to prepare 
some new 1H-benzo[e][1,4]diazepin-2(3H)-one derivatives for their biological studies. 
 The requisite starting material1,4-benzodiazepines (ADZ-03) was prepared by 
following the reported procedure. The 2-amino-4’-flouro-benzophenone (ADZ-01) 
was reacted with chloroacetylchloride to afford 2-chloro-N-(2-(4’-fluorobenzoyl) 
phenyl)acetamide (ADZ-02). It was subsequently converted to 1,4-benzodiazepines 
by the modification of the known hexamethylenetetramine-(HMTM)-based 
cyclization reaction developed by Blazevic and Kajfez.54-55 ADZ-03 thus obtained 
was reacted with a variety of alkyl halide using KOH  in DMF to give 1-substituted-5-
(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one (ADZ-04a-j). To achieve 5- 
substituted 1,4-benzodiazepines (ADZ-05a-j), 5-(4-fluorophenyl)-1H-benzo[e][1,4] 
diazepin-2(3H)-one (ADZ-03) was treated with various aromatic aldehydes in the 
presence of potassium hydroxide in toluene. The newly synthesized compounds were 
characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. 
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6.6 Results and discussion 
Scheme: Synthesis of some new benzodiazepine derivatives 
Scheme-01 
 
Scheme-02 
 
Where R= CH3, CH(CH3)2,  R1= CH3, F, Cl, NO2,   X=Br 
 
 Synthesis of 1-and 3-substituted 1,4-benzodiazepinederivatives is shown in 
sheme 1 and 2. The starting material, 2-amino-4’-flouro-benzophenone ADZ-01 was 
reacted with chloroacetyl chloride in toluene at room temperature to afforded 2-
chloro-N-(2-(4’-fluorobenzoyl)phenyl)acetamide. The latter was converted in to 1,4-
benzodiazepines ADZ-03 by following the literature methods using ammonium 
acetate and hexamine in EtOH.54-55 The N-alkylation of 1,4-benzodiazepines with 
various alkyl halide in DMF at below 15 oC in the presence of potassium hydroxide 
proceeded smoothly to furnish a series of 1-substituted-5-(4-fluorophenyl)-1H-
benzo[e][1,4]diazepin-2(3H)-one ADZ-04a-j in good yields. Reaction time and (%) 
of yield is summarized in Table-1. 
 On the other hand, the condensation of of 1,4-benzodiazepines ADZ-03 with 
aromatic aldehydes in the presence of potassium hydroxide in reluxing provided a 
series of new 3-substituted-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
ADZ-05a-j in excellent yields (Table-2).  
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A variety of 3-arylidine benzodiazepines bearing  electron donating and electron 
withdrawing groups such as 3,4-diOCH3; 4-OCH3; H; 2,5-diOCH3; 2-OH; 4-F; 4-Br; 
4-Cl; 4-NO2 and 3-NO2 were prepared. 
Table-1: Synthesis of 1-substituted benzodiazepine derivatives 
Entry R Yield (%) Time hrs 
ADZ-04a -CH3 87 2.0 
ADZ-04b -CH2CH3 83 2.5 
ADZ-04c -(CH2)2CH3 88 3.0 
ADZ-04d -CH(CH3)2 84 2.5 
ADZ-04e -(CH2)3CH3 80 3.0 
ADZ-04f -CH2CH(CH3)2 89 3.5 
ADZ-04g (CH2)4CH3 90 2.5 
ADZ-04h -(CH2)2CH(CH3)2 88 4.0 
ADZ-04i C6H11 79 4.5 
ADZ-04j -CH2C6H44-NO2 90 4.0 
 The structures of ADZ-03 were conformed on the basis of their elemental 
analysis and spectral data (MS, IR, and1H NMR).The analytical data for ADZ-03 
revealed a molecular formula C15H11FN2O2 (m/z 254).The 1HNMR spectrum revealed 
a singlet at   4.31ppm assigned to –CH2 group, a four multiplet signals at δ = 7.04–
7.57 ppm assigned to the aromatic protons, and one broad singlet at δ = 8.83 ppm 
assigned to -CONH groups. 
Table-2: Synthesis of 3-arylidine benzodiazepine derivatives 
Entry R1 Yield (%) Time hrs 
ADZ-05a H 90 2.0 
ADZ-05b 3-NO2 85 2.5 
ADZ-05c 3,4-diOCH3 83 3.0 
ADZ-05d 4-OCH3 87 2.5 
ADZ-05e 4-Cl 94 3.0 
ADZ-05f 4-F 90 3.5 
ADZ-05g 4-NO2 92 2.5 
ADZ-05h 4-Br 89 4.0 
ADZ-05i 2-OH 80 4.5 
ADZ-05j 2,5-diOCH3 81 4.0 
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 The newly synthesized compounds ADZ-04a-j were conformed on the basis 
of their elemental analysis and spectral data (MS, IR, 1H NMR and 13C NMR). The 
structure of ADZ-04a was supported by its mass (m/z 268) which agree with its 
molecular formula C16H13FN2O, its 1H NMR spectrums held a singlet at δ =3.42 ppm 
assigned to -CH3, two doublet signals observed at δ =3.75-3.78 (1H, J=10.5Hz) and 
4.78-4.81 (1H, J=10.5Hz) assigned to –CH2 group, and four multiplet signal observed 
at δ =7.05-7.65 assigned to the aromatic protons. 
 All synthesized compounds ADZ-05a-j were conformed on the basis of their 
elemental analysis and spectral data (MS, IR,1H NMR and 13C NMR).The analytical 
data for ADZ-05a revealed a molecular formula C22H15FN2O(m/z 342). Its 1H NMR 
signals held at δ = 6.39 (s. 1H, CH), 7.08-7.12 (m, 1H, Ar), 7.21-7.37 (m, 7H, Ar), 
7.46-7.53 (m, 3H, Ar), 7.76-7.79 (m, 2H, Ar), 8.15 (s, 1H, -CONH). 
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6.7 Conclusion 
 
 In summary, we have demonstrated a simple and effective strategy for the 
synthesis of novel1-and 3-substituted 1,4-benzodiazepines. The reaction of 1,4-
benzodiazepines  either with various alkyl halide or a variety of aromatic aldehydes in 
the presence of potassium hydroxide afforded the desired 1-and 3-substituted 1,4-
benzodiazepine derivatives (ADZ-04a-j and ADZ-05a-j) in excellent yields.  
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6.8 Experimental section 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (300 MHz), 1H (400 MHz),13C (75 MHz) and 13C (100 MHz)  
NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl3 and 
DMSO. Chemical shifts are expressed in δ ppm downfield from TMS as an internal 
standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 
mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI rotary 
evaporator. Melting points were measured in open capillaries and are uncorrected. 
 
? General procedure for the synthesis of 2-chloro-N-(2-(4-
fluorobenzoyl)phenyl) acetamide (ADZ-02). 
 
 To a solution of 2-amino-4’-fluorobenzophenone (0.0046 mol) in toluene 
(10mL), a solution of chloroacetyl chloride (0.0049 mol) in toluene (2 mL) was added 
drop wise at 0 °C within 0.5 h. The reaction mixture was further stirred at room 
temperature for 5 h. The resulting reaction mixture was evaporated to dryness. The 
crude product was triturated with ethanol (10 mL) and the crystalline solid separated 
was collected by filtration to give desired product ADZ-02 in 87-90% yield. 
 
? General procedure for the synthesis of 5-(4-fluorophenyl)-1H-beno[e] 
[1,4]diazepin-2(3H)-one (ADZ-03). 
 
 To a solution of 2-chloro-N-(2-(4-fluorobenzoyl)phenyl)acetamide (0.0068 
mol) in ethanol (40 mL), hexamethylenetetramine (HMTM; 0.015 mol) and 
ammonium acetate (0.015 mol) were added. The reaction mixture was stirred at reflux 
temperature for 3 h. Then the reaction mixture was evaporated to dryness. Distilled 
water (30mL) was added, and the resulting suspension was stirred at 60 °C for 0.5 h. 
The suspension was cooled to 20 °C and filtered. The crude product was crystallized 
from toluene to obtained ADZ-03 in 80-85% yield. 
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? General synthesis of 1-substituted-5-(4-fluorophenyl)-1H-benzo[e] 
[1,4]diazepin-2(3H)-one (ADZ-04a-j). 
 
 To solution of 5-(4-fluorophenyl)-1H-beno[e][1,4]diazepin-2(3H)-one (0.0039 
mol) in DMF (10 ml), potassium hydroxide (0.0046 mol) and appropriate alkyl halide 
(0.0039 mol) were added at 0oC. The reaction mixture was stirred for 3-5 h at this 
temperature. The progress of reaction was monitored by thin layer chromatography. 
After completion of reaction mixture, it was poured into cold water. The solid 
separated was filtered, washed with water and dried. The crude product was 
recrystallized from ethanol to give analytical pure product in 79-90% yield. 
 
? General synthesis of 3-benzylidene-5-(4-fluorophenyl)-1H-
benzo[e][1,4]diazepin-2(3H)-one (ADZ-05a-j) 
 
 5-(4-Fluorophenyl)-1H-beno[e][1,4]diazepin-2(3H)-one (0.0039 mol), 
potassium hydroxide (0.0039 mol) and appropriate aromatic aldehydes  (0.0039 mol) 
were taken in toluene (20 mL). The reaction mixture was heated to reflux for 8-10 hrs. 
The progress of reaction was monitored by thin layer chromatography. After 
completion of reaction mixture cooled to room temperature and the solid separated 
product was filtered, washed with cold toluene and dried.  The crude product was 
recrystallized from ethanol to give corresponding product ADZ-05a-j in 80-94% yield. 
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? Spectral data of the synthesized compounds 
 
2-chloro-N-(2-(4-fluorobenzoyl)phenyl)acetamide ADZ-02. White solid, mp 126-
128°C; Rf 0.49 (8:2 hexane-EtOAc); IR (KBr): 3373, 3072, 2895, 2828, 1694, 1635, 
1482, 1343, 1298 cm-1; MS (m/z): 291 [M+]; Anal. Calcd for C15H11ClFN2O2: C, 
61.76; H, 3.80; N, 4.80; Found: C, 61.74; H, 3.82; N, 4.82. 
 
5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-03. White solid, mp 
172-174°C; Rf 0.42 (8:2 hexane-EtOAc); IR (KBr): 3182, 3120, 3068, 3051, 2955, 
1693, 1672, 1504, 1232, 1024, 839, 810, 731, 690 cm-1; 1H NMR (300 MHz, CDCl3): 
δ 4.31 (S, 2H, CH2),  7.04-7.09 (m, 2H, Ar), 7.15-7.19 (m, 2H, Ar), 7.26-7.33 (m, 1H, 
Ar), 7.49-7.57 (m, 3H, Ar), 8.83 (s, 1H, NH); MS (m/z): 254 [M+]; Anal. Calcd for 
C15H11FN2O2: C, 70.86; H, 4.36; N, 11.02; Found: C, 70.84; H, 4.34; N, 11.03. 
 
5-(4-fluorophenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04a. 
White solid, mp 112-114°C; Rf 0.38 (8:2 hexane-EtOAc); IR (KBr): 3072, 2895, 2828, 
1694, 1635, 1482, 1343, 1298, 1050, 880, 834, 756 cm-1; 1H NMR (300 MHz, CDCl3): 
δ 3.42 (s, 3H, CH3), 3.75-3.78 (d, 1H, CH, J=10.5Hz), 4.78-4.81 (d, 1H, CH, 
J=10.5Hz), 7.05-7.10 (m, 2H, Ar), 7.20-7.29 (m, 1H, Ar), 7.32-7.37 (m, 2H, Ar), 
7.54-7.65 (m, 3H, Ar); 13C NMR: (100 MHz, CDCl3): δ 34.23, 56.53, 114.83, 115.05, 
121.33, 123.69, 127.67, 129.62, 131.30, 131.39, 131.45, 134.72, 134.75, 143.54, 
162.19, 164.66, 168.13, 169.30; MS (m/z): 268 [M+]; Anal. Calcd for C16H13FN2O: C, 
71.63; H, 4.88; N, 10.44; Found: C, 71.64; H, 4.84; N, 10.42. 
 
1-ethyl-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04b. Yellow 
solid, mp 162-164°C; Rf 0.44 (8:2 hexane-EtOAc); IR (KBr): 3078, 2865, 2821, 1686, 
1620, 1462, 1341, 1298, 1054, 834, 780 cm-1; MS (m/z): 282 [M+]; Anal. Calcd for 
C17H15FN2O: C, 72.32; H, 5.36; N, 9.92; Found: C, 72.34; H, 5.38; N, 9.96. 
 
5-(4-fluorophenyl)-1-propyl-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04c. 
Yellow solid, mp 123-125°C; Rf 0.30 (8:2 hexane-EtOAc); IR (KBr): 3068, 3024, 
2958, 2900, 1684, 1495, 1482, 808, 732, 690 cm-1; MS (m/z): 296 [M+]; Anal. Calcd 
for C18H17FN2O: C, 72.95; H, 5.78; N, 9.45; Found: C, 72.95; H, 5.78; N, 9.46. 
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5-(4-fluorophenyl)-1-isopropyl-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04d. 
White solid, mp 98-100°C; Rf 0.25 (8:2 hexane-EtOAc); IR (KBr): 3118, 3067, 3054, 
2958, 2901, 1683, 1582, 1469, 810, 705 cm-1; 1H NMR (300 MHz, CDCl3): δ 1.22-
1.24 (d, 3H, CH3), 1.50-1.60 (d, 3H, CH3), 3.70-3.74 (d, 1H, CH), 4.53-4.58 (m, 1H, 
CH), 4.68-4.71 (d, 1H, CH), 7.05-7.11 (m, 2H, Ar), 7.23-7.26 (m, 1H, Ar), 7.42-7.52 
(m, 3H, Ar), 7.61-7.63 (m, 2H, Ar); MS (m/z): 296 [M+]; Anal. Calcd for 
C18H17FN2O: C, 72.95; H, 5.78; N, 9.45; Found: C, 72.97; H, 5.79; N, 9.47. 
 
1-butyl-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04e. Yellow 
solid, mp 88-90°C; Rf 0.28 (8:2 hexane-EtOAc); IR (KBr): 3154, 3085, 2968, 2910, 
1685, 1564, 1420, 1350, 1232, 854, 696 cm-1; MS (m/z): 310 [M+]; Anal. Calcd for 
C19H19FN2O: C, 73.53; H, 6.17; N, 9.03; Found: C, 73.57; H, 6.19; N, 9.07. 
 
5-(4-fluorophenyl)-1-isobutyl-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04f. 
Yellow solid, mp 72-74°C; Rf 0.34 (8:2 hexane-EtOAc); IR (KBr): 3156, 3058, 2968, 
2905, 1985, 1564, 1369, 810, 694 cm-1; MS (m/z): 310 [M+]; Anal. Calcd for 
C19H19FN2O: C, 73.53; H, 6.17; N, 9.03; Found: C, 73.50; H, 6.11; N, 9.10. 
 
5-(4-fluorophenyl)-1-pentyl-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04g. White 
solid, mp 93-95°C; Rf 0.25 (9:1 Chloroform: Methanol); IR (KBr): 3110, 3056, 2956, 
2845, 1345, 1254, 1056, 842, 730, 698 cm-1; MS (m/z): 324 [M+]; Anal. Calcd for 
C20H21FN2O: C, 74.05; H, 6.53; N, 8.64; Found: C, 74.07; H, 6.59; N, 8.67. 
 
5-(4-fluorophenyl)-1-isopentyl-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04h. 
Yellow solid, mp 84-86°C; Rf 0.23 (8:2 hexane-EtOAc); IR (KBr): 3125, 3089, 3021, 
2985, 1236, 1056, 854, 795, 830, 698 cm-1; 1H NMR (400 MHz, CDCl3): δ 0.64-0.71 
(dd, 6H, 2 x CH3), 1.22-1.33 (m, 1H, CH), 3.51-3.57 (m, 1H, CH), 3.63-3.66 (d, 1H, 
CH), 4.28-4.35 (m, 1H, CH), 4.62-4.65 (d, 1H, CH), 5.19 (s, 2H, CH2), 6.95-7.00 (m. 
2H, Ar), 7.10-7.14 (m, 1H, Ar), 7.17-7.19 (m, 1H, Ar), 7.32-7.34 (d, 1H, J=8.28Hz 
Ar), 7.45-7.53 (m, 3H, Ar); 13C NMR: (100 MHz, CDCl3): δ 22.10, 22.54, 25.48, 
36.65, 44.74, 53.52, 57.14, 115.16, 115.37, 122.17, 124.33, 129.92, 130.13, 131.33, 
131.42, 131.48, 134.94, 134.97, 142.63, 162.89, 165.38, 168.93, 169.36; MS (m/z): 
324 [M+]; Anal. Calcd for C20H21FN2O: C, 74.05; H, 6.53; N, 8.64; Found: C, 74.10; 
H, 6.65; N, 8.77. 
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1-cyclohexyl-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-04i. 
Yellow solid, mp 137-139°C; Rf 0.35 (8:2 hexane-EtOAc); IR (KBr): 3074, 2856, 
2828, 1694, 1635, 1482, 1343, 1298, 1058, 840, 732 cm-1; MS (m/z): 333 [M+]; Anal. 
Calcd for C21H21FN2O: C, 74.98; H, 6.29; N, 8.33; Found: C, 74.90; H, 6.25; N, 8.37. 
 
5-(4-fluorophenyl)-1-(4-nitrobenzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-
04j. Yellow solid, mp 157-159°C; Rf 0.49 (8:2 hexane-EtOAc); IR (KBr): 3241, 3068, 
3015, 2956, 2881, 1330, 1268, 1054, 834, 830,756, 701 cm-1; MS (m/z): 389 [M+]; 
Anal. Calcd for C21H16FN3O3: C, 67.86; H, 4.14; N, 10.79; Found: C, 67.90; H, 4.15; 
N, 10.77. 
 
3-benzylidene-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one ADZ-05a. 
Yellow solid, mp 192-195°C; Rf 0.25 (8:2 hexane-EtOAc); IR (KBr): 3450, 3110, 
3054, 2990, 2932, 2854, 1456, 1305, 1250, 1005, 805, 732, 695 cm-1; 1H NMR (400 
MHz, DMSO): δ  6.39 (s. 1H, CH), 7.08-7.12 (m, 1H, Ar), 7.21-7.37 (m, 7H, Ar), 
7.46-7.53 (m, 3H, Ar), 7.76-7.79 (m, 2H, Ar), 8.15 (s, 1H, NH); 13C NMR: (100 MHz, 
DMSO): δ 115.25, 115.46, 118.09, 121.39, 122.58, 126.58, 126.74, 127.50, 128.07, 
128.19, 128.92, 129.90, 129.95, 131.80, 131.89, 134.41, 134.44, 134.75, 138.93, 
140.54, 162.45, 164.26, 164.94, 171.00; MS (m/z): 342 [M+]; Anal. Calcd for 
C22H15FN2O: C, 77.18; H, 4.42; N, 8.18; Found: C, 77.20; H, 4.45; N, 8.22. 
 
5-(4-fluorophenyl)-3-(3-nitrobenzylidene)-1H-benzo[e][1,4]diazepin-2(3H)-one 
ADZ-05b. Yellow solid, mp 202-204°C; Rf 0.28 (8:2 hexane-EtOAc); IR (KBr): 3390, 
3072, 2856, 2832, 1684, 1635, 1482, 1356, 1298, 830, 750, 700 cm-1; 1H NMR (300 
MHz, DMSO): δ 6.44 (s. 1H, CH), 7.06-7.11 (m, 1H, Ar), 7.24-7.40 (m, 4H, Ar), 
7.50-7.67 (m, 3H, Ar), 7.82-7.93 (m, 3H, Ar), 8.08-8.11 (d, 1H, J=8.1Hz, Ar), 8.58 (s, 
1H, NH);13C NMR: (100 MHz, DMSO): δ 120.15, 120.47, 121.01, 126.53, 126.79, 
127.80, 129.01, 131.73, 134.32, 135.48, 137.11, 137.15, 137.24, 139.46, 141.68, 
143.84, 147.81, 152.92, 175.11; MS (m/z): 387 [M+]; Anal. Calcd for C22H14FN3O3: 
C, 68.21; H, 3.64; N, 10.85; Found: C, 68.20; H, 3.67; N, 10.83. 
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3-(3,4-dimethoxybenzylidene)-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H) 
-one ADZ-05c. Yellow solid, mp 189-191°C; Rf 0.21 (8:2 hexane-EtOAc); IR (KBr): 
3232, 2997, 2906, 2833, 1683, 1670, 1506, 1363, 1265, 1026, 848, 802, 761, 731, 690 
cm-1; MS (m/z): 402 [M+]; Anal. Calcd for C24H19FN2O3: C, 71.63; H, 4.76; N, 6.96; 
Found: C, 71.67; H,4.71; N, 6.93. 
 
5-(4-fluorophenyl)-3-(4-methoxybenzylidene)-1H-benzo[e][1,4]diazepin-2(3H)-
one ADZ-05d. Yellow solid, mp 223-225°C; Rf 0.24 (8:2 hexane-EtOAc); IR (KBr): 
3442, 3202, 2956, 2916, 2845, 1656, 1504, 1345, 1240, 834, 803, 765, 705 cm-1; MS 
(m/z): 372 [M+]; Anal. Calcd for C23H17FN2O2: C, 74.18; H, 4.60; N, 7.52; Found: C, 
74.22; H,4.61; N, 7.57. 
 
3-(4-chlorobenzylidene)-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one. 
ADZ-05e.Yellow solid, mp 192-194-225°C; Rf 0.26 (8:2 hexane-EtOAc); IR (KBr): 
3076, 2964, 2891, 2837, 1691, 1676, 1483, 1155, 1091, 842, 761, 734, 688 cm-1; MS 
(m/z): 376 [M+]; Anal. Calcd for C22H14ClFN2O: C, 70.12; H, 3.74; N, 7.43; Found: C, 
70.14; H,3.75; N, 7.45. 
 
3-(4-fluorobenzylidene)-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
ADZ-05f. Yellow solid, mp 167-169°C; Rf 0.25 (8:2 hexane-EtOAc); IR (KBr): 3373, 
3072, 2895, 2828, 1694, 1635, 1482, 1298, 784, 746, 698, cm-1; MS (m/z): 360 [M+]; 
Anal. Calcd for C22H14F2N2O: C, 73.33; H, 3.92; N, 7.77; Found: C, 70.35; H, 3.95; N, 
7.72. 
 
5-(4-fluorophenyl)-3-(4-nitrobenzylidene)-1H-benzo[e][1,4]diazepin-2(3H)-one 
ADZ-05g. Yellow solid, yield 93%, mp 217-219°C; Rf 0.23 (8:2 hexane-EtOAc); IR 
(KBr): 3452, 3154, 3072, 2895, 2828, 1694, 1635, 1482, 1343, 1298, 784, 765, 702, 
684 cm-1;  MS (m/z): 387 [M+]; Anal. Calcd for C22H14FN3O3: C, 68.21; H, 3.64; N, 
10.85; Found: C, 68.23; H, 3.62; N, 10.85. 
 
3-(4-bromobenzylidene)-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
ADZ-05h. Yellow solid, mp 183-185°C; Rf 0.29 (8:2 hexane-EtOAc); IR (KBr): 3420, 
3074, 2923, 2956, 1695, 1680, 1459, 1154, 1056, 845, 761, 734, 690 cm-1;  MS (m/z): 
420 [M+]; Anal. Calcd for C22H14BrFN2O: C, 62.72; H, 3.35; N, 6.65; Found: C, 
62.75; H, 3.34; N, 6.75. 
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5-(4-fluorophenyl)-3-(2-hydroxybenzylidene)-1H-benzo[e][1,4]diazepin-2(3H)-
one  ADZ-05i. Yellow solid, mp 152-154°C; Rf 0.42 (8:2 hexane-EtOAc); IR (KBr): 
3485, 3078, 2854, 2831, 2685, 1456, 1256, 854, 705, 684 cm-1;  MS (m/z): 358 [M+]; 
Anal. Calcd for C22H15FN2O2: C, 73.73; H, 4.22; N, 7.82; Found: C, 73.75; H, 4.24; N, 
7.85. 
 
3-(2,5-dimethoxybenzylidene)-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H) 
–one ADZ-05j. Yellow solid, mp 144-145°C; Rf 0.25 (8:2 hexane-EtOAc); IR (KBr): 
3473, 3078, 3045, 2954, 2895, 2828, 1684, 1645, 1484, 1325, 1250, 854, 735, 697 
cm-1;  MS (m/z): 402 [M+]; Anal. Calcd for C24H19FN2O3: C, 71.63; H, 4.76; N, 6.96; 
Found: C, 71.67; H,4.71; N, 6.93. 
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1H NMR spectrum of compound ADZ-03 
 
 
1H NMR spectrum of compound ADZ-04a 
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1H NMR spectrum of compound ADZ-04h 
 
 
Expanded 1H NMR spectrum of compound ADZ-04h 
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1H NMR spectrum of compound ADZ-05a 
 
 
Expanded 1H NMR spectrum of compound ADZ-05a 
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1H NMR spectrum of compound ADZ-05b 
 
 
1H NMR spectrum of compound ADZ-05d  
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13C NMR spectrum of compound ADZ-04a 
 
 
13C NMR spectrum of compound ADZ-05a 
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MASS spectrum of compound ADZ-04i  
 
 
MASS spectrum of compound ADZ-04j 
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MASS spectrum of compound ADZ-05e 
 
 
MASS spectrum of compound ADZ-05i 
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IR spectrum of compound ADZ-03  
 
 
IR spectrum of compound ADZ-05c 
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Research Summary 
 
 
 The work comprised in the Thesis entitled “Studies on Novel Bioactive 
Heterocyclic Compounds” is summarized as follows. 
 
 In Chapter 1, we have presented an efficient four step protocols for the 
synthesis of diversely substituted novel pyrimidines. A series of chlorinated 
pyrimidines were synthesized from easily available Biginelli 3,4-dihydropyrimidin-
2(1H)-ones. The chlorinated pyrimidines were then subjected to condition normally 
employed Suzuki-Miyaura coupling reaction with various phenylboronicacid 
derivatives in the presence of palladium catalyst to obtain C-phenyl pyrimidines with 
good yields.  
 
 In Chapter 2, we have described (E)-selective synthesis of novel pyrimidine 
derivatives from pyrimidine phosphorous ylide with a variety of aldehydes via Wittig 
reaction in the presence of sodium tripolyphosphate as a base in aqueous media. 
Sodium tripolyphosphate has the several advantages of being stable, low cost and less 
toxic. All the synthesized compounds were evaluated for their antimicrobial activity. 
The investigation of antibacterial and antifungal screening revealed that all the tested 
compounds showed moderate to significant activity.  
 
 In Chapter 3, a facile synthesis of a library containing trisubstituted pyrazoles 
and isoxazoles functionalized with cyclopropyl, thiomethyl and carboxamide moieties 
has been described. As a part of ‘green chemistry’ approach, we employed 
condensation reaction of various ketene dithioacetals with hydrazine hydrate or 
hydroxyl amine hydrochloride in solvent free reaction condition under microwave 
irradiation. The present procedure is significant over the existing methods to develop 
this class of molecules with excellent yield, purity and simple isolation of products. 
 
 In Chapter 4, the heterocyclizations of various ketene dithioacetals with 5-
aminopyrazole derivative were studied in details, and the influence of the reaction 
parameters and the aminoazole structure on the direction of the reaction was 
established. We found that the reaction of various ketene dithioacetals with 5-amino- 
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pyrazole derivative were faster and afforded the pyrazolo[1,5-a]pyrimidine in good 
yield in the presence of K2CO3 as a base and isopropyl alcohol. This study led to the 
development of a simple approach for synthesis of pyrazolo[1,5-a]pyrimidines, 
substances that potentially interesting biological and medicinal properties. 
 
 Chapter 5 described the synthesis of a series of substituted pyrroles as a 
atorvastatin analogs. The targeted compound were achieved from novel 1,4-
dicarbonyl compounds and amino side chain using pivalic acid as a catalyst and 
cyclohexane and THF as binary solvent under microwave irradiation technique. All 
the synthesized compounds were evaluated for their antimicrobial activity. The 
investigation of antibacterial and antifungal screening revealed that some of these 
agents posseses moderate to potent activity.  
 
 In Chapter 6, we have demonstrated a simple and effective strategy for the 
synthesis of novel 1-and 3-substituted 1,4-benzodiazepines. The reaction of 1,4-
benzodiazepines  either with various alkyl halide or a variety of aromatic aldehydes in 
the presence of potassium hydroxide afforded the desired 1-and 3-substituted 1,4-
benzodiazepine derivatives in excellent yields. 
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